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1If you desire the spleen and will laugh yourself into stitches, follow me.
William Shakespeare (1564-1616) (Twelfth Night, Act 3;2:62-63)
This general introduction gives an extensive review on topics that are covered in this thesis, 
such as the spleen, transplantation and tolerance, as well as the Massachusetts General Hos-
pital miniature swine model in relation to transplantation. It is the author’s opinion, that this 
background information is benefi cial for a better understanding of the studies and their aims 
as described in the chapters following the introduction. 
HISTORICAL VIEW ON THE SPLEEN
The spleen is an enigmatic organ with a peculiar anatomy and physiology; its history is full 
of fables and myths, but it is also full of realities. The question “Este igitur splenatam neces-
sarius?” (“Is the spleen necessary for survival?”) has been the central question for physicians 
such as Galen, Vesalius, Malpighi, Billroth, Gray, Gross, and Mayo. It remained unanswered 
until recently. 
The modern English term “spleen” descends from the Grecian “σπλήν” (splén), which may have 
been derived from “σπλαγχνον” (splanchnon: a viscus) or from “σπάω” (spaw: to draw). The an-
cients believed that this viscous organ draws spoiled parts of the blood to itself, making both 
of these derivations equally plausible. Take away the “sp” in splén and the Latin term lien is 
born. The Teutonic term (and modern Dutch term) for spleen, milt, and its Germanic form, milz, 
off er additional suggestions as to possible splenic function; they are related to the milt (roe 
or spawn) of a male fi sh, meaning soft like a spleen. Milt is also related to the Icelandic melta, 
which means “to digest” (1,2).
In ancient times the spleen was thought to be related to the digestive system. Erasistratus 
believed that the spleen maintained the symmetry of the abdomen, but had no further func-
tion. Plato claimed that its function was to keep the liver ”bright and shining”. Hippocrates 
proposed a vital balance of four essential humours of the body: blood, phlegm, golden bile 
and black bile. In spite of the lack of anatomical and histologic knowledge in this period, he 
had described the anatomy of the spleen with remarkable accuracy. The description of func-
tion, however, was described diff erently from that of today; the liver was supposed to be the 
source of golden bile and the spleen of black bile. Galen believed that ”humours unsuitable 
for its nutriment are discharged by the spleen through a canal into the stomach”. He called the 
spleen: ”Splenum mysterii organon” (3).
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During the 17th and 18th century the main contributions to the study of the spleen consisted 
of careful anatomical dissections. In 1777 William Hewson recognized associations with the 
lymphatic system. Rudolph Virchow demonstrated in 1846 that the follicles in the spleen were 
related to the white blood cells, and in 1885 Ponfi ck recognized the ability of the spleen to 
remove particles from the blood (4).
About thirty years later, Morris and Bullock described the spleen as an important organ in the 
resistance to infections (5). O’Donnell reported a case of ”acute septicemia” in a 6-year-old 
boy 2 years after splenectomy in 1926. The boy’s father who had had a splenectomy in 1919 
also died ”of septic pneumonia, manifesting a similar lack of resistance to the disease” (3). 
Perla and Marmoston discussed the role of the spleen in resistance against infection in 1935 
(6). It was only after the publication of King and Shumacker on postsplenectomy infections in 
1952 (7), that there was a rise in concern over the decrease in resistance against infections as a 
consequence of splenectomy. After this publication, the immunological aspects of the spleen 
became increasingly the targets of scientifi c interest. 
THE SPLEEN
Now we come to the spleen, of it we know nothing. So much for the spleen.
Emil du Bois-Reymond (1818-1896)
Embryology
During embryogenesis, the formation of the splanchnic mesodermal plate (SMP) at day 12 is 
the initial event in the development of the spleen, part of the formation of the asymmetrical 
left-right axis. When formation of the SMP is defective, then no spleen is formed (8,9). Pro-
genitor cells of the erythroid and myeloid lineages are the fi rst cells to colonize the spleen, 
and, at day 14.5 hematopoietic stem cells lodge in the spleen (10). From the 4th week of ges-
tation, mesenchymal cells in the dorsal mesenterium of the foregut form lobules. Several of 
these lobules fuse, resulting in the defi nite form of the spleen. The dorsal part (spleno-aortic 
ligament, between spleen and dorsal body wall) of the dorsal mesenterium, containing the 
splenic artery and pancreatic tail, lengthens and is pulled to the left by the growing greater 
curvature of the stomach. Then, it fuses with the dorsal parietal peritoneum at the level of 
the left kidney, becoming splenorenal ligament. The ventral part of the dorsal mesenterium 
becomes the gastrosplenic ligament (together with the more caudal greater omentum) with, 
cranially, the short gastric vessels and, caudally, the left gastro-epiploic vessels (11).
Frank Dor BW.indd   12 18-08-2006   15:02:13
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1Anatomy
The spleen is an oblong, aubergine-coloured organ, with the size of a clenched fi st and the 
shape of a bean. In adult humans, the size varies from 12-15 cm (length), 4-8 cm (width), 3-4 
cm (thickness). Its weight is approximately 150g in healthy adults (12). The spleen is located 
in the left upper quadrant of the abdominal cavity, sheltered by the 9th-11th ribs (13) (Figure 
1). The spleen is soft in consistency, friable and is shaped by adjacent, fi rmer viscera. Together 
with the visceral peritoneum it forms strong suspensory attachments to the stomach (gastro-
splenic ligament), diaphragm (phrenicosplenic ligament), kidney and pancreas (splenorenal 
or pancreaticosplenic ligament), colon (phrenicocolic ligament) and sometimes with a peri-
toneal fold to the abdominal wall on the left posterolateral aspect (14) (Figure 2). The medial 
side of the spleen has a long fi ssure; this forms the hilus, which is the site of the main entrance 
and exit for the blood vessels (13). There are no lymphatics leading into the spleen; in contrast 
to the lymph nodes, which are inserted in the lymph circulation, the spleen is inserted in the 
blood circulation.
Around the spleen is a strong fi brous capsule with collagenous trabeculae extending into in-
side the parenchyma. The splenic parenchyma can be divided into white and red pulp as can 
be seen on fresh surgical specimens. 
The spleen is the largest lymphoid tissue of the body, accounting for about 25% of the body’s 
lymphocytes. Blood fl ow through the spleen is immense relative to its size: this 150g organ 
in adult humans (less than 0.3% of the body weight) receives about 200-300 ml/min (~5% 
3
4
4
5
6
Figure 1. Anatomical position of the human spleen. 
1, spleen; 2, kidney; 3, duodenum; 4, pancreas; 5, abdominal aorta; 6, inferior vena cava.
See addendum for colour version
Frank Dor BW.indd   13 18-08-2006   15:02:13
Chapter 1
14
of cardiac output) (15). The bulk of this blood fl ow percolates through the splenic red pulp 
– the part of the spleen which functions as a general fi lter, removing particulate matter and 
damaged erythrocytes from the circulation (16-19). However, this blood fl ow also supplies the 
other, more immunologic compartment of the spleen with both antigen and lymphocytes. 
This compartment, the white pulp (accounting for approximately 5-20% of the splenic paren-
chyma in humans (20)), is the splenic version of secondary lymphoid tissue, and it constitutes 
the major initiator of immune responses against blood-borne antigens (21). The white pulp is 
organized as lymphoid sheaths, with B and T cell compartments, around the branching arte-
rial vessels.
The splenic artery enters the spleen at its hilum and immediately branches into smaller “tra-
becular” arteries, which in turn branch into even smaller “central” arteries. These central arter-
ies course through the splenic parenchyma, eventually branching into “penicilliary” arterioles 
that empty into the red pulp. Investing the central arteries and penicilliary arterioles is a con-
centric cuff  of lymphocytes, the great majority of which are T cells. These cuff s, termed the 
periarteriolar lymphocytic sheaths (PALS), constitute the T cell zones of the spleen. Periodi-
cally, usually at arterial branch points, B-lineage lymphoid follicles, either primary or second-
ary, appear as outgrows of the PALS. 
Surrounding the primary follicle or mantle zone of the secondary follicle (and the PALS in ro-
dents) is the marginal zone (MZ), a uniquely splenic lymphoid compartment. The MZ contains 
both B and T cells (usually a majority of the former), and is thought to be the site in which splenic 
B and T cells initially encounter blood-borne antigens (21,22). Indeed, the MZ appears to be a 
primary site of entry of both B and T lymphocytes into the white pulp. MZ B cells in the spleen 
Figure 2. Anatomy of the upper abdomen with respect to the spleen.
See addendum for colour version
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1are strategically positioned at the blood-lymphoid interface and are programmed to initiate a 
fast and intense antibody response to blood-borne viral and bacterial agents (23,24). Their abil-
ity to respond vigorously to antigen and polyclonal activators make MZ B cells key players in the 
early response to pathogens in the blood stream. The specialized functions of these innate-like 
lymphocytes bridge the gap between the early innate immune response and the slower adap-
tive antibody response, aff ected mainly by the more prolifi c follicular B cells (25).
The spleen lacks high endothelial venules (HEV; as in lymph nodes), but it is thought that spe-
cialized MZs subserve an analogous function to the HEVs in other secondary lymphoid sites 
(26). MZs are not found in secondary lymphoid tissues other than spleen.
Histology 
The splenic parenchyma can be divided into two general components: the white pulp (± 5-
20%) and the red pulp (± 85%) enclosed by a capsule and interspersed by trabeculae (27).
Capsule
The capsule is composed of dense connective tissue with a few smooth muscle cells, refl ect-
ing the minimal contractile capacity of this capsule in man (in dogs it is highly contractile) 
(28). Serosa covers the capsule except at the hilus where vessels enter the spleen. From the 
inner surface of the capsule a branching network of trabeculae subdivides the spleen into 
communicating compartments. These trabeculae carry the blood and lymph vessels into the 
splenic pulp (21,29,30).
White pulp
The white pulp is composed of lymphatic tissue, primarily lymphocytes. In the fresh state, it 
appears as small, round pale white or gray areas surrounded by red pulp (hence the name 
“white pulp”). However, by H&E with light microscopy, it appears deeply basophilic due to the 
concentration of lymphocytes. 
The white pulp is composed of 3 major compartments that are easily recognized in routinely 
stained histological sections (Figure 3A). These compartments are the PALS, the lymphoid fol-
licle (LF) and the MZ (31).
The PALS will parallel the course of the central arteries. The lymphocytes that make up the 
PALS are primarily T-lymphocytes. The presence of the artery helps distinguish the PALS from 
LFs that may also form along the course of the central artery. The PALS is the T-lymphocyte 
compartment of the white pulp in which T-lymphocytes are interspersed in concentric layers 
of stromal cells around a central artery (Figure 3A). The lymphocytes of the PALS are mostly 
recirculating cells. The PALS is a site of T-cell clonal expansion. A small percentage of the T-cells 
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within the PALS are in an activated state, demonstrated by IL2-receptor (CD25) expression. 
The other T-cells are in a resting state (31).
The LFs of the spleen are globular structures attached to the PALS (Figure 3B) with similar 
structure as LFs in other lymphoid organs (32). Like LFs in the lymph node, these are com-
posed chiefl y of B-lymphocytes. Germinal centers (GC) with mantle zones (B-cells) and MZs 
(B- and T-cells) may be present and result in the formation of large nodules known as Malpi-
ghian corpuscles. They can be diff erentiated into primary and secondary LFs. The primary LF 
consists of a homogeneous aggregate of small B-cells in an inactivated state. Upon activation 
the primary LF will become a secondary LF with a GC surrounded by a small rim of remaining 
small B-cells, the lymphocyte corona (LC) (Figure 4). This GC of the secondary LF consists of 
diff erentiated B-cells (centroblasts and centrocytes), a few T-cells, and follicular dendritic re-
ticulum cells. In the LFs, a special type of dendritic cells (follicular dendritic cells) is found (33), 
which are able to bind immune complexes. They can maintain immune complexes on their 
cell surface for a long period without phagocytosis. This seems to play a role in the down-
regulation of the production of plasma cells (34). 
GCs provide a site for rapid proliferation of B-cells with isotype switching and affi  nity matura-
tion. Upon maturation of the GC, cell division stops and cells diff erentiate into memory cells 
or plasma cells, which acquire the ability to migrate out of the GC (35). A specifi c type of 
mononuclear macrophages is present that phagocytose defective lymphoid cells and debris 
in the GC (36). 
A B
Figure 3. 
(A) Cross section of the spleen with white and red pulp zones (Giemsa-stained). 
(B) Schematic representation.
See addendum for colour version
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1
The GC is surrounded by a small border of small lymphocytes (in fact the pre-existent cells of 
the former primary follicles); these form called the LC or mantle zone. The LC in its turn is en-
closed by medium-sized lymphocytes, mostly B-cells, the MZ. The MZ is an anatomical demar-
cation between the white pulp and the red pulp. The real border is formed by the perifollicular 
zone (27). A great part of the arterial circulation within the MZ terminates intercellularly, and 
at the outer side of the MZ sinuses are present, which are smaller than the sinusoids of the red 
pulp. The MZ provides an environment, which by its low blood fl ow allows a prolonged and in-
timate contact between antigens in the bloodstream and the lymphocytic system (31,36,37).
Lymphoid cells in the MZ have been demonstrated to possess surface immunoglobulin (Ig) 
(mainly IgM, in absence of IgD), as well as receptors for Fc-fragments and complement factors 
(C3b and C3d) (31,36,37). It is because of this low fl ow in combination with a specifi c type of 
B-cells that the MZ is supposed to have an important role in the primary immune response 
to T-cell independent antigens type 2 (TI-2 antigens) like the polysaccharide encapsulated 
bacteria, e.g., pneumococci, meningococci, and Haemophilus infl uenzae. The MZ is a distinct 
anatomical lymphocyte compartment in the spleen with unique immunohistological features 
(38).
Red pulp
The red pulp consists of a loose reticular tissue, rich in capillaries and venous sinusoids. These 
sinusoids comprise approximately 30% of the volume of the red pulp. They form a meshwork 
with many interconnections, but also bulb-like extensions with blind ends projected into the 
cord tissue (27,39). The sinusoids have an unique endothelium of longitudinally arranged cells. 
These run parallel to the long axis of the sinusoids like the staves of a barrel, and possess close 
junctional complexes at regular intervals along their lateral surfaces to the white pulp veins. 
GCLF
LC
Figure 4. Lymphoid follicle (LF) in the spleen. LF, lymphoid follicle; GC, germinal center; LC, lymphocyte corona.
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Slit-like spaces, which can be penetrated by cells fl owing from the pulp cords, separate the 
endothelial cells. The basal membranes have been shown to contain actin and myosin, which 
can probably contract to vary the tension in the endothelial cell and the dimensions of the in-
terendothelial slits. The interendothelial slits are a critical point in the pathway of particulates 
through the spleen and in the fi ltration function (18,40-42). 
Part of the red pulp tissue has a reticuloendothelial nature with small aggregates of B- and 
T-lymphocytes and many mononuclear phagocytes. Morphometrically, the size of the lym-
phoid, non-fi ltering red pulp compartment seems to equal that of the white pulp (43). The 
macrophages are not simply phagocytic cells, but also have secretory capacities and in this 
way enhance the immunogenicity of antigens. They have the ability to produce components 
of complement factors, interferon, hematopoietic colony-stimulating factors and fi broblast-
stimulating factors. This whole system is part of the so-called mononuclear phagocytic system 
(MPS) (44).
Vasculature, lymphatics and innervation
Arterial supply
As 5-10% of the cardiac output at rest passes through the spleen, the spleen has to be richly 
vascularized. It is supplied by the tortuous (in later life often calcifi ed) splenic artery, which 
is the largest of the three branches of the celiac trunk, which originates from the abdominal 
aorta. After passing the upper body of the pancreas horizontally, giving a few branches to the 
stomach (left gastro-epiploic artery and short gastric artery) and pancreas (large pancreatic 
artery), the splenic artery divides into several branches about 1-3 cm from the hilum. These 
branches will divide further, into superior and inferior branches (enabling partial splenecto-
my), subdividing into several smaller branches and fi nally enter the spleen in the hilus. Ramifi -
cations of the splenic arterial branches develop internally into trabecular arteries, which pass 
through the white pulp as central arteries, branches of which supply the lymphatic nodules 
in the white pulp. From the centre of the lymphatic node the artery can pass through to the 
red pulp or split into branches in the marginal zone. Via marginal zone sinuses the blood can 
also reach the red pulp. The red pulp is assumed to have two systems for the blood circulation, 
which will be described under Microcirculation, below. 
Venous drainage
The venous drainage commences in the venous sinusoids, located in the red pulp, subse-
quently draining into trabecular veins. The trabecular veins terminate in branches that unite 
to form the splenic veins and follow the arteries at the hilus of the spleen. Here, it receives the 
short gastric and left gastro-epiploic veins. The large retropancreatic splenic vein represents 
40% of the total portal fl ow. It passes along the dorsal and superior part of the pancreas and, 
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1with the superior mesenteric vein, becomes the portal vein. At a short distance before the 
superior mesenteric vein, the inferior mesenteric vein empties into the splenic vein.
Lymphatic drainage
In contrast to the extensively-distributed blood vessels, the lymphatic vessels in the spleen 
are few in number. Lymphatic capillaries originating in the splenic capsule and trabeculae 
converge in lymph nodes of the hilus outside the spleen and subsequently drain along the 
arteries into parapancreatic, celiac and para-aortal nodes.
Innervation
The spleen merely has a vasomotor innervation from the celiac ganglion and plexus. 
The nerve supply follows the splenic artery in the hilus and innervates the musculature of the 
branching vessels. Sympathetic nerve fi bres densely innervate the spleen. Their endings con-
tact immune cells within the spleen, particularly in areas of T cells and macrophages (building 
the neuroimmune junction). Neurotransmitters are released into the vicinity of nerve termi-
nals and bind to specifi c postsynaptic receptors on the surface of these cells. Local bi-direc-
tionality exists through cytokines and neurotransmitters from immune cells that modulate the 
release of sympathetic neurotransmitters from nerve terminals. This complex ‘dialog’ depends 
on microenvironmental factors such as infectious agents, and this ‘conversation’ is needed to 
balance the function of both the sympathetic nerve terminal and the immune system. Activa-
tion of the sympathetic nervous system and also the resting sympathetic nervous tone are im-
portant for controlling innate and adaptive immune responses (45). Also, preganglionic para-
sympathetic fi bres of the right vagal nerve follow the splenic artery into the spleen, although 
the role of parasympathetic innervation of the spleen remains obscure (46). 
Microcirculation and lymphocyte circulation
Microcirculation 
The microcirculation of the blood in the spleen is perhaps the most complex of any organ in 
the body. It contains blood with a packed cell volume twice that of arterial blood. Most stud-
ies of the microcirculation in the spleen have been performed in animals and the results were 
often extrapolated to the human spleen. It is not clear whether these results are suffi  ciently 
representative for the human situation, because the histology and subsequently the micro-
anatomy of the human spleen seem to diff er between species (21, 27, 31, 47). However, be-
cause of diffi  culties in investigation of the spleen in humans, we have to rely on well-designed 
animal experiments to provide useful hints in the elucidation of the complex mechanisms in 
the human spleen.
The spleen is the only organ specialised in the fi ltration of blood. It has been suggested that 
there is a fast and a slow pathway of the bloodstream in the red pulp of the spleen for which 
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two compartments are assumed to exist for this bloodstream within the spleen. The fi rst sys-
tem is the closed circulation with direct connection via the sinusoids and collecting veins to 
the trabecular veins (Figure 5). The second (more important) system is the open circulation 
with arterial vessels ending blindly in the red pulp cord spaces. From the cords, the blood runs 
intercellularly and subsequently is collected in sinusoids, from which it will be transported 
by pulp veins to trabecular veins. The fast compartment is intra-vascular, whereas the slow 
compartment is in the reticular meshwork (19,48).
Some arterial capillaries of the red pulp show cyclic changes in luminal calibre, with some-
times a very low to absent fl ow. Erythrocytes pass through interendothelial slits in venous 
sinus walls always from the reticular meshwork into the sinuses (18). 
Lymphocyte circulation
A unique feature of lymphocytes, in contrast to all other cells of the blood, is their continuous 
migration between lymphoid and non-lymphoid organs through the lymphatic and blood 
vessels. Granulocytes and monocytes mostly remain in organs once they have left the blood 
stream, but lymphocytes may temporarily leave the blood stream and return to it at a later 
stage (lymphocyte recirculation). This recirculation of lymphocytes is important for their abil-
ity to recognise antigens throughout the body and for the interaction between accessory 
and lymphoid cells in initiating immune reactions (27). The extent of lymphocyte recirculation 
in the spleen by the blood far outweighs the total number of lymphocytes using the classi-
cal route via lymph vessels and thoracic duct. In a young adult human about 2,5x1014 lym-
phocytes recirculate through the spleen per day, which is approximately 8 times more than 
through all lymph nodes (49). The lymphocytes enter the spleen through the arterial blood 
stream and migrate to several splenic compartments.
Figure 5. Schematic representation of the blood stream in the spleen.
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1T-lymphocytes rapidly enter the central part of the PALS, while B-lymphocytes persist in more 
peripheral parts of the PALS, and by 24 hours are evenly distributed throughout the LC. A few 
migrating B-cells are found in the GCs, but no T-cells. It is unknown as yet whether the venous 
route or the lymphatic route is the most important outfl ow for lymphocytes of the spleen; 
probably the venous route is more important than that via lymphatic vessels. The exact migra-
tory mechanisms and routes of the lymphocyte subsets through all the splenic compartments 
are very complex and have not yet been fully clarifi ed (50,51). 
Functions of the spleen
The spleen is a unique organ in the immune system; fi rst, it is the only organ that can clear low 
opsonized antigens from the blood stream, secondly, it is the sole organ that is specialised in 
producing antibodies in a short time after contact with antigens. Besides this, the spleen is a 
true lymphoid organ with several organized lymphoid compartments. Because of its central 
position in the blood stream and its large blood supply, the spleen represents an important 
meeting point between antigenic information transported by the blood and the immune 
system. It possesses a wide range of the immune cell repertoire and its specifi c architecture 
allows unique functions. The functions of the spleen can be divided into non-immunological 
and immunological. 
Non-immunological
Filtration of the blood is the best known and a(n) (quantitatively) important function of the 
spleen. The reticular meshwork in the red pulp, with the terminal arterial vessels and the venous 
sinusoids, is specialised in fi ltration of the blood. When blood passes the endothelial wall of the 
sinusoids, blood cells have to pass through the interendothelial slits. These slits are only small 
in diameter; hence, during this passage the blood cells have to deform, subsequently to regain 
their normal form (Figure 6). If the cells loose their deformation capacity or if the cell walls are 
Figure 6. Passage of an erythrocyte through a sinusoid.
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too fragile, they cannot pass through this fi ltration system (52). Erythrocytes with intracellular 
inclusions (pittings, Howell-Jolly bodies, intra-cellular organisms such as malaria, etc.) can be 
cleared of these inclusions during the passage without destroying the entire cell. The mem-
brane of the cell reseals and subsequently passes into the sinuses and the general circulation. 
The perisinusoidal phagocytic cells will clear the inclusions and the aged blood cells (53, 54).
The spleen has a reservoir function for a large number of all kinds of blood cells by means of 
a process that is not yet understood. This storage function is mainly for platelets, but also for 
erythrocytes and lymphocytes. Of all platelets in the body, approximately 30% may be stored 
in the spleen. The spleen is the largest lymphoid organ with 25% of all white blood cells of the 
body, mainly lymphocytes. Only 5% of the red cells are supposed to be stored in the spleen. 
The number of blood cells in the spleen at a given time depends on the presence or absence 
of pathology in the spleen and/or of the blood cells. In the reticular meshwork, the hematocrit 
of the blood is twice that of arterial blood. The spleen appears to function as a ”nursery” for 
reticulocytes after their release from the bone marrow (BM) (55), and is supposed to play a 
role in fi nal maturation. Reticulocytes have a reduced negative surface charge, are less fl ex-
ible, contain unnecessary organelles and are bigger than mature red cells. The reticulocytes 
will be sequestered in the red pulp for two days because of these properties, thus allowing 
them to mature. After maturation, the erythrocytes will be remodelled, loose certain adhesion 
molecules, and then emerge into the circulation (56-58).
Additional known functions of the spleen are hematopoiesis during fetal life and, when he-
matopoiesis in the BM is failing, e.g., from dysplasia or myelofi brosis, the spleen can regain its 
fetal role in extramedullary hematopoiesis (59). It also has a positive eff ect on factor VIII serum 
levels, inhibits serum angiotensin-converting enzyme activity, and participates in reutilization 
of iron from destroyed erythrocytes (56,60,61). It is even suggested that the spleen has a role 
in lipid metabolism, demonstrated by lower HDL-cholesterol and higher triglyceride serum 
levels after splenectomy (62). 
Immunological
Phagocytosis of foreign particles can be promoted by interaction with opsonins, serum factors 
that enhance their uptake by specifi c phagocytosing cells. The spleen has a prominent role 
in the generation of opsonins (4,63). Phagocytes in the spleen, together with macrophages 
in the liver, synthesise the majority of components of the classical pathway of complement 
(63). Whereas the MPS in the liver is the main site of phagocytosis of opsonized particles, the 
spleen is the major organ for the phagocytosis of non-opsonized foreign particles. 
In experiments in rabbits, the phagocytosing capacity for non-opsonized particles appeared 
to be sixty times as eff ective in spleen as in liver when corrected for weight (reviewed by 
Lockwood) (63). The unique microvasculature of the spleen supposedly contributes to the 
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1specialised function of the spleen in the phagocytosis of insuffi  ciently-opsonized particles 
(34,42,64). The greatly retarded blood fl ow in the red pulp cords allows a very intimate and 
prolonged contact between antigens and phagocytes. Thus, particles can be ingested with-
out specifi c ligand-receptor interactions. 
An important practical implication of this specialised phagocytosing capacity is that the 
spleen is the most important site of clearance in the early phase of bacterial invasion before 
suffi  cient amounts of specifi c antibody have been produced. This is particularly important 
for blood-borne antigens, like polysaccharide-encapsulated micro-organisms (e.g., pneumo-
cocci) (56,65).
The spleen also plays a part in the alternative complement pathway. Complement factors 
work synergistically with antibodies in promoting phagocytosis of bacteria. In the presence 
of the complement factor C3b, the Ig opsonization degree required for phagocytosis is de-
creased 100-fold. Moreover, lysis of bacteria can take place by complement factors only. In the 
primary immune response to TI-2 antigens, C3d is also an important factor, and a high density 
of C3d-receptors is found in the MZ of the spleen (66).
Generation of specifi c antibody is primarily dependent upon the spleen. The spleen is the 
site of IgM-specifi c antibody generation very early after exposure to blood-borne antigen. 
The fi rst contact of antigens entering the spleen via the blood and immunocompetent cells 
occurs in the MZ, a structure exclusively present in the spleen (67, 68). The MZ has a unique 
microvasculature, enabling a very low blood fl ow. Also, specialised macrophages, antigen pre-
senting cells, and a subset of intermediate-sized B-cells with a specifi c phenotype (IgM+, IgD-, 
and strongly CD21+) are predominantly found (67-70). Although B-cells with this phenotype 
can also be found in other lymphoid tissues, the splenic MZ contains the largest accumula-
tion of this type of B-cells in the body. When the blood enters the MZ sinusoids, there is a 
considerable increase in fl ow area diameter, with a subsequent decrease in blood fl ow. Similar 
as in the red pulp, a sluggish fl ow results; this enables close contact between antigens and 
phagocytes or lymphoid cells, and between diff erent cell subtypes involved in the immune 
response (34,64).
Because the spleen is a major lymphoid organ, it also plays an important role in the primary 
humoral and secondary immune response. After encountering antigens in the MZ-sinuses, 
antigen-specifi c B-cells migrate to the LFs (36). From here they can either diff erentiate to pro-
duce antibodies (plasma cells) or to B-memory cells. The primary immune response is very 
important and can provide antibody production within 6 hours after the fi rst contact with 
an antigen. The MZ B-cells are particularly well-equipped for rapid and easy activation in a 
primary immune response (68). 
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The spleen is also of importance in the secondary immune response, since it especially pro-
motes the formation of memory cells of B- and T-lymphocytes (56,63). It is specifi cally involved 
in the immune response to TI-2 antigens. These antigens, generally polysaccharides, are the 
antigenic component of the capsule of encapsulated bacteria such as Streptococcus pneu-
moniae, Haemophilus infl uenzae and Neisseria meningitides. The immune response to TI-2 anti-
gens is characterized by the need of T-cell-produced factors, although it is independent of the 
actual presence of T-cells (71-73). After splenectomy, this response is signifi cantly decreased 
or even absent. The initiation of the response to polysaccharide antigens (TI-2 antigens) takes 
place in the MZ (74). In rodents, TI-2 antigens were found to localize specifi cally on antigen-
presenting cells in the MZ, and the elimination of MZ cells abrogated the immune response 
to such antigens (75). As described above, MZ B-cells have a distinct immunophenotype. By 
their high expression of CD21, the receptor for complement fragment C3d, MZ B-cells play a 
specifi c role in the immune response to TI-2 antigens, as these antigens are able to bind C3d 
(64,66). In this way, TI-2 antigen-C3d complexes can bind to, and activate, MZ B-cells (64,66).
Another special feature of the spleen is the generation of tuftsin, originating from the Fc-frag-
ment of IgG. This is a tetrapeptide reported to exert stimulatory eff ects on activity and migra-
tion responses of phagocytic cells (76,77).
Recently, Feleder et al. demonstrated a new function of the spleen, namely an antipyretic 
response to lipopolysaccharides (LPS) (78,79). They postulate that the spleen naturally limits 
the fever response by inhibiting the avidity of Kupff er cells to LPS. The latest data indicate that 
this inhibitory factor is a lipid produced by the spleen (79). A summary of the functions of the 
spleen is given in Table 1.
Table 1. Functions of the spleen.
White Pulp Red Pulp
Antibody production Filter function
Initiation of humoral response Phagocytosis (in particular to TI-2 antigens & badly-
opsonized particles)
Lymphocyte reservoir Reservoir of thrombocytes and immature erythrocytes
Hematopoiesis (fetal life, extramedullary hematopoiesis) Hematopoiesis (fetal life, extramedullary hematopoiesis)
Role in alternative complement pathway Inhibition of angiotensin converting enzyme
Iron reutilization
Tuftsin production
Positive eff ect on factor VIII
Lipid metabolism
Inhibition of LPS-induced fever
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1Consequences of splenectomy 
Although incidental reports mentioned a relationship between splenectomy and infection, 
it was not until 1952 that a causative association was reported between splenectomy (for 
congenital haemolytic anaemia) and the occurrence of meningitis with sepsis (7). Since then 
the increased risk of infection and septicemia directly related to splenectomy has been well 
defi ned in the literature. Such infections are now generally termed ”Overwhelming Post-Sple-
nectomy Infections” (OPSI). In most cases, the OPSI syndrome is caused by one of the fol-
lowing micro-organisms: Streptococcus pneumoniae (50%), Neisseria meningitides (12%), Esch-
erichia coli (11%), Haemophilus infl uenzae (8%) and Staphylococcus aureus (8%), but also by 
mycobacteria, viruses and parasites (80-84).
The frequency of OPSI is dependent on age and the cause of splenectomy. The highest fre-
quencies were found after thalassemia and Hodgkin’s disease and the lowest frequencies after 
trauma (85). Singer reported an overall frequency of 4.25% with a mortality of 2.52% (86). In 
patients who had had a splenectomy for traumatic splenic rupture the mortality due to sepsis 
was 0.58%; after thalassaemia, however, it was 11.0%. In the total population, the incidence of 
mortality due to sepsis was 0.01%. In a more recent review about OPSI in 12514 post-splenec-
tomy patients, under 16 years of age an OPSI frequency of 4.4% was found with a mortality 
of 2.2%, but for adults these Figureures were 0.9% and 0.8% respectively. Overall there was 
3.6% morbidity and 1.8% mortality. The highest incidence of OPSI is generally found in infancy 
and childhood. Patients who have undergone splenectomy for hematologic diseases, reticu-
loendothelial diseases or portal hypertension have a higher incidence than those undergoing 
splenectomy for trauma (80, 86-92). Most frustrating is the high overall mortality rate of OPSI 
of about 50% (56,80,81,85,93,94).
As indicated above, there is a signifi cant decrease in the primary immune response to bacte-
rial capsular polysaccharide antigens after splenectomy (80-82). These antigens belong to the 
group of TI-2 antigens, and other antigens of this type also give a similar decreased immune 
response after splenectomy (24,95). Another cause for the increased risk of OPSI is a decrease 
in phagocytic activity, in particular with respect to phagocytosis of poorly- or non-opsonized 
antigens. After a splenectomy, the phagocytic function will be partly taken over by the liver. 
However, the liver needs a higher level of antigen opsonization. This may present an important 
problem, especially with respect to TI-2 antigens, like encapsulated bacteria, which are badly 
opsonized (24), in particular because the spleen-dependent specifi c TI-2 antibody response 
is hampered. A lower phagocytic activity also results from decreased tuftsin concentrations 
after splenectomy (93,96).
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The general ability to generate a specifi c antibody response after the fi rst contact with blood-
borne antigen, the primary immune response is also reduced. This is consistent with a low pro-
duction of IgM after splenectomy (97-99). The alternative complement pathway also seems to 
be impaired after splenectomy, with normal functioning of the classical pathway.
After splenectomy, the ability of the body to fi lter the blood will be reduced, which results in 
an increase of erythrocytes with inclusions, like vacuoles and Howell-Jolly bodies and with 
surface pits, in the circulation (100,101). The ability to remove intracellular organisms, such as 
malaria and bartonella, is also reduced. The loss of splenic maturation for reticulocytes causes 
a high percentage of immature erythrocytes and reticulocytes in the blood stream (56).
Another less important impairment that can have consequences is a decreased reservoir func-
tion for blood cells. There will be an increase of platelets and a prolonged residence time of 
lymphocytes in the blood shortly after splenectomy. However, after a few months the platelet 
counts seem to be normalised (56). The eff ects of splenectomy in humans and animals are 
summarized in Table 2.
The pig spleen 
Aliter catuli longe olent, aliter sues. 
(Puppies and pigs have a very diff erent smell.)
Plautus (254 BC-184 BC) 
Since the experiments described in this dissertation are related to pig spleen transplantation, 
a short section on the pig spleen in relation to spleens from other mammals seems to be 
justifi ed.
Table 2. Eff ects of splenectomy.
Immunological Non-immunological
Reduced phagocytic activity of badly opsonized antigens Reduced fi lter function
Decreased tuftsin formation Increase of reticulocytes
Lower IgM serum level Thrombocytosis
Prolonged survival of lymphocytes in blood Increase in serum ACE
Reduced alternative complement 
pathway activity
lower HDL-cholesterol, higher triglyceride
Increased auto-antibody activity
Diminished numbers T-suppressor cells
Diminished antipyretic response to LPS
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1In comparison with the human spleen, the porcine spleen is a much longer (up to 1 meter in 
length), more fi sh-shaped organ, with an average weight of 8g/kg body weight, which is ap-
proximately 4 times more than a human spleen. The bright-red colored organ has a surface 
marbling produced by the prominence of the splenic copuscles. It has a more or less dorso-
ventral orientation (Figure 7A); its dorsal end fi ts between the fundus of the stomach, the 
cranial pole of the left kidney, and the distal pancreas; these relationships are not immediate 
as fat invariably intervenes. The spleen is more tightly attached to the stomach by the short 
Figure 7. 
A. Abdominal viscera of the pig, ventral view. From: Swindle MM. Comparative anatomy of the pig. Technical Bulletin SRC 2002.
B. The Abdomen of the pig. Left lateral view. From: Textbook of Veterinary Anatomy,3rd Ed. Dyce, Sack, Wensing (eds.) 2002, Elsevier, pp776-785. 
1, heart; 2, diaphragm, cut; 3, aorta; 4, caudal vena cava; 5, left lateral lobe of the liver; 6, greatly distended stomach; 7, greater omentum 
(gastrosplenic ligament); 8, spleen; 9, jejunum; 10, left kidney; 11, mass of ascending colon.
A
B
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gastric blood vessels and therefore is not as pedunculate an organ as it is in the dog (102). Its 
middle portion is in contact with the stomach and the intestine. When the stomach is moder-
ately full, the spleen lies opposite the last three or four ribs, and its ventral end crosses the cos-
tal arch or even the median plane. When the stomach is greatly dilated, the spleen is pushed 
to the vicinity of the last rib (Figure 7B). 
The accent of the diff erent functions of the spleen diff ers quite a bit in diff erent animal species. 
For example, the human spleen’s main function, besides its fi lter function, is the immunological 
defense of the body, whereas in the dog and horse, the spleen plays a major role in storage of cells 
and is less important as a lymphoid organ. The pig spleen plays an intermediate role between de-
fense and storage, but resembles the human spleen greatly. Histologically, there are no major dif-
ferences between the pig spleen and the human spleen (Houser SL, personal communication).
TRANSPLANTATION TOLERANCE 
Background
Fifty years ago, Dr Joseph Murray and colleagues performed the fi rst kidney transplantation 
in Boston, USA (103). They could not have imagined that organ transplantation is now con-
sidered one of the two or three most important advances in medicine to have been made 
in the twentieth century (104). How transplantation came to be a clinical discipline can be 
pieced together perusing two volumes of reminiscences collected by Paul I. Terasaki during 
1991-1992 from many of the persons who were directly involved. One volume was devoted 
to the discovery of the major histocompatibility complex (MHC), with particular reference to 
the human leukocyte antigens (HLA) that are widely used today for tissue matching (105). All 
of the contributions described in both volumes can be traced back in one way or the other to 
the demonstration more than a half century ago by Peter Brian Medawar that the rejection of 
allografts is an immunologic phenomenon (106, 107). 
Ten years later (1953) Billingham, Brent and Medawar (108) showed that tolerance to skin 
allografts could be induced by inoculating fetal or prenatal mice with immunocompetent 
spleen cells from adult donors. Because of their immunologic immaturity, the recipients were 
incapable of rejecting the spleen cells whose progeny survived indefi nitely. Specifi c unre-
sponsiveness to donor strain tissues was retained as the recipient animals grew to adult life, 
whereas normal reactivity evolved to third party grafts and other kinds of antigens. They and 
others (109-111) observed in animal models that siblings became permanent hematopoietic 
chimeras if fusion of their placentas existed in utero, allowing fetal cross-circulation; such ani-
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1mals permanently accept each other’s skin (112). It was predicted that this “natural chimerism” 
would induce tolerance to other donor-specifi c tissues and organs. 
However, they soon learned (113-115) in rodents that the penalty for infusing immunocom-
petent hematopoietic cells could be graft-versus-host disease (GVHD) unless there was a close 
genetic relationship (i.e., histocompatibility) between the donor and recipient. This was the 
beginning of modern transplantation immunology, an extensive history of which has been 
written by Brent (116), one of its principal architects. 
During the past three decades, enormous progress has been made in the fi eld of transplan-
tation, due in large part to the availability of eff ective immunosuppressive drugs. Although 
all of these agents suppress the immune response nonspecifi cally with respect to antigen, 
the most eff ective ones exhibit suffi  cient selectivity so that rejection can be avoided without 
undue compromise of the host’s ability to respond to microbial pathogens. Nevertheless, pa-
tients on immunosuppressive medications are constantly walking a tightrope between the 
consequences of too little suppression (i.e., rejection) and too much suppression (infections 
or cancer) of their immune system (117). In addition, even in patients without complications 
due to their immunosuppression, there is an inexorable loss of transplanted organs due to 
chronic rejection at a rate of approximately 5% per year (118).
For these reasons, ever since the description of acquired tolerance to allografts in mice by 
Medawar and colleagues appeared in 1953 (108), a major goal of both clinicians and immu-
nologists in the fi eld of transplantation has been the induction of donor-specifi c tolerance in 
transplant recipients.
Tolerance is long-lasting non-reactivity of the immune system to a specifi c set of antigens, 
maintained without ongoing immunosuppression. The key feature of the immune system is 
tolerance to self-antigens. In transplantation, the ultimate goal is tolerance to donor-antigens. 
What has been most frustrating about this quest has been the fact that a very large number 
of successful approaches to the induction of tolerance have been reported in rodent models, 
but have failed when attempted in large animals, especially in nonhuman primates and in 
humans (Table 3). Indeed, as clinical results of organ transplants using standard immunosup-
pression are so good, at least in the short-term, most clinicians are no longer interested in 
testing new approaches to tolerance induction unless their eff ectiveness has already been 
demonstrated in large animal models.
But why should there be such a diff erence in the ability to induce tolerance in mice versus 
large animal species? Since it is much easier and far less expensive to carry out experiments 
in mice than in large animals, an answer to this question could have important practical as 
well as theoretical implications. Adams et al. (119) demonstrated that sequential exposure 
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to sublethal infections by certain pathogenic viruses makes mice more resistant to tolerance 
induction by a protocol previously shown to result reproducibly in mixed chimerism and tol-
erance in mice (120). Assays for alloantigen-primed T cells in vitro following viral exposure 
confi rmed that the priming led to cells with specifi city cross-reactive between the pathogens 
and the allogeneic cells, a hypothesis, which, as they point out, has been proposed before as 
a possible reason for the frequent association of clinical rejection episodes with intercurrent 
viral infections (121).
On the other hand, the implications of these studies for the more general question of why 
it is more diffi  cult to induce tolerance in large versus small animals, are not entirely clear. In-
deed, the induction of tolerance through mixed chimerism is one of the few methodologies 
(Table 3) that has been shown to work not only in mice, but also in large animals (122,123) and 
most recently in humans (124,125).
Furthermore, the most obvious diff erence between small and large animal species with re-
gard to tolerance induction is in the response to vascularized organ allografts (126). Skin graft 
survival is the hardest to prolong (127) unless the grafts are placed after a vascularized graft 
from the same donor strain, which suggests that vascularized grafts are themselves tolero-
genic (128). Thus, studies utilizing a protocol for induction of tolerance to a vascularized organ 
allograft are needed for answering this general question.
Among the diff erences between rodents and large animals that have been suggested to ac-
count for this discrepant behavior in response to vascularized grafts are the markedly diff er-
ent tissue expression patterns of class II MHC antigens (129). These antigens, which are the 
most potent stimulators of the helper pathway in rejection reactions, are notably absent from 
Table 3. Methods that have induced transplantation tolerance.
Method Mice Large animals and humans
Enhancement + -
DST + -
Peptides + -
Anti-MHC mAb’s + -
Calcineurin inhibitors + -
ALS + -
Anti-CD24 + -
Anti-CD25 + -
Total lymphoid irradiation + +/-
Anti-CD3 toxin + +/-
Costimulatory blockade + +/-
Chimerism + +
ALS=anti-lymphocyte serum; DST=donor-specifi c transfusion
From: Sachs DH. Tolerance: of mice and man. J Clin Invest 2003;111:1819-1821.
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1the vascular endothelial cells of rodents, but expressed constitutively in all large animals that 
have been studied, including humans. Indeed, in the Transplantation Biology Research Center 
at the Massachusetts General Hospital in Boston, USA, it has been shown, using intra-MHC 
recombinant lines of pigs, that matching for class II antigens permits uniform induction of 
tolerance to renal allografts by a short course of cyclosporin (130), one of the many methods 
that allows tolerance induction to vascularized organ allografts in mice across full MHC bar-
riers (Table 3). The importance of an intact thymus to the induction of tolerance by this route 
has also been demonstrated (131), something that is markedly aff ected by age, stress, drugs, 
and infection - all of which may also be relevant to the diff erence between large and small 
animal models.
Rejection
Graft rejection occurs as a consequence of polymorphisms in histocompatibility genes, 
primarily those located within the MHC (132). T cells respond to foreign (allogeneic) MHC 
molecules in the same fashion as to any foreign protein: they secrete cytokines, divide, and 
diff erentiate (133). This generates a large population of activated eff ector cells, primarily T 
cells and macrophages, which are the primary mediators of graft destruction. Alloreactive 
T cells can recognize antigens present in transplanted tissues by 1 of 2 distinct pathways. In 
the direct pathway, the responding T cells recognize intact allogeneic MHC molecules on the 
surface of donor-derived antigen presenting cells (APCs), whereas in the indirect pathway, 
recipient APCs process donor-derived allo-MHC molecules into peptides and then present 
those peptides to T cells on self-MHC molecules. It is generally accepted that the direct path-
way predominates in the immediate aftermath of transplantation, when graft-resident APCs 
(passenger leukocytes) migrate to the surrounding lymphoid tissue, where they stimulate al-
loresponsive T cells. As donor-derived APCs are relatively short lived, the indirect pathway of 
allorecognition is generally believed to predominate as the alloresponse progresses (134). 
Central versus peripheral tolerance
Experimental methods to induce transplantation tolerance are typically divided into 2 catego-
ries. “Central” tolerance refers (in most instances) to the use of BM transplantation as a means 
to induce hematopoietic chimerism (135). This results in the coexistence of donor- and recipi-
ent-derived lymphoid and myeloid cells. As a result, developing T cells that are donor-reactive 
are deleted before they can exit the thymus, in the same manner as self-reactive T cells (136). 
“Peripheral” tolerance refers to the use of antibodies (or occasionally pharmacologic agents) 
that block or modulate T cell activation or growth factor receptor pathways in mature T cells. 
In most instances, this has the net result of promoting apoptosis among the T cells that are 
responding to alloantigens (137). 
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An important characteristic of alloimmune responses is the high frequency of T cells that are 
able to recognize and respond to alloantigens (primarily the products of genes encoded with-
in the MHC) (138). Because of this, and based on data from studies on rodent models, many 
investigators believe that it is necessary to achieve large-scale deletion of alloreactive T cells 
in order to create transplantation tolerance (137). Both central and peripheral tolerance strat-
egies achieve this during the early “induction” phase of therapy (i.e., the fi rst 1–2 weeks after 
transplantation). In the case of central tolerance, this alone appears to be suffi  cient, as newly 
developing T cells with potential anti-donor reactivity will be eliminated within the thymus 
following encounter with donor-derived cells (135,136). However, in the case of peripheral 
tolerance strategies, a large body of data derived from experimental animals suggests that 
following depletion, the “maintenance” phase of tolerance requires regulatory T cells (Tregs) 
that can act on both any remaining alloresponsive T cells and on new thymic emigrants (Fig-
ure 8). 
TRANSPLANTATION TOLERANCE IN THE CLINIC?
There are two major problems in the fi eld of clinical transplantation. First, although short-
term graft survival rates have been improved, these have not been accompanied by improve-
ments in long-term outcomes (139). Accompanying the problem of late graft loss are the 
complications of continual immunosuppressive therapy, which include markedly increased 
Figure 8. From Walsh PT, Taylor DK, Turka LA. J Clin Invest. 2004; 114: 1398–1403.
Deletional strategies employed at or around the time of transplant reduce the number of potentially alloreactive T cells (eff ector T cells) and 
facilitate the action of Treg subsets. During the maintenance phase of tolerance, these Tregs, either naturally-occurring or induced, can thus act 
more effi  ciently on a greatly reduced number of eff ector T cells. Cell number, as denoted on the y axis, represents an illustration as to how the 
relative ratio of eff ector versus Treg subsets alters during the establishment of transplant tolerance. 
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1risks for cardiovascular disease, opportunistic infections, and malignancy. Secondly, there is 
the problem of the organ shortage. For those without living donors, waiting times for renal 
transplantation can exceed 5 years, although they can be maintained with dialysis. Since a 
chronic substitute for heart, lung or liver function is not available, in the year 2003 more than 
2700 patients in the USA alone died, waiting for transplants. 
Therefore, transplantation research has been focused on designing eff ective ways to induce 
transplantation tolerance. Tolerance would improve graft outcome, obviate the need for 
chronic immunosuppression, and expand the supply of donor organs (140). Given the recent 
experimental evidence for tolerance induction through a number of strategies, such as co-
stimulation blockade, lymphocyte depletion and chimerism (141,142), the next problem is 
how to move these fi ndings to the clinic. The dilemma arises of how to test new approaches 
in patients for which there is already exists a therapy that is successful in the short-term. One 
option is to test tolerance-inducing strategies by adding them to the existing immunosup-
pressive drug combinations. But then how could one distinguish tolerance from global im-
munosuppression? There is also concern that many tolerance-inducing strategies would be 
inhibited by the present regimen of immunosuppressive agents (143, 144).
There are several possible solutions. The fi rst trials might aim to induce partial tolerance, and 
require that patients continue on at least one well-tested immunosuppressive agent (145). In 
a recent study, the CD52 antibody alemtuzumab (CAMPATH-1H) was given peri-transplant to 
partially deplete T cells and B cells in recipients of cadaveric kidney grafts (146). Patients were 
then maintained on monotherapy with half-dose CyA. The alemtuzumab induction allowed 
satisfactory long-term patient and graft survival equivalent to that seen with standard triple 
immunosuppression, while avoiding steroid therapy (146,147). From the patient’s viewpoint, 
a steroid-free regimen with the security of a small dose of CyA, may be more acceptable than 
the immunologists’ dream of tolerance.
It may also be possible to initially test tolerance induction therapies in patients for whom 
conventional immunosuppressive therapy is not eff ective, such as organ recipients that have 
been previously sensitized to donor antigens from blood transfusions or from previous failed 
transplants. This diffi  cult setting off ers one ‘ethical’ outlet for trials of new therapeutic strate-
gies, although it would be diffi  cult to determine, should graft rejection occur, whether failure 
is due to the experimental therapy, or the diffi  culty of imposing tolerance on a primed im-
mune system.
At the Massachusetts General Hospital in Boston, USA, a study was initiated for the induction of 
renal allograft tolerance in patients with multiple myeloma and consequent kidney failure with 
the idea that concomitant BM transplantation may not only allow establishment of immuno-
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logical tolerance, but might also produce a ‘‘graft-versus-myeloma’’ eff ect. The protocol used for 
tolerance induction was derived from rodent studies (148,149), and was translated into clinical 
studies for the treatment of patients with hematological malignancies without further treat-
ment options, and the low toxicity and relatively low incidence of GVHD of this mixed chime-
rism approach was thereby confi rmed in a clinical setting (150,151). The protocol was extended 
to myeloma patients with end-stage renal failure, a patient group that is usually not considered 
for BMTx due to poor general health. The tolerance protocol includes cytoreductive treatment 
with cyclophosphamide, T cell depletion with ATG and 7 Gy thymic irradiation followed by com-
bined renal allograft and BM transplantation from the same HLA-identical related donor with 
a very short course of post-transplant CyA (approximately 60 days). In total, six patients have 
been treated so far, with a follow-up period between 2 months and 5 years. Four of these pa-
tients have been transplanted under a protocol sponsored by the Immune Tolerance Network 
(ITN). All six patients achieved initial macrochimerism. Results have been published on the two 
initial patients (not on the ITN protocol), in whom tolerance has been achieved at 3.5 and 5.5 
years of follow-up (124,125). These initial results provide proof of principle that tolerance can 
be intentionally achieved in patients using combined simultaneous nonmyeloablative BMTx 
and kidney transplantation. Further details of the ITN study will be published soon.
This protocol was used as the basis for another ITN clinical tolerance protocol for combined 
kidney/BM transplantation in haploidentical transplant recipients without hematological ma-
lignancy. While only recently initiated, preliminary results of this trial are encouraging.
Diligent patient monitoring should also be included in tolerance clinical trials, to detect any 
signs of graft rejection at the earliest possible stage, and to allow rescue therapy with conven-
tional drugs to prevent organ damage. The availability of surrogate biomarkers of rejection or 
tolerance, preferably blood-borne, would enable better monitoring and individual tailoring 
of pharmacological and biological therapies. Traditional functional responses such as mixed 
lymphocyte reaction or cytotoxic T-lymphocyte assays, or even their limiting dilution equiva-
lents, are labor-intensive and are not sensitive enough to adequately predict whether or not a 
patient has become tolerant to the graft. It is thus imperative for immunologists to defi ne sets 
of biomarkers as diagnostics for graft rejection or acceptance.
In the end, the ideal tolerance-inducing strategy may be one that involves multiple approach-
es. The present regulatory requirements make it unlikely that a tolerance-inducing strategy 
can be licensed for use before safety and effi  cacy are demonstrated. If that strategy is only 
eff ective in combination with another agent, then the chances for its development are dimin-
ished. Additional complications arise because a successful tolerance-inducing regimen may 
require administration over only a short time. As a result, the profi t margin to a pharmaceutical 
may be smaller than it is for immunosuppressive therapies. If for this and the preceding com-
mercial reasons, pharmaceutical companies are unable to progress with tolerance-induction 
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1studies, it will be up to academic or health-service-based manufacturing facilities to develop 
these strategies. Establishing tolerance induction as a viable alternative for immunosuppres-
sion after organ transplant is, however, a reasonable goal that can be achieved through coop-
eration between basic and clinical researchers, regulatory authorities and industry.
THE MASSACHUSETTS GENERAL HOSPITAL MINIATURE SWINE MODEL
I like pigs. Dogs look up to us. Cats look down on us. Pigs treat us as equals.
Sir Winston Churchill (1874 - 1965)
Swine, Sus scrofa domesticus, are widely used in medical research. Most of the animals are 
small domestic farm breeds, but miniature swine are widely used for chronic studies where 
the signifi cant growth of the domestic breeds would be an issue. They share anatomic and 
physiologic characteristics with humans that make them a unique and viable model for bio-
medical research. The cardiovascular anatomy, physiology and response to atherogenic diets 
have made them a universally standard model for the study of atherosclerosis, myocardial 
infarction and general cardiovascular studies. Their gastrointestinal anatomy has some sig-
nifi cant diff erences from that of humans; however, the physiology of their digestive processes 
has made them a valuable model for digestive diseases. The urinary system of swine is similar 
to humans in many ways, especially in the anatomy and function of the kidneys. Swine are 
also a standard model for skin and plastic surgical procedures and have been developed as 
models of transdermal toxicity. The anatomy and physiology of organs such as the liver, pan-
creas, kidney and heart have also made this species the primary species of interest as poten-
tial organ donors for xenotransplantation. All swine commonly used in research are Sus scrofa 
domesticus, whether they are farm or miniature breeds. The main diff erence between breeds 
is size at sexual maturity. Domestic breeds typically reach 100 kg by 4 months of age and min-
iature breeds typically range from 25-50 kg at the same age (152) (Figure 9).
The MGH miniature swine herd was developed for studies of transplantation biology and has 
been selectively inbred at the MHC, termed Swine Leukocyte Antigens (SLA) in swine, and in-
tentionally outbred for minor antigens, although one strain is available with near-compatibil-
ity for minor antigens also (153,154). Three independent MHC alleles derived from the found-
ing breeding pair are maintained, as well as four additional intra-MHC recombinants, which 
have been recognized and subsequently bred to homozygosity (Figure 10). These animals 
exhibit many physiologic and immunologic similarities to humans, including MHC class II ex-
pression on renal endothelium, and they provide a large animal model that allows transplant 
combinations approximating most relevant human transplants. 
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Of relevance to the present studies is that kidney allografts (but not heart allografts) between 
MHC two-haplotype class I-mismatched pigs that receive a 12-day course of cyclosporine A 
(CyA) are uniformly accepted (155). A subsequent kidney allograft, matched to the original 
donor, will be accepted long-term without the need for further immunosuppressive therapy 
(156). Furthermore, a successfully transplanted kidney induces tolerance to a donor-specifi c 
or donor-matched (i.e., class I-mismatched to the recipient) heart allograft transplanted at the 
same time, whereas the heart, if transplanted in the absence of a kidney (but with a 12-day 
Figure 10. Schematic diagram of the origin of available homozygous porcine MHC (SLA) haplotypes. 
Partially inbred SLAaa, SLAcc, and SLAdd haplotypes were derived from the original founder miniature swine. Recombination events between the MHC 
class I and class II haplotypes have been identifi ed and maintained as homozygous, recombinant haplotypes SLAff , SLAgg, SLAhh, SLAjj, and SLAkk.
 
Figure 9. MGH miniature swine, 4 months old, weighing 25 kg.
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1course of CyA), is rejected within 55 days (33-55 days) and begins to develop chronic allograft 
vasculopathy (CAV) after 4 weeks (155). The mechanism whereby the kidney induces toler-
ance to the heart remains uncertain, though both passenger leukocytes and parenchymal 
cells appear to play a role (157). The tolerogenic eff ect of the kidney is not due to antigen 
load alone since the transplantation of two (matched) hearts, although resulting in long-term 
graft survival (>190 days), does not prevent CAV from developing (158). There is evidence that 
peripheral blood lymphocytes (PBL) from tolerant animals, when primed in vitro with donor 
antigen, suppress antidonor cytotoxic T cell reactivity by naïve recipient-matched PBL (159). 
The suppression is cell dose-dependent, radiation-sensitive, and requires cell-to-cell contact, 
suggesting that the presence of peripheral regulatory cells plays a role in the induction of 
tolerance. Antigen-specifi c regulation of the IL-2α expression on CD8 single-positive PBL is 
thought to be an important event associated with the development of this tolerance (160).
However, kidney Tx across a class I disparity is not successful in older swine (> 55 months), 
presumably because the thymus is involuted (161). The potential clinical approach of trans-
planting a kidney in order to induce tolerance to a heart (even if it is considered justifi ed 
to transplant a kidney solely for this purpose) is therefore unlikely to be applicable in adult 
patients. The importance of the thymus in this model has been confi rmed by Yamada and his 
colleagues (162-164). Prior thymectomy abrogates both survival of the kidney and its protec-
tive eff ect on the heart (163). In euthymic recipients, there is an initial cellular infi ltration in 
the renal graft that, between 30-60 days, diminishes and is associated with T cell apoptosis, 
associated with tolerance induction, whereas in thymectomized recipients the infi ltrate per-
sists with activation and proliferation, resulting in rejection (165,166). Tx of vascularized donor 
thymic tissue with the kidney in a thymectomized host is followed by graft survival and toler-
ance (164). In view of the involution of the the thymus relatively early in life, any approach that 
involves the Tx of thymic tissue may have a limited clinical role. 
Of relevance to this thesis is that the induction of hematopoietic cell chimerism by a nonmy-
eloablative regimen and BM transplantation allowed subsequent (5-12 months later) kidney 
(167,168) or cardiac (169) Tx to be performed successfully over a minor antigen barrier in the 
absence of immunosuppressive therapy. Cardiac transplantation perfomed across this barrier 
in untreated recipients resulted in rejection within 44 days (21-44 days), whereas survival was 
>153 days (>153 - >362 days) in the chimeric recipients. No CAV or GVHD was seen.
If immunosuppression is with CyA for 12 days, a renal allograft across a two-haplotype full 
mismatch is rejected (170). Kidney graft survival can be achieved across this barrier if tacroli-
mus is continuously infused (for 12 days) to maintain trough levels of >35 ng/ml (170), but this 
level may not be clinically applicable. When a level of even 20-26 ng/ml is maintained, chronic 
allograft glomerulopathy develops. In vitro assays demonstrated that PBL from tolerant pigs 
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produce inhibitory cytokines, suggesting the involvement of regulatory mechanisms. It is not 
known whether a fully-mismatched kidney allograft is tolerogenic to a donor-specifi c or do-
nor-matched heart graft. It is not yet known whether an isolated heart allograft across a full 
mismatch will be rejected if immunosuppression is with CyA for 12 days, but the fact that CyA 
does not prevent graft failure over even a MHC class I barrier indicates that it would not protect 
against a full MHC barrier. Studies are continuing to investigate the effi  cacy of tacrolimus over 
a full MHC barrier; preliminary data suggest that it will be inadequate to prevent rejection.
The above studies in MGH miniature swine previously performed at the Transplantation Biol-
ogy Research Center of the Massachusetts General Hospital / Harvard Medical School, Boston, 
USA, will act for comparison in our studies of spleen allotransplantation.
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The three ways of success: persistence, persistence, persistence.
T.R. Roosevelt (1858-1919)
AIMS OF THIS DISSERTATION
The ultimate goal in clinical allotransplantation and xenotransplantation is to achieve donor-
specifi c immunological tolerance or long-term unresponsiveness to the transplanted organ in 
the absence of continuing immunosuppressive therapy. This would allow long-term graft sur-
vival of the organ without the risks and complications of pharmacologic immunosuppressive 
therapy. A novel approach to achieving this aim may be through spleen transplantation. 
In Aim #1, we shall attempt to establish a relevant pre-clinical large animal model for spleen 
transplantation in Massachusetts General Hospital MHC-defi ned miniature swine. 
In Aim #2, the pathobiology of spleen graft rejection and acceptance will be determined in 
the miniature swine model.
By spleen transplantation in MHC-matched (minor-mismatched), MHC-Class I-mismatched, or 
fully-MHC-mismatched donor-recipient combinations carried out with a short course of im-
munosuppressive therapy, we shall: 
- attempt to induce prolonged hematopoietic cell chimerism and monitor recipients for pos-
sible graft-versus-host-disease (Aim #3). 
- investigate whether recipients of spleen allografts exhibit in vitro cellular donor-specifi c un-
responsiveness and/or long-term spleen allograft survival (Aim #4). 
- determine which immunosuppressive regimen would be optimal for tolerance induction 
using spleen transplantation in miniature swine (Aim #5).
In Aim #6 we shall assess whether successful MHC-mismatched spleen transplantation, with 
or without the induction of mixed chimerism and/or in vitro cellular donor-specifi c unrespon-
siveness, is tolerogenic and allows subsequent successful transplantation of a donor MHC-
matched kidney without further immunosuppressive therapy, and by which mechanism such 
tolerance or unresponsiveness is induced.
In Aim #7, the spleen shall be investigated as a source of hematopoietic progenitor cells or 
stem cells. 
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In Aim #8, preliminary information will be obtained on whether there is likely to be a role for 
spleen transplantation in the induction of tolerance in discordant xenotransplantation in a 
pig-to-baboon transplantation model. 
In Aim #9, possible complications of spleen transplantation or the immunosuppressive regi-
men will be identifi ed and described. 
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ABSTRACT
In some rat and guinea pig strain combinations, transplantation of an allogeneic spleen has 
been demonstrated to induce tolerance spontaneously to itself and to another donor-specifi c 
organ; prior irradiation of the recipient results in graft-versus-host disease (GVHD). In other 
combinations, following spleen transplantation (SpTx), a state of tolerance has been achieved 
when the recipient’s immune system has been weakened, e.g., by a pharmacologic agent, ir-
radiation, or native splenectomy. The data indicate that, if a balance can be achieved between 
the host-versus-graft and graft-versus-host responses, tolerance develops, possibly due to the 
development of suppressor/regulatory cells. There have been a number of unsuccessful stud-
ies in large animals, but none in which knowledge of the major histocompatibility complex 
of the donor and recipient has been known. SpTx has been performed in approximately 50 
humans for a number of reasons; no clear immunologic advantage has been reported. GVHD 
has been documented in at least three patients, and was lethal in one despite excision of the 
donor spleen. In 23 of 30 patients whose blood was exposed extracorporeally to a pig spleen 
for a matter of hours in the treatment of sepsis, porcine microchimerism has been detected 
at follow-up two months to eight years later. The advantages of tolerance over chronic immu-
nosuppressive therapy are so great that an approach that has tolerogenic potential, such as 
SpTx, would seem worthy of further investigation in a suitable large animal model.
INTRODUCTION
The induction of donor-specifi c transplantation (Tx) tolerance without long-term immuno-
suppressive therapy is the ultimate goal in both alloTx and xenoTx. The spleen has long been 
recognized as potentially tolerogenic and, in some species, can act as a source of hematopoi-
etic cell restoration. 
Carrel was probably the fi rst to explore experimental spleen autoTx in 1910 (1). The possibil-
ity of the transplanted spleen contributing to a state of neutral reactivity, a balance between 
the host-versus-graft reaction and the graft-versus-host (GVH) reaction, was emphasized by 
Simonsen in 1953 (2). The concept of hematopoietic restoration by the intact spleen following 
whole body irradiation (WBI) fi nds its basis in the work of Jacobsen (3,4), in which shielding 
of the spleen from lethal WBI resulted in hematopoietic cell restoration and clinical survival 
of rodents. 
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SPLEEN TRANSPLANTATION IN RODENTS
Rats
Spontaneous development of tolerance (Table 1A)
With the development of the techniques for SpTx in rodents (5-10), Bitter-Suermann described 
spontaneous survival of vascularized spleen allografts in certain major histocompatibility 
complex-incompatible rat strain combinations (11). The spleen conferred a state of specifi c 
tolerance upon the recipient, as judged by subsequent skin and pancreas allograft survival 
(12-14). Spleen grafts, which were usually accepted, were rejected if the donor had been sub-
lethally-irradiated prior to Tx. The graft induced lethal graft-versus-host disease (GVHD) if the 
recipient had received a similar dose of WBI. This observation pointed to immunological com-
petence of both graft and host as a prerequisite for the successful induction of this type of Tx 
tolerance (12). The recipient would die of GVHD if the donor had been actively pre-sensitized 
by injections of spleen and thymus cells from the recipient before SpTx, or if the recipient had 
undergone native splenectomy immediately before SpTx (14). 
Although prolongation of survival of a transplanted pancreas occurred when the spleen was 
included en bloc with the pancreas, 50% of the recipients developed GVHD and died (15,16). 
Prior donor-specifi c blood transfusion and a 26-day course of cyclosporine therapy prevented 
GVHD and was followed by indefi nite pancreas-spleen graft survival (16). If a spontaneously-
accepted WAG-to-AGUS rat spleen allograft was removed after 3-5 months, and only at that 
time was a pancreas allograft inserted, 68% of these grafts survived.
Subsequent transplanted organs or tissues from the same strain as the spleen donor survived 
indefi nitely if transplanted 6 weeks to 5 months after SpTx or together with the spleen graft. 
This proved to be the case even if the spleen graft had atrophied or had been surgically re-
moved by this time (11,17). 
In studies by others, however, although the transplanted spleen was not rejected, its presence 
did not lead to prolonged survival (or tolerance) of a donor-specifi c skin graft and, indeed, in 
some studies there was evidence of sensitisation (18). Early studies by Bitter-Suermann et al. 
showed no eff ect on solid organ survival by the injection of donor-strain splenocytes into the 
recipient (19). This discrepancy with the results obtained following SpTx has been explained 
by the observation that the preparation of a single cell suspension not only disrupts the ar-
chitecture of the organ but also alters the proportion of cellular elements to be transferred 
(7,11). There have been several studies by others with varying outcome (20-22), but these will 
not be reviewed here.
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Induction of tolerance by immune manipulation (Table 1B)
When AGUS recipients were pre-treated with a mixture of spleen, thymus, liver, and blood cells 
from PVG donors, administered intravenously 8-22 days prior to SpTx, 72% of the spleen grafts 
survived longer than four months, in contrast to spleen allografts in non-prepared recipients 
where survival was approximately three weeks (23,24). Skin allografts in naïve recipients sur-
vived approximately eight days, whereas AGUS rats bearing successful long-term spleen al-
lografts accepted subsequent skin allografts permanently. Even after removal or late atrophy 
(‘absorption’) of accepted spleen allografts, the rats remained tolerant to skin allografts. Two 
rats accepted skin that had been grafted four months after the spleens had been ‘absorbed’ 
Table 1A. Organ transplant survival after spleen transplantation in rats without immunosuppression
First Author Rat strains Organ Tx with spleen Organ survival Reference 
Bitter-Suermann PVG->AGUS skin 8d Nature 1974;247: 465-466
AGUS->VG skin >3m
Wistar->AGUS skin >4-5m
Taub (LewisxBN)F1 kidney 5m Proc Eur Dial Transplant
Assoc 1976;12:423-428
Tilney Aug->(As x BN)F1 skin with 
presensitized
7d J Surg Res 1977;22:54-58
spleen isografts
Aug->(LewisxBN)F1 skin with 
presensitized
7d
spleen isografts
Bramis (LewisxBN)F1->Lewis kidney >90d Transplant Proc 1977;9;1:341-346
skin >72d
Bitter Suermann WAG->AGUS pancreas indefi nite Transplantation 1978;26:28-34
Blanchard ACI-> Lewis heart 9d J Microsurg 1980;1:381-386
Lewis -> ACI heart 20d 
Shah WAG -> AGUS pancreas 4-10m Transplantation 1980;30: 83-89
Gugenheim (LewisxBN)F1->Lewis skin 9d Transplantation 1983;36:470-471
Blanchard ACI -> Lewis kidney 17d J Microsurg 1985;6:26-31
Lewis -> ACI kidney 93d
Gray Lewis->DA islets <14d (3) J Surg Res 1986;40:77-84
>100 (3)
Schulak Fischer->Lewis pancreas 18d Transplant Proc 1987;29:1013-1014
LBN->Lewis pancreas 11d
ACI->Lewis pancreas 7d
Duncan (WAGxAGUS)F1->AGUS heart (WAG) >100d Transplantation 1987;44:553-558
Wakely Lewis->BN pancreas >12d Transplantation 1990;49:241-245
BN->Lewis pancreas 11d
Pirenne BN->Lewis small bowel 23d Transplant Proc 1993;25:1206
Suzuki ACI->DA skin indefi nite Transplantation 1997;64:650-654
Takano Wistar (P->F1) skin (P) 80% 1-2w Transplant Proc 1998;30:2685-2686
d=days, w=weeks, m=months, P=parent, F1=fi rst off spring
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(after remaining viable for fi ve months after grafting), demonstrating that persistence of a vi-
able spleen graft was not essential for skin graft survival in this model. The mechanism of the 
prolonged survival of the spleens in these pretreated rats was uncertain. 
Although confi rmatory studies have been reported, not all subsequent investigators have 
confi rmed the ability of a splenic allograft to induce tolerance or prolonged hyporesponsive-
ness.
Mice
In mice, the age of the spleen donor was not found to be a major infl uence on outcome of 
SpTx (25). SpTx has also been utilised to study the anemia of chronic infl ammation (26).
Guinea pigs
Spontaneous development of tolerance
Based on Billingham’s previous conclusions regarding bone marrow Tx, Bitter-Suermann et al. 
concluded from their rat studies that a spleen graft could launch and sustain GVH reactivity 
Table 1B. Organ transplant survival after spleen transplantation in rats with host immunosuppression or immunomodulation
First Author Rat strains Organ Tx with spleen Immunosuppression/
Immunomodulation
Organ survival Reference
Tauber Lewis->ACI heart Delayed SpX d3 indefi nite J Microsurg 
1981;2:261-268
Gray Lewis->DA islets CyA 10 mg/kg for 14d Indefi nite J Surg Res 
1986;40:77-84
Pollak Lewis->ACI heart Delayed SpX d3 indefi nite Transplantation 
1986;42:528-531
Wakely Lewis->BN pancreas DST on d-7 10d Transplantation 
1990;49:241-245
Lewis->BN pancreas DST on d-7 >143d
CyA for 26d
Westra BN->Lewis heart CyA 25 on d2 >100 d Transplantation 
1991;52:952-955
Pirenne BN->Lewis small bowel CyA on d2 52d Transplant Proc 
1993;25:1206
Suzuki Lewis->Fischer344 skin Tacrolimus for 14d indefi nite Transplantation 
1997;64:650-654
Hakamata Wistar->Lewis pancreas Tacrolimus for 14d 21d Biochem Biophys 
Res Commun 2001; 
286:779-785
CyA= Cyclosporine A, SpX= host splenectomy, WBI=whole body irradiation, DST=donor-specifi c blood transfusion
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when (a) graft and host diff ered at major or minor histocompatibility loci, (b) the graft con-
tained immunocompetent cells, and (c) the host was immunoincompetent, either for a genet-
ic reason, from age, or because of exogenous immunosuppression (19,27). Bitter-Suermann 
and Shevach, however, observed that a majority of untreated guinea pigs (of strain 2) under-
going SpTx (from strain 13) succumbed to GVHD approximately six weeks after Tx, which was 
not in accordance with the third prerequisite above (19). The recipients were immunocom-
petent and not immunosuppressed but, after receiving a spleen allograft, they behaved as if 
exogenously immunosuppressed. These authors believed this to be the only animal model in 
which an allograft induced lethal GVHD in a healthy immunocompetent host quite capable of 
rejecting an organ transplant from a third party donor.
Mechanism of tolerance induction
In guinea pigs with long-term surviving spleen grafts, the response against the donor was 
markedly suppressed in the mixed lymphocyte reaction (MLR). Furthermore, cells were pres-
ent in the tolerant spleen recipients that were capable of suppressing the MLR response of 
normal host-strain cells towards donor-strain cells (28), although the period of MLR hypore-
sponsiveness was rather short-lived. Donor-strain cardiac allografts survived indefi nitely in 
immunologically-uncompromised recipients that had received passive transfer of cells from 
guinea pigs with long-standing spleen transplants. The presence of the cardiac graft further 
enhanced MLR suppression, whereas most cardiac-allografted controls had vigorous MLR re-
sponses to donor-stimulated cells after rejection of their cardiac transplants.
There was some discrepancy between the in vivo and in vitro data. A number of recipients 
of spleen allografts had markedly suppressed MLR responses, and their cells were uniformly 
capable of transferring tolerance in vivo but did not show adoptive MLR suppression in vitro. 
In vivo tolerance could be transferred by cells taken from animals four weeks after spleen al-
lografting, a time when the activity of the MLR ‘suppressor’ cells was not prominent in vitro 
(29,30). 
These experiments suggested the presence of regulatory cells capable of transferring MLR 
unresponsiveness and Tx tolerance to normal hosts, although it was not determined whether 
the cells involved were of recipient or graft origin. The state of unresponsiveness, favouring 
the survival of second donor-strain allografts, appeared to be weak during the fi rst few weeks 
after SpTx. Skin allografts, for example, did not survive if placed earlier than 6-8 weeks after 
SpTx (13,31). 
Following SpTx in rats, unresponsiveness developed as early as one week (32-35). T cells ob-
tained from the recipient’s lymph nodes and native spleen exhibited reduced MLR to donor-
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strain cells, but responded normally to third party cells. In contrast, T cells obtained from 
the spleen graft were unresponsive to both donor and third-party stimulators. Therefore, al-
though donor-specifi c T suppressor cells appeared in the recipient’s lymph nodes and spleen 
within one week of SpTx, at this time antigen-nonspecifi c suppressor cells predominated in 
the spleen graft. Only minimal cytotoxic T cell activity could be detected in the spleen graft, 
with the host spleen and lymph nodes being devoid of cytotoxic T lymphocytes. Sera ob-
tained one or two weeks following SpTx did not contain cytotoxic antibodies, and only a very 
weak response could be detected at one month. 
SPLEEN TRANSPLANTATION IN LARGE ANIMALS
Apart from one early report of implantation of an allogeneic spleen in the peritoneal cavity in 
chickens (36), all reports have been in dogs or pigs. 
Allotransplantation in dogs (Table 2A)
In the early 1960s, several groups performed SpTx in dogs, with comparable results (Table 2A). 
Spleens transplanted into untreated recipients underwent rejection within a few days. Mar-
chioro et al documented a viable spleen graft after 200 days in a dog treated with azathioprine 
for only the fi rst 125 days (37). Prior treatment of the recipient with WBI (150-300 cGy) protected 
the spleen from rejection (37), but produced a more pronounced GVH response, with anemia, 
thrombocytopenia, and lymphocytopenia (38). Protecting the spleen from lethal WBI did not 
result in survival, but an intravenous (unirradiated) homogenate of the native spleen did (39). 
Eff ects of SpTx on a concomitantly-transplanted donor-specifi c organ (Table 2B)
In untreated dogs, the simultaneous Tx of spleen and kidney from the same donor prolonged 
survival to 20 days, compared with 11 days when the kidney was transplanted alone (37). 
Azathioprine therapy could prolong graft survival for from 2 to 7.5 months at which time, 
although the kidneys showed signs of chronic rejection, the splenic architecture remained 
normal (37). Administering WBI (100-450 cGy) to the recipient prior to SpTx resulted in hemo-
lytic anemia in 8 of 12 dogs, which required repeated blood transfusion, and yet provided no 
protection to the renal allografts (37). Although the survival of renal allografts was prolonged 
when combined with simultaneous native splenectomy and SpTx, these animals developed 
a wasting disease, characterized by anorexia, weight loss, occasionally bloody diarrhea, and 
anemia, suggesting a GVH reaction, several of them dying from infection. Others have not 
found SpTx to be benefi cial to survival of a second donor-specifi c organ. 
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Hoff man et al (40) reported that immunization of the donor with horse red blood cells prior 
to SpTx led to the development of anti-horse red blood cell antibodies in the recipient. Fur-
thermore, immunization of the recipient (after SpTx) with sheep red blood cells resulted in 
the production of anti-sheep red blood cell antibodies in the original donor after autologous 
retransplantation of the spleen. These observations demonstrated a transfer of sensitized 
lymphocytes in the transplanted spleens.
Allotransplantation for hemophilia A (Table 2C)
Experimental SpTx with the intention to cure hemophilia A has been carried out in a variety 
Table 2A. Spleen allotransplantation in dogs
First Author (n) Immunosuppression Outcome Reference
Moore 29 none 19/29 early infarction Ann Surg 1960;152:374-387
1 spleen not rejected d65
Fisher 20 SpX rejection <10d Surg Gyn Obst 1961;112:455-462
24 WBI (300-500 cGy) at Tx 22/24 died
16 WBI (100-300 cGy) at Tx 1/16 died
12 WBI (300-500 cGy) prior 9/12 spleens grossly normal at d14
to Tx
Dammin 43 none rejection 7-9d Ann NY Acad Sci 1962;99:861-869
? WBI (250 cGy) poor survival ?d
14 nitrogen mustard 6 died early <5d
7 died <8d
1 survived 32d
no diff erence with untreated
Montague 18 nitrogen mustard 2/18 died (hematopoietic depression) J Surg Res 1962;2:130-135
SpX 4/18 died (early thrombosis spleen)
7/8 died 5-8d
No protection to spleen 
rejection
Wheeler 43 none 21/43 operative failure J Surg Res 1962;2:114-123
rejection <1w
Fiscus 7 WBI (300 cGy) death (6/7) < 10d Surg For 1963;14:182-185
Jordan 36 none 11 died (early thrombosis) Ann NY Acad Sci 1964;120;612-625
25 rejection 5-12d
7 WBI (300 cGy)+SpX GVHD, died <10d
Marchioro 4 none 2-8 d survival Ann NY Acad Sci 1964;120:626-651
4 WBI (150 cGy) on d-8 4-7 d survival
WBI (300 cGy) on d-1 5-7 d survival
7 AZA 2-11d survival
Mahajan 57 26/57 successful J Surg Res 1965;5:413-427
-12 none rejection 5-8d
-14 6-mercaptopurine 25% spleen graft survival 13-28d
AZA=Azathioprine, y=years
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Table 2B. Spleen + kidney allotransplantation in dogs
First Author (n) Immunosuppression Outcome Reference
Simonsen 1 none spleen rejected on d4 accelerated 
kidney rejection
Acta Pathol Microbiol Scand 
1953;32:36-84
Kountz 9 none kidney no prolongation Surg Forum 1962;13:59-62
9 SpX kidney 7 days prolongation wasting 
disease
Marchioro 7 none 3 died (pneumonia) 
4 survived 25d
Ann NY Acad Sci 1964;120:626-651
prolonged kidney survival 9d
12 WBI (100-450 cGy) survival 6-32 d 
hemolysis (9)
spleen rejection<10d
accelerated kidney rejection
11 AZA survival 6d-7.5m
kidneys protected from acute 
rejection
Dubois 29 none spleen rejection <10d kidney no 
prolongation
Biomedicine 1976;25:221-223
Hoff man 29 none 15/29 successful Eur Surg Res 1984;16:40-46
+autologous kidney no prolongation 
retransplantation
Table 2C. Spleen allotransplantation for hemophilia in dogs
First Author (n) Immunosuppression Outcome Reference
Webster 2 none 52-72h survival North Carolina Med J
correction of hemostasis 1967;28:505-507
Norman 2 none factor VIII 0% <24d Surgery 1968;64:1-16
4 AZA+CS+ALS
+actinomycin C
prolonged factor VIII synthesis
Marchioro 1 matched AZA+CS viable on d93, no factor VIII 
increase
Transplant Proc 1969;1:316-
320
1 mismatched AZA+CS rejection <15d
Marchioro 1 AZA+CS viable 47d, no factor VIII 
increase
Science 1969;10:188-190
McKee 8 ? 7-8m(2), no factor VIII increase J Lab Clin Med 1970;75:391-
402
Groth 4 AZA+ALS survival 3-8d Surgery 1974;75:725-733
h=hours, CS= corticosteroids, ALS=-anti- lymphocyte serum
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of dog models. Although it could not be clearly demonstrated that the level of factor VIII in-
creased, satisfactory graft perfusion and survival were demonstrated for more than 8 months 
(41). Webster et al described successfully functioning spleen allografts in severe classical he-
mophilia; immediate correction of the hemostatic defect and improvement in blood coagula-
tion was achieved (42,43). Others have had more mixed results. 
Combined pancreas-spleen allotransplantation in pigs (Table 3)
Two groups (44,45) have investigated the immunologic eff ect of transplanting the spleen with 
the pancreas in pigs. None of the pigs undergoing pancreas Tx alone showed signs of rejec-
tion while receiving cyclosporine for 28 days, but several combined pancreas-spleen graft 
recipients rejected their grafts before this time, some as early as one week (44,45), suggesting 
that the presence of the spleen was immunogenic; in no case did signs of GVHD develop. 
Human spleen xenotransplantation in pigs (Table 3)
There has been one brief and limited report in which pigs were treated with a single dose of 
cyclophosphamide (30mg/kg i.v.) four days before Tx of a human spleen (46). Two of fi ve pigs 
developed transient GVHD-like signs two to three weeks later. The number of human hemato-
poietic cells detected in these pigs, particularly in the bone marrow, was reported to be higher 
than in pigs that had undergone injection of human splenocytes only, but details were not 
reported. The human spleens, however, eventually appeared to be rejected. 
SPTX IN HUMANS
Human spleen autoTx has been reported, but will not be reviewed here. 
Table 3. Spleen allo- and xeno transplantation in pigs 
First Author (n) Procedure Immunosuppression Outcome Reference
Dafoe 8 Pancreaticoduodenal graft CyA+CS rejection 7-16d Transplantation 1985;40:579-584
+spleen
Dafoe 5 Pancreaticoduodenal graft CyA+CS no eff ect Transplantation 1986;42;686-687
+irradiated spleen graft no rejection d28
Gänger 7 Pancreaticoduodenal graft none rejection <1w Eur Surg Res 1987;19:323-328
+spleen
Li 5 Human spleen graft CPP stable chimerism
GVHD
rejection <2w
Transplant Proc 2000; 
32:1103-1104
CPP=cyclophosphamide,GVHD=graft-versus-host disease
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Allotransplantation
Clinical experience with spleen alloTx began in the early 1960s. 
For hypogammaglobulinemia, hemophilia, or Gaucher’s disease (Table 4A)
In one patient with hypogammaglobulinemia, it was hoped that the transplanted spleen, do-
nated by the patient’s mother, would alleviate a state of immune defi ciency (37), but no rise in 
serum antibody levels was observed during the three months for which the spleen survived. 
One spleen was transplanted from father to son for hemophilia A (47); factor VIII levels did not 
rise and, because of severe bleeding, the graft had to be excised after 4 days. The transplanted 
spleen was found to be markedly swollen and had ruptured. More recently, successful SpTx 
has been described (48, 49); in one case, factor VIII was increased and no spontaneous hem-
orrhage occurred during two years of follow-up (48). In a case report of SpTx for Gaucher’s 
disease, a spleen graft from an unrelated living donor resulted in a temporary improvement in 
the patient’s biochemical parameters, but was fi nally rejected by day 40 (50,51); chimerism of 
erythrocytes was documented 3-6 weeks after SpTx, and the patient developed in vitro donor-
specifi c hyporesponsiveness (52).
For malignant disease (Table 4B)
In four patients with terminal malignancies, the purpose of SpTx was to superimpose a state 
of altered immunologic reactivity, and thus suppress the growth of the neoplasms (37). In an 
eff ort to generate a GVH reaction against the tumor, potential spleen donors, who also had a 
terminal malignancy, were sensitized with tumor cell suspensions from the patient 12 to 56 
days before Tx. Recipient splenectomy was performed in all patients, and immunosuppression 
with azathioprine was initiated several days before the transplant. If rejection of the spleen 
Table 4A. Clinical spleen allotransplantation for hypogammaglobulinemia, hemophilia, and Gaucher’s disease
First Author (n) Indication Outcome/Complications Graft Survival Reference
Marchioro 1 hypogammaglobulinemia no gammaglobulin
production
3m Ann NY Acad Sci 
1964;120:626-651 
Hathaway 1 hemophilia hemorrhage 7d Transplantation 1969;7:73-75
Groth 1 Gaucher’s disease hemolysis & cachexia 40d Lancet 1971;1:1260-1264
(irradiated spleen 300 cGy) temporary benefi t
Chimerism erythrocytes
Donor-specifi c
hyporesponsiveness
Clin Exp Immunol 
1972;10:359-365.
Xia 1 hemophilia (mother-to-son) clinical improvement >2y Chin Med J (Engl) 
1992;105:609-611
Liu 3 hemophilia clinical improvement (2) <5y (2) Arch Surg 1995;130:33-39
Xiang 1 hemophilia clinical improvement >5 m Transplant Proc 
2002;34:1929-1931
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were suspected, prednisone and actinomycin C were added. None of these patients demon-
strated cessation or regression of tumor growth, and hypersplenism was reported in 3 out of 4 
patients. This was transient in two but sustained in one, when it was associated with hemolytic 
anemia, leukopenia, and thrombocytopenia. Bitter-Suermann suggested that the failure of 
the donor spleen to generate an immunologic response to the malignant disease (a graft-ver-
sus-tumor eff ect) may have been due to the use of immunosuppressive drug therapy that may 
have aff ected both graft and host reactions. Thus, the results “may have been masked, without 
invalidating the underlying concept of a transfer of cancer immunity” (13). 
In a leukaemic patient, a spleen was transplanted from his healthy identical twin (53), and 
remained viable for six months without immunosuppression, but without benefi cial eff ect on 
the leukaemia. Others, however, have reported shrinkage of hepatocellular carcinomas and 
reduced serum alpha-fetoprotein levels after SpTx (54).
Combined pancreas-SpTx (Table 4C)
In the 1980s, several groups included the donor spleen to improve the perfusion of the pan-
creas graft when performing pancreas Tx. Starzl et al. reported the fi rst four cases (55), im-
munosuppression consisting of cyclosporine and corticosteroids. No immunologic benefi t 
appeared to result from the presence of the donor spleen in any patient. In a blood group A 
recipient of a composite graft from a donor of group O, urgent splenectomy was necessary 
after 6 days because of a severe hemolytic anemia associated with a positive Coomb’s test and 
the presence of anti-A isoagglutinins. After removal of the transplanted spleen, the isoagglu-
tinins disappeared over nine weeks. 
Deierhoi et al. (56) reported one case of lethal GVHD after HLA-mismatched composite pan-
creas-SpTx. One week after Tx, the patient developed a progressive leukopenia, which persist-
ed after discontinuing azathioprine therapy and irradiating the spleen (1000 cGy over three 
days). Twenty days after the transplant, donor splenectomy was performed. Over the next two 
weeks, severe cutaneous GVHD was followed by multi-organ failure. Human leukocyte anti-
gen-typing of blood lymphocytes revealed 80-100% to be of donor type. Cyclosporine was 
Table 4B. Clinical spleen allotransplantation for malignant disease
First Author (n) Indication Outcome/Complications Graft Survival Reference
Marchioro 4 terminal carcinoma hemolytic anemia (1)
leukopenia (1)
10d-8m Ann NY Acad Sci 
1964;120:626-651
Raccuglia 1 leukemia No GVL eff ect 5m, viable Clin Exp Immunol 
1973;14:1-18
Liu 3 hepatocellular 
carcinoma
shrinkage of tumors,
decrease AFP
5-11m Arch Surg 
1995;130:33-39 
AFP = alpha-fetoprotein, GVL= graft-versus-leukemia
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discontinued and high-dose corticosteroids begun but the patient succumbed from systemic 
candidiasis.
Two additional cases of GVHD after pancreas-SpTx have been reported by Gonwa et al. (57). 
Both patients developed leukopenia and thrombocytopenia, which in one patient did not 
respond to therapy, necessitating excision of the spleen graft. Mixed hematopoietic cell chi-
merism was present, although the extent was not reported. The second patient, who also 
developed skin GVHD, responded well to irradiation of the spleen. 
The largest and most recent study on composite pancreas-SpTx was reported by Booster et 
al (58). In order to prevent GVHD, in 11 of 12 grafts, during cold storage of the donor organs 
before Tx, the spleen alone was irradiated (600 cGy). No GVHD was observed, but no immuno-
logic advantage of SpTx was identifi ed. In four patients, a search was made for chimerism, and 
lymphocyte chimerism of 14-20% was detected in two of them. 
Xenotransplantation
Although clinical xenogeneic SpTx does not appear to have been performed, several hundred 
patients, with a variety of disease states, have had their blood or plasma perfused through pig 
(or other animal) spleens (59-62). The clinical response to extracorporeal spleen perfusion in 
patients with septic conditions has been reported to be good. Details of this form of therapy 
are limited, but a careful investigation by Paradis et al (63) (into the possibility that these 
patients had become infected with porcine endogenous retrovirus) documented that 23 of 
the 30 patients tested demonstrated pig microchimerism. None of these patients had been 
exogenously immunosuppressed at the time of the procedure (which lasted only hours) or 
since, and yet microchimerism had persisted for between two months and eight years since 
spleen perfusion had taken place. 
Table 4C. clinical combined pancreas-spleen allotransplantation
First Author (n) Indication Outcome/Complications Graft Survival Reference
Starzl 4 Diabetes hemolytic anemia (1) 6d-11m Surg Gynec Obstet 1984;159:265-272
Gonwa 2 Diabetes GVHD (2) 16-24d Transplantation 1985;40:299-304 
hemolytic anemia (1) 
Sollinger 7 Diabetes less complications ? Transplant Proc 1985;27:360-362
Munda 4 Diabetes no side eff ects 12d-8m Transplant Proc 1985;27:353-357
Deierhoi 1 Diabetes lethal GVHD 19d Transplantation 1986;41:544-546
Peltenburg 1 Diabetes spleen graft rupture <3d Transplantation 1992;53:226-228
accelerated rejection
Booster 12 Diabetes accelerated rejection (1) 2d-9m Transplantation 1993;56:1098-110.
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COMMENT
There is convincing evidence of a tolerogenic eff ect by the transplanted spleen under various 
conditions in some rodent models. Several studies have indicated that a balance between 
host-versus-graft and GVH responses can be achieved after SpTx, leading to long-term surviv-
al of both the spleen and a second donor-specifi c organ. There is evidence to suggest that the 
induction of tolerance is associated with the development of regulatory cells. A donor-specifi c 
organ transplant can be protected from rejection by the transfer of cells from an animal with 
a long-surviving spleen graft.
In large animals and humans there has been no defi nite evidence that SpTx results in toler-
ance to itself or improves survival of a concomitantly-transplanted second organ. Indeed, the 
prevailing evidence is that the transplanted spleen is rejected, as is any other organ. However, 
no study in large animals has investigated the potential of this approach in a comprehensive 
way in a model in which knowledge of the major histocompatibility complex of both donor 
and recipient was known. What is clear from clinical SpTx is that a GVH response can result and 
can be severe enough to cause lethal GVHD, indicating the spleen’s potential in counteracting 
the usual host response that occurs after organ Tx. 
The benefi ts of inducing a state of tolerance in a recipient of an organ allograft, and the ad-
vantages of this state over chronic pharmacologic immunosuppressive therapy, are consider-
able. It would seem worth investigating SpTx in a large animal model, such as the Massachu-
setts General Hospital major histocompatibility complex-defi ned miniature swine Tx model, 
in which there is considerable experience of the Tx of other organs. We are currently undertak-
ing such a study (64).
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ABSTRACT
Background: Spleen transplantation (SpTx) between some strains of rodents can lead to do-
nor-specifi c tolerance either spontaneously or following a short course of immunosuppres-
sion. The aim of the present study was to develop a surgical technique for SpTx in miniature 
swine to investigate its immunological impact in a large animal model.
Methods: The preferred surgical technique of SpTx (n=8) involved excision of the donor 
spleen with its vascular pedicle to the aorta and portal vein. Carrel patches of donor aorta and 
portal vein were respectively anastomosed to the abdominal aorta and inferior vena cava of 
the (splenectomized) recipient. The results in four MHC-matched pairs that were mismatched 
for the porcine allelic antigen are reported. Two recipients were untreated, one received a 12-
day course of cyclosporine (CyA) alone, and one received thymic irradiation (TI; 700 cGy) and 
CyA. Hematopoietic cell chimerism was followed by FACS, and graft survival was assessed by 
histology. 
Results: SpTx was technically successful. In two untreated pigs, chimerism was detected in 
the blood (max. 5% for 17 and 25 days, respectively) and lymph nodes (max. 6% for 28 and 
56 days, respectively), but both grafts showed histological rejection by day 28. In two treated 
pigs, chimerism was present in the blood for 47 and 57 days, respectively, and rejection was 
prevented, with follow-up for 57 and 217 days, respectively. 
Conclusion: SpTx in MHC-matched pairs treated with CyA +/- TI results in prolonged chime-
rism, associated with the development of tolerance to the transplanted spleen. 
INTRODUCTION
In some rodent models, transplantation (Tx) of the spleen has resulted in the spontaneous de-
velopment of tolerance to the graft and to a subsequently transplanted donor-specifi c organ 
(reviewed in 1). In other models, the same result was achieved if a short course of immunosup-
pressive therapy was administered at the time of SpTx. There is some evidence that the induc-
tion of tolerance was associated with the development of regulatory cells in the recipient. If 
the recipient’s immune response was suppressed further, graft-versus-host disease (GVHD) 
resulted. Importantly, a state of tolerance was not induced by the Tx of spleen cells rather than 
of the intact whole organ. 
Studies carried out in large animal models have not been able to duplicate the results achieved 
in rodents (1). However, in none of these investigations have large animals been used in which 
the major histocompatibility complex (MHC) of the donor and recipient was known. SpTx has 
been reported in humans (1), but in none has the recipient clearly benefi ted from the proce-
dure. Hemolytic anemia, often combined with thrombocytopenia and leukopenia, and GVHD 
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(which has been fatal in one patient) have been reported, demonstrating the potential of 
the spleen’s graft-versus-host immune response. Hematopoietic cell chimerism has also been 
reported. 
It seems realistic to anticipate that, if the immune responses of both host and donor spleen 
are balanced, a state of tolerance could be achieved that might allow the concomitant or 
subsequent Tx of another donor-specifi c organ. This approach might also have potential in 
achieving T cell tolerance to a discordant xenograft. Before further clinical investigations are 
undertaken, which carry some risk to the patient, this approach requires exploration in a suit-
able large animal model. Since there have been no studies in large animals in which the MHC 
of the donor and recipient was known, we have initiated a series of studies in Massachusetts 
General Hospital MHC-inbred miniature swine. We here report the development of the surgi-
cal technique of SpTx, and the results in four MHC-matched pairs. In view of the benefi cial 
immunosuppressive eff ect associated with native splenectomy reported in rodent studies (1), 
the recipient spleen was excised in all cases. 
MATERIALS AND METHODS
Animals
Animals were selected from our herd of MHC-inbred miniature swine (2). Spleen donors were 
3-11 months old, weighed 14-72 kg and were positive for the pig allelic antigen (PAA), an al-
lelic non-histocompatibility marker of no known function (3). Recipients were 4-13 months 
old, weighed 12-72 kg, and were negative for PAA. Donor and recipient were matched for 
weight, blood group (all of type O), and MHC antigens, and mismatched for minor antigens. 
Eight spleen transplants have been performed. All animal care procedures were in accordance 
with the Principles of Laboratory Animal Care formulated by the National Society for Medical 
Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of 
Laboratory Animal Resources and published by the National Institutes of Health (NIH publica-
tion No. 86-23, revised 1996).
Operative procedures
Catheters were inserted into the right carotid artery and internal and external jugular veins in 
both donor and recipient pigs. In the recipient, the carotid artery catheter was removed at the 
end of the operation, the venous catheters remaining in situ for 28 days. 
Our initial technique (n=2) involved donor splenectomy and end-to-side anastomoses of the 
donor suprapancreatic splenic artery to the recipient infrarenal abdominal aorta and of the 
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donor splenic vein to the infrarenal inferior vena cava (IVC). The diameter of the splenic ves-
sels in the donor pigs used was small (<5 mm), and this approach was complicated by ste-
nosis and/or thrombosis of these vessels at the anastomotic sites. We therefore developed a 
technique in the donor (n=6) where the splenic artery and celiac axis were mobilized to the 
aorta to enable a Carrel patch of aorta to be taken with the graft. The splenic vein was dis-
sected to its confl uence with the superior mesenteric vein to enable a cuff  of portal vein to 
be included. 
Donor operation (Figure 1A)
After midline laparotomy, the splenic mesentery was divided. In the pig, at least one accessory 
splenic artery, arising from the left gastroepiploic artery with sometimes an additional small 
branch from the short gastric arteries, contributes a blood supply to the distal spleen, and this 
was ligated and divided with its accompanying vein. The pancreas was mobilized from around 
the splenic vessels. The main splenic artery was mobilized to its origin from the celiac axis. The 
common hepatic artery was identifi ed and preserved to maintain perfusion of the liver during 
the dissection. The celiac axis was traced and dissected down to its origin from the aorta. The 
left gastric artery and a small branch to the diaphragm were ligated and divided. After division 
or resection of the tail of the pancreas, the splenic vein was dissected to its confl uence with 
the superior mesenteric vein where it forms the portal vein. After heparinization (300 units/
kg), the aorta and portal vein were sequentially doubly clamped (to prevent congestion of the 
splenic graft), and portal venous and aortic segments were excised with the splenic vessels 
to provide arterial and venous cuff s (Carrel patches) to facilitate insertion into the recipient 
(Figure 1A). (Blood was withdrawn from the donor before the clamping of the aorta and IVC 
for subsequent transfusion into the recipient). The donor pig was then euthanized. The donor 
spleen was weighed (average weight 8g/kg bodyweight) and biopsied. The spleen was then 
placed in a tray of cold (4oC) saline, and the splenic artery was fl ushed with approximately 40 
ml/kg bodyweight of cold (4oC) electrolyte solution for kidney preservation (Baxter, Deerfi eld, 
IL) until the venous effl  uent was clear (Figure 1B). The spleen was then reweighed (demon-
strating that the fl ushing procedure resulted in spleen weight loss of 30-50%) and biopsied 
again. The spleen was then implanted into the recipient. 
Recipient operation (Figure 1C) 
After midline laparotomy and native splenectomy, the infrarenal aorta and IVC were mobi-
lized, and heparin (100 units/kg) administered. The donor spleen was implanted by anasto-
mosing the cuff  of donor aorta (from which the celiac axis and splenic artery arise) end-to-side 
to the recipient abdominal aorta, and the cuff  of portal vein (into which drains the splenic 
vein) end-to-side to the IVC, using continuous sutures of 5-0 polypropylene (Figure 1C). Re-
perfusion of the donor spleen resulted in a fall in hematocrit of approximately 25% (from 
approximately 40% to 30%) accompanied by a modest fall in platelets, and so (unirradiated) 
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Figure 1. Surgical technique of spleen transplantation in miniature swine. 
(A) In the donor, excision of the spleen involves dissection of the splenic artery and celiac axis to the aorta and of the splenic vein to its confl uence 
with the superior mesenteric vein to form the portal vein, which necessitates total pancreatectomy. Before transplantation into the recipient, the 
hepatic artery stump will be shortened.
(B) Flushing of the spleen graft with cold (4oC) electrolyte solution for kidney preservation trough the splenic artery, while placed in a tray of cold 
(4oC) saline, until the effl  uent from the splenic vein is clear. 
(C) In the recipient, end-to-side anastomoses are performed between the cuff  of the donor aorta to the distal abdominal aorta and between the 
cuff  of the donor portal vein to the IVC.
See addendum for colour version
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packed red blood cells, drawn from the spleen donor before euthanasia, were infused. At the 
end of the operative procedure, the donor spleen was positioned superfi cial to the bowel, im-
mediately under the anterior abdominal wall in the left or right fl ank. 
Split-thickness skin harvesting from donor and recipient
After euthanasia of the donor, split-thickness skin was aseptically harvested with a Zimmer 
dermatome. For cryopreservation, segments of skin were spread on nylon gauze and placed 
in petri dishes containing RPMI 1640 and an equal volume of balanced salt solution containing 
15% dimethylsulfoxide (cryopreservation medium; Microbiological Associates, Walkersville, 
MD). The skin was frozen at 1°C/min in a Planer freezing apparatus (G.V. Planer, Subury-on-
Thames, Middlesex, UK) and stored at -80°C. In the recipient, skin was harvested as described 
above before laparotomy.
Skin grafting in the recipient
Split skin grafts of self, donor, and third party MHC-matched and MHC-mismatched pigs were 
performed by techniques published previously (4) approximately two months after SpTx. Be-
fore use, the skin was rapidly thawed and washed three times with RPMI 1640 medium. Grafts 
were placed on a deep split-thickness bed on the recipient’s dorso-lateral thorax. Grafts were 
examined daily until macroscopic rejection occurred, and rejection was confi rmed by histo-
logical examination of sequential biopsies. 
Biopsies
Biopsies of the cervical thymus, mesenteric lymph nodes, bone marrow, and splenic graft were 
taken immediately pre-reperfusion, and subsequently on post-Tx days 14, 28, and then at in-
creasing intervals. A biopsy of the transplanted spleen was taken two hours after reperfusion. 
Splenic graft (wedge) biopsies and mesenteric lymph node biopsies were performed through 
an abdominal fl ank incision. All biopsies were examined histologically and by fl ow cytometric 
analysis for the presence of donor (PAA-positive) cells. Whenever a skin rash developed or 
there was diarrhea, skin and/or rectal biopsies were taken and examined for histopathologic 
features of GVHD. Biopsies for histological examination were fi xed in 10% formalin, processed 
overnight, and paraffi  n-embedded. Five-micron sections were stained with hematoxylin and 
eosin, and examined by light microscopy, with systematic attention being paid to the follow-
ing anatomic structures - red pulp, white pulp, stroma, and blood vessels. A full autopsy was 
performed at the time of death or euthanasia. 
Thymic irradiation 
With the aim of reducing the number of mature T lymphocytes, thymic irradiation (TI) (700 
cGy) was administered from a cobalt irradiator on day –1, as described previously (5).
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Immunosuppressive therapy
Cyclosporine (CyA) (Sandimmune, generously provided by Novartis Pharmaceutical Corpora-
tion, East Hanover, NJ) was administered intravenously as a single daily infusion at a dose of 
10-30 mg/kg (adjusted to maintain a whole blood trough level of 400-800 ng/mL) for 12 con-
secutive days, starting on the day of the SpTx. CyA levels were determined by a monoclonal 
fl uorescence polarization immunoassay (Abbott Laboratories, Dallas, TX), which measures the 
parent compound, but not metabolites.
Monitoring and supportive therapy
Blood cell count, serum chemistry, and CyA levels were determined daily for 28 days by routine 
methods. All pigs received daily prophylactic enrofl oxacin (5 mg/kg/d i.v.) while indwelling 
venous catheters were present, which was usually for 28 days. During this period, dalteparin 
(Fragmin, Pharmacia & Upjohn, Kalamazoo, MI) 100 IU/kg was administered subcutaneously 
daily as prophylaxis to prevent thrombosis in the catheters and in the vessels of the trans-
planted spleen. 
Preparation of cell suspensions and fl ow cytometry
These procedures and the antibodies used have been described previously (5-7). Flow cytom-
etry was carried out on blood, lymph nodes, thymus and bone marrow at intervals to deter-
mine the presence of hematopoietic cell chimerism. 
RESULTS
Immediate posttransplant outcome
Since this surgical technique has been adopted, there have been no anastomotic or thrombotic 
complications. Biopsies taken after cold fl ushing of the spleen (pre-reperfusion) revealed normal 
splenic architecture but with a reduced number of red blood cells in the sinusoids (Figure 2A). In 
two of the six cases, reperfusion injury was documented on splenic biopsies taken two hours after 
reperfusion. In one case, for uncertain reason, the donor developed cardiac arrest during mobiliza-
tion of the spleen, and there was a period of warm ischemia before the spleen could be excised. 
In the other, the donor suff ered a prolonged period of hypotension during mobilization of the 
spleen. In both cases, biopsies showed disruption of the splenic architecture with increased poly-
morphonuclear cell infi ltration and, in one case, congestion and hemorrhage (not shown). Both 
animals died suddenly several hours after operation. Autopsy showed no other abnormalities. 
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In the remaining four cases, in which no insult to the spleen was documented, the post-reper-
fusion biopsies demonstrated normal splenic architecture (Figure 2B) with some polymorpho-
nuclear cell infi ltration (Figure 2C). Post-Tx recovery was uneventful. There were slight increas-
es in serum amylase and lipase between days 1-4, which were possibly related to handling 
of the pancreas at the time of native splenectomy; these fi ndings were not associated with 
clinical features of pancreatitis.
Long-term posttransplant outcome
By 28 days, one of the grafts was frankly rejected, and the other revealed evidence of immi-
nent rejection (Figure 3). Neither spleen was excised at this stage, and yet neither pig dem-
onstrated any clinical or biochemical abnormalities during the period of follow-up, which 
A B
C
Figure 2. Histology of spleen biopsies taken after cold fl ushing (pre-reperfusion) (A) and two hours after reperfusion (B, C). 
(A) Normal splenic architecture but with a reduced number of red blood cells in the sinusoids.
(B) Normal splenic architecture following uneventful spleen transplantation.
(C) polymorphonuclear cell infi ltration two hours post-reperfusion after uneventful spleen transplantation.
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extended for 88 and 160 days, respectively. The pig that received CyA alone did not reject its 
graft, but it died suddenly on day 57 from an unrelated volvulus (Figure 3). Between post-Tx 
days 6 and 10, this pig developed transient features of cutaneous GVHD (grade 1) on biopsy, 
that resolved spontaneously. The recipient that received both CyA and TI did not reject its 
splenic graft and was euthanized on day 217 (Figure 3). 
Histological examination of spleen biopsies
At the time of splenic biopsy, the macroscopic appearance correlated well with the histologi-
cal fi ndings. A spleen of aubergine (dark purple) color and soft texture, with good pulsation of 
the splenic artery, and bleeding from the biopsy site, indicated a viable graft. 
Splenic biopsies from the two untreated recipients demonstrated normal histology on day 14 in 
one case and an atypical lymphocytic proliferation with cellular pleomorphism and an increase 
in mitotic activity (resembling posttransplant lymphoproliferative disease) in the other, perhaps 
a harbinger of early rejection (not shown). The stroma in the latter graft had foci of atypical lym-
phocytic pleomorphic infi ltration. Identifi able blood vessels looked normal. By day 28, there was 
multifocal hemorrhage (Figure 4A) which, by day 56, was associated with focal areas of fi brinoid 
necrosis, a reduction in the extent of the white pulp, and vessel wall necrosis. These features 
were consistent with acute rejection. Moreover, by day 28, the graft which had revealed a prolif-
eration of lymphoid tissue previously, now showed frank necrosis and hemorrhage on biopsy.
Despite evidence of rejection, both spleens were left in situ. On day 88, a biopsy of the more 
necrotic of the two grafts revealed a loss of architecture, large areas of necrosis surrounded by 
Spleen graft survival 
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Figure 3. Period of CyA therapy and survival of spleen grafts (assessed by histology) in MHC-matched minor-mismatched miniature swine 
(n=4). Pigs #14526 and #14867 received no immunosuppressive therapy, whereas pigs #14697 and #14687 received a 12-day course of CyA. In 
addition, TI (700 cGy) was administered to pig #14687. Pig #14697 died on day 57 from an unrelated volvulus, with a viable spleen graft.
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Figure 4. Histology of spleen grafts. 
(A) Rejected graft on day 28 in an untreated pig, showing hemorrhage and fi brinoid necrosis.
(B) Rejected graft on day 90, showing large areas of necrosis surrounded by palisading histiocytes, with some fi brous replacement of the red and 
white pulp.
(C+D+E) Spleen graft on day 160 (130 days after rejection) in an untreated pig, indicating features suggestive of stromal regeneration and 
cellular repopulation. 
(C) H&E staining showing the red pulp, 
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palisading histiocytes and some fi brous replacement of the red and white pulp (Figure 4B). A 
few remnants of Malpighian corpuscles could be identifi ed in the white pulp. The vessels were 
entirely necrotic, whereas the stroma still showed some viable cells. The other graft, on day 
160, looked surprisingly normal macroscopically. Histologically, no normal white pulp could 
be identifi ed, but there was a fi broblast-like proliferation occupying most of the red pulp, as-
sociated with an infl ammatory component of histiocytes and lymphocytes (Figure 4C). The 
stroma was intact and viable. Compared with a normal spleen, few blood vessels could be 
identifi ed, but those present were grossly normal. Our impression was that diff use necrosis 
had been avoided, signifi cant stromal recovery had taken place, and some repopulation of the 
spleen with viable cells had occurred (Figure 4D&E).
The transplanted spleens of the two pigs receiving CyA showed no features of rejection up to 
days 57 (death) and 217 (euthanized), respectively (Figure 4F).
Flow cytometry for hematopoietic cell chimerism
Replacement in the spleen of donor splenocytes by recipient lymphocytes (mainly CD3+/CD8+ 
T cells and CD16+ cells, not shown) occurred over the course of the fi rst 2-4 weeks in all four pigs, 
but was more rapid in the two animals in which the spleen was rejected (Figure 5A). All recipi-
ent pigs received a transfusion of packed red blood cells from the spleen donor at the time of 
SpTx. These packed red blood cells contained small numbers of leukocytes. Transfusion of these 
packed red blood cells alone (without SpTx) has been demonstrated to lead to chimerism of 
<1% for <2 days (not shown).
The two untreated pigs remained chimeric (1-5%) for PAA+ donor cells in the blood until days 17 
and 25, respectively (Figure 5B), and donor cells were found in the lymph nodes until day 56. Add-
ing a 12 day-course of CyA to the regimen (without TI) resulted in a prolongation of chimerism in 
the blood (1-6%) until day 53 (Figure 5B). Four days later the pig was found dead, and autopsy dem-
onstrated a volvulus with secondary peritonitis. Because of autolysis of the tissues, FACS could not 
be successfully performed. Chimerism had been documented in the lymph nodes and spleen graft 
on day 29. In the pig that received a 12-day course of CyA and TI, chimerism (1-8%) persisted in the 
blood until day 54 (Figure 5B), the donor cells consisting mostly of T lymphocytes (CD3+, CD4+, 
CD8+, not shown). Chimerism was detectable in the lymph nodes on days 28 and 217, the day of 
euthanasia (but not on days 12, 104 and 149) and in the thymus on days 60, 69 and 217 (Figure 6). 
Both CD1+ and CD3+ cells were detected in the thymus, suggesting the presence of immature 
cells. In none of the four recipients was chimerism detected in the bone marrow on any occasion.
(D) vimentin staining showing a central artery in an atrophic Malpighian corpuscle. 
(E) atrophic white pulp on a PCNA stain with counterstained lymphocytes using hematoxylin. 
(F) Normal architecture on day 217 in a pig treated with a 12-day course of CyA and TI.
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Figure 6. CD1+ (left) and CD3+ (right) populations of PAA+ donor cells in the recipient thymus on day 69 in a pig treated with a 12-day course 
of CyA and TI. PAA+ donor cells made up 3% of the total number of thymocytes.
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B
Figure 5. Chimerism in the transplanted spleen (A) and recipient blood (B) after spleen transplantation (n=4). Spleens were transplanted from 
PAA+ donors into PAA- recipients.
(A) Percentage of PAA+ donor cells in the transplanted spleen in untreated (n=2, dashed lines) and CyA-treated (n=2, straight lines) recipients.
(B) Percentage of PAA+ donor cells in the blood in untreated (n=2, dashed lines) and CyA-treated (n=2, straight lines) recipients.
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Skin grafting
Grafting of frozen self, donor, donor-type, and fully-mismatched skin was performed on day 
65 in the two untreated pigs and on day 73 in the pig treated with CyA and TI. In all three pigs, 
all skin grafts except self underwent rejection within 8-23 days, confi rmed by histology. 
DISCUSSION
Our study demonstrates that, using the surgical technique we have developed, SpTx in minia-
ture swine is feasible. Several previous groups, using diff erent anastomotic techniques, have 
reported a high incidence of technical failure in large animals (9-13). We believe that the in-
clusion of Carrel patches in the donor preparation is an important feature contributing to the 
success of the technique.
The splenic artery and vein, particularly in young pigs of <25 kg, are of small diameter and, 
without the use of microsurgical techniques, are diffi  cult to anastomose to the recipient ves-
sels. This has proved a problematic aspect of the technique in other animal models, fi rst noted 
by Carrel in 1910 (9). By dissecting the splenic vessels down to the abdominal aorta and portal 
vein, respectively, and taking a cuff  of these vessels, anastomoses can be performed without 
risk of stenosis or thrombosis. We have, however, taken the precaution of administering dalte-
parin during the early post-Tx period, partly to prevent thrombosis in these vessels, and partly 
to maintain patency of the indwelling venous lines in the neck (10). 
Using the technique described here, the donor pig has been euthanized to obviate the need 
to perform reconstructive surgery on the aorta and portal vein. In a clinical setting, however, 
anastomoses of the splenic artery and vein directly to the recipient aorta and IVC would be 
possible using microsurgical techniques. Furthermore, if required, reconstructive procedures 
on the donor aorta and portal vein would be feasible using synthetic vascular prostheses or 
autologous vein grafts. 
In two experiments, hemodynamic instability in the donor resulted in injury to the spleen fol-
lowing reperfusion. This injury appeared to be associated with the sudden deaths of these two 
animals, possibly as a result of cytokine release. No cause for the deaths could be determined 
at autopsy. This experience, however, has provided evidence that technically satisfactory Tx of 
a well-preserved spleen can be confi rmed by biopsy taken two hours after reperfusion.
From our initial experience, it would appear that the spleen in the pig represents 8g/kg body 
weight, which is much more than its weight in humans, in whom the normal spleen repre-
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sents only 2g/kg (8). Whether the relative masses of the spleens may be associated with diff er-
ent immunological eff ects following SpTx remains unknown, but it is possible that observa-
tions made in miniature swine may not be representative of those in other animals, including 
the human. Nevertheless, the MHC-inbred miniature swine represents the best large animal 
model in which to explore the phenomenon of tolerance associated with SpTx reported in 
numerous rodent models (1).
Our study indicates that donor lymphoid cells in the spleen are uniformly replaced by cells of 
recipient origin, but that this occurs more rapidly when rejection is occurring. The distribution 
of PAA in our herd has been well described for several lymphoid tissues and blood cells (3), but 
not previously for the spleen. In the PAA+ donor pigs in the present study and in subsequent 
experiments not reported here (Chapter 5), 95-100% of splenocytes were PAA+. The percent-
age of donor (PAA+) cells remaining in the spleen in the two untreated, rejecting pigs was 
0-4% by day 15, whereas it remained at >15% on day 29 in both treated pigs and at 4% on day 
215 in the long-term survivor. In subsequent studies not reported here, we have confi rmed 
that, when rejection is occuring in the absence of immunosuppression, host (PAA-) cells large-
ly replace donor cells in the spleen within 12 days (Chapter 5). However, when rejection is 
prevented, donor cells are only slowly replaced, and persist for several weeks or months.
We also document the histopathologic appearances of acute rejection in the spleen trans-
planted across a minor-antigen barrier. (In contrast to some reported studies in large animals 
(1), complete rejection of the spleen graft was tolerated without obvious clinical detriment 
to the recipient pig.) Hemorrhage and necrosis developed, followed by some fi brous replace-
ment of the splenic tissue, similar but not identical to the changes previously described in the 
rodent and canine models (1). In one spleen graft that was followed for 130 days after rejec-
tion, signifi cant regeneration of stroma and repopulation with cells took place. 
Successful SpTx was accompanied by chimerism in the blood. As chimerism was lost earlier in 
those pigs that rejected the spleen, we conclude that immunosuppressive therapy prolonged 
the period of chimerism, though not necessarily the extent of chimerism (which remained at 
1-8% in all cases). Previous work by others at our center (7) has demonstrated that untreated 
MHC-matched kidney recipients achieved chimerism of only 0.2-0.7%, and this was lost within 
7 days, whereas the percentage of donor cells in the blood of our untreated spleen recipients 
was 1-6% and was detectable for 17-25 days. Chimerism in the blood after MHC-matched 
kidney transplantation in recipients given a 12-day course of CyA has also been reported to 
be a maximum of only 0.7%, but persisted for 40-60 days (7). In contrast, in the present study, 
chimerism after SpTx was sometimes nearly 10 times higher than this, although it lasted for 
about the same period of time (54-57 days). Only following bone marrow Tx have greater lev-
els of chimerism been detected in MHC-matched pairs, but this has been in association with 
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regimens that involved myeloablation (e.g., with whole body irradiation or cytotoxic drug 
therapy) and/or specifi c T cell depletion with a potent immunotoxin (14).
In addition, all spleen recipients demonstrated chimerism on at least one occasion in mesen-
teric lymph nodes and, in the CyA/TI-treated pig, donor cells were detected in the thymus on 
days 61, 69 and 217. Chimerism in the thymus has not been reported following kidney Tx in 
MHC-matched miniature swine (7). We did not detect donor cells in the bone marrow on any 
occasion, suggesting that engraftment in the bone marrow did not occur.
In the limited experience reported in the present paper, tolerance to the transplanted spleen 
would appear to have been induced by a regimen of 12 days CyA and TI and probably by CyA 
alone (although the death of the pig from a volvulus precludes certainty in this respect). In 
comparison, a 12-day course of CyA leads to 100% survival of MHC-matched kidney trans-
plants in miniature swine (7). In untreated recipients, two thirds of MHC-matched kidney 
grafts survived indefi nitely (15). Although the numbers in our study are small, tolerance to the 
spleen graft did not appear to be achieved in the absence of CyA therapy.
In the present study, tolerance to donor-specifi c skin grafts was not achieved, although graft 
survival was possibly slightly prolonged at 8-23 days (compared to a mean of 12 days reported 
previously from our center (2,16)). Pig skin expresses immunogenic alloantigens that can lead 
to skin graft rejection despite tolerance to other donor tissue and donor-specifi c unrespon-
siveness in vitro (17). Our fi ndings are therefore consistent with rejection due to the presence 
of skin-specifi c antigens.
We are currently investigating the outcome of SpTx across class I and full MHC barriers. 
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ABSTRACT
Spleen transplantation has established donor-specifi c tolerance in rodents, but not in large 
animals or humans. We report the histopathology of rejection in an established model of 
spleen transplantation in MHC-defi ned miniature swine. Of 17 spleen transplants, rejection 
was observed in 2 grafts transplanted into untreated MHC-matched, minor antigen-disparate 
recipients (Group 1) and in 5 grafts transplanted into fully MHC-disparate recipients (Group 
2), one of which was untreated and 4 of which received some form of immunosuppressive 
therapy. Following biopsy and/or necropsy, fi xed allograft tissue sections were treated with 
multiple stains, immunohistochemical markers, and TUNEL assay. Common features of rejec-
tion occurred in grafts from both groups, but with varying time courses. Necrosis developed 
as early as day 8 in Group 2 and day 28 in Group 1, ranging from focal fi brinoid necrosis of arte-
riolar walls and sinusoids to diff use liquefactive necrosis, usually associated with hemorrhage. 
Other features of rejection included white pulp expansion by atypical cells and decreased 
staining of basement membranes and reticular fi bers. A doubling of the baseline TUNEL index 
preceded histologically identifi able rejection. This study establishes histologic guidelines for 
diagnosing and, perhaps, predicting acute rejection of splenic allografts transplanted across 
known histocompatibility barriers in a large animal model. 
INTRODUCTION
Since 1910, spleen allotransplantation (SpTx) has been performed for various reasons in ro-
dents, large animals, and humans (1). In some rodent models, there is clear evidence that a 
transplanted spleen can induce a state of donor-specifi c tolerance, and allow long-term sur-
vival of both the transplanted spleen and another donor-specifi c organ without exogenous 
immunosuppressive therapy (1-3); however, in large animals and humans, its tolerogenic ca-
pacity has not been demonstrated (1,4,5). We are currently investigating whether SpTx can 
induce tolerance in MHC-defi ned miniature swine, a clinically-relevant large animal model. No 
study of SpTx has been made previously in any large animal model in which information on 
the major histocompatibility complex (MHC) of both recipient and donor was known. 
Bitter-Suermann (6) described the morphologic features of SpTx in rats, and there have been 
several reports in outbred dogs (4,7-12). Most reports on human spleen allograft rejection 
have not included detailed histologic descriptions. In our current studies in miniature swine, 
histologic and immunohistochemical studies were performed to determine the course after 
SpTx with or without various immunosuppressive regimens. We here characterize previously 
unreported histologic features of spleen allograft rejection, and suggest a systematic grad-
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ing system based on histopathologic features, similar to those used to evaluate rejection of 
transplanted hearts and kidneys. 
As the transplanted spleen can induce a state of tolerance to itself and to a second donor-spe-
cifi c organ (13), the histopathological interpretation of spleen biopsies may become clinically 
relevant.
METHODS
Animals
Pigs were selected from our herd of MHC-inbred miniature swine, of blood group O (14). 
Spleen donors were 5.1 ± 3.3 months old, weighed 31.9 ± 20 kg, and were positive for the pig 
allelic antigen (PAA), an allelic non-histocompatibility marker with no known function (15). 
Weight-matched recipients were 5.2 ± 4.5 months old, weighed 31.2 ± 28.7 kg, and were nega-
tive for PAA. SpTx has been carried out over a minor antigen (Group 1; n=4), MHC class I (n=1), 
or full MHC (Group 2; n=12) histocompatibility barrier (Table 1). 
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use of 
Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH publication No. 86-23, revised 1996), and were ap-
proved by the Massachusetts General Hospital Subcommittee on Research Animal Care.
Surgical procedures
The technique of SpTx has been described previously (16). Wedge biopsies of the donor spleen 
were taken immediately before explantation from the donor, after fl ushing, two hours after 
reperfusion in the recipient, and subsequently through an abdominal fl ank incision on post-Tx 
days 14, 28, and then at increasing intervals. In one untreated recipient (#14534) in Group 2, 
additional spleen biopsies were taken on days 4, 8, and 11. Biopsies were taken from diff erent 
sites in the spleen on each occasion, working from distal to proximal. Bleeding resulted from 
biopsy of a viable spleen graft, but not from a totally-rejected graft (Grade 3, see below). The 
bleeding could be readily controlled by cautery coagulation, and the application of pressure 
to the biopsy site for 10 minutes, sometimes with the use of Surgicel (Ethicon, Somerville, 
NJ). Examination and interpretation of a total of 106 biopsies form the basis of this study. The 
grafts were evaluated macroscopically with regards to size, color, consistency/texture, arterial 
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pulsation, and bleeding at the biopsy sites. All biopsies were examined histologically and by 
fl ow cytometric analysis for the presence of donor (PAA-positive) cells. 
Immunosuppressive therapy
The immunosuppressive regimen for each recipient pig is summarized in Table 1. Cyclospo-
rine (CyA) was administered daily by an intravenous (i.v.) infusion for 12-45 days. Whole body 
and/or thymic irradiation were administered from a cobalt irradiator (17,18).
Histological examination
Tissues were fi xed in 10% formalin and embedded in paraffi  n, or frozen in tissue medium (Tis-
sue-Tek OCT 4583, Miles, Elkhart, IN) and stored at -80°C. Five-micron histologic sections were 
cut from paraffi  n blocks, stained with hematoxylin and eosin (H&E) and studied by light mi-
croscopy. To assess possible changes in elastic tissue, basement membrane integrity, and col-
lagen deposition, special stains included periodic acid-Schiff  (PAS), trichrome, Verhoeff  elastic, 
Table 1 Immunosuppressive regimens and outcome.
Group Animal # Immunosuppression
WBI TI CyA Outcome (day of rejection (a))
 1: MHC- matched 14526 - - - Rejection (b) (28)
14867 - - - Rejection (27)
14697 - - 12 days No rejection
14687 - + 12 days No rejection
MHC Class I- mismatch 15111 - + 12 days No rejection
2: MHC-mismatched 14534 - - - Rejection (8)
14646 - + - (CPP) Rejection (16)
14840 - + 28 days Rejection (62)
14832 - + 12 days Rejection (47)
15029 - + 23 days No rejection (c)
15051 + + 45 days No rejection
15242 + + 45 days No rejection
15311 + + 45 days Rejection ( 61)
15328 + + 45 days No rejection
15399 + + 30 days No rejection
15410 + + 45 days No rejection
15446 + + 45 days No rejection
CyA = cyclosporine at 10-30 mg/kg i.v. daily to maintain a whole blood trough level of 400-800 ng/mL; CPP = cyclophosphamide (3x 20 mg/kg 
iv on days -5,-4 and -3); WBI = whole body irradiation (100 cGy on day -2); TI =thymic irradiation (700 cGy on day-1).(a) Based on histological 
examination of the spleen graft; (b) Defi ned as the development of Grade 3 changes (coagulative necrosis, see Table 2); (c) Died from infection.
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and reticulin stains. Immunohistochemical study of sections included the use of monoclonal 
antibodies to α-smooth muscle actin (SMA; clone 1A4, Sigma, St Louis, MO), vimentin (Santa 
Cruz Biotechnology, Santa Cruz, CA), and proliferating cell nuclear antigen (PCNA; clone PC10, 
Dako, Carpinteria, CA) on fi xed tissue. Macrophage/L1 protein/calprotectin Ab-1 (clone Mac 
387, NeoMarkers, Fremont, CA) was used to label macrophages on 5-micron cryosections of 
tissue. Binding was visualized by using horseradish peroxidase-conjugated secondary anti-
bodies (Vector, Burlingame, CA). Bound antibodies were revealed by incubation of forma-
lin-fi xed and cryopreserved sections in aminoethylcarbazole (Dako). Sections were counter-
stained with hematoxylin solution (Richard-Allan Scientifi c, Kalamazoo, MI). Negative controls 
omitted the primary antibodies. 
Apoptosis was determined by a terminal deoxyribonucleotidyl transferase-mediated, dUTP 
nick end labeling (TUNEL) assay on paraffi  n sections. After deparaffi  nization, treatment with 
proteinase K (Fisher Scientifi c, Fairlawn, NJ) for 15min at room temperature, and quenching in 
2% H
2
O
2
, tissue sections were incubated with biotinylated dUTP (Boehringer, Indianapolis, IN) 
and terminal deoxyribonucleotidyl transferase (Promega, Madison, WI) for 1h at 37ºC. Slides 
were then blocked, washed with phosphate-buff ered saline, and incubated with avidin-bio-
tin complex horseradish peroxidase (Dako). Following development with diaminobenzidine 
(Zymed Laboratories, South San Francisco, CA), slides were counterstained with methyl green. 
Positive controls included sections of human adenocarcinoma of the colon, in which apopto-
sis is common. For negative controls, distilled water was substituted for deoxyribonucleotidyl 
transferase. The TUNEL index (TuI) was calculated as the mean number of TUNEL-positive cells 
counted in 10 random microscopic fi elds at x200 magnifi cation.
Flow cytometry 
Spleen biopsies were processed into single cell suspensions, and red blood cells were lysed. 
The concentration was adjusted to approximately 1x107 cells/mL, and 100μL (1x106 cells) 
were distributed into each staining tube. The following swine-specifi c antibodies were used: 
anti-CD1 (76-7-4, mouse IgG2aK), anti-CD3 (898H2-6-15, mouse IgG2aK), anti-CD4 (74-12-4, 
mouse IgG2bK), anti-CD8α (76-2-11, mouse IgG2aK), anti-CD16 (G7, mouse IgG1), and anti-
PAA (1038H-10-9, mouse IgMK). Two-color staining using fl uorescein isothiocyanate-conju-
gated CD1, CD3, CD4, CD8, CD16 and biotinylated PAA antibody was used to determine the 
proportion of donor versus recipient lymphocytes, with appropriate negative isotype con-
trols. As a second-step antibody, phycoerythrin streptavidin (Pharmingen, San Diego, CA) was 
used. Data were acquired using a Becton Dickinson FACScan (San Jose, CA) and analyzed with 
WinList mode analysis software (Verity Software House, Topsham, ME).
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Fluorescence in situ hybridization (FISH)
FISH was performed on gender-mismatched grafts using a paraffi  n pretreatment reagent kit 
as recommended (Vysis, Downers Grove, IL). Five-micron fi xed graft tissue sections were de-
paraffi  nized, digested with proteinase K, and hybridized overnight in a Hybrite chamber with 
a porcine combined XF/YCy3 paint (CA-1685, Cambio, Cambridge, UK), with X labeled with fl u-
orescein isothiocyanate (FITC) and Y labeled with cyanine 3 (Cy3). Nuclei were stained with 4’, 
6-diamidino-2-phenylindole (DAPI). Sections were examined with a fl uorescence microscope 
(Olympus, Model Bx60F-3, Tokyo, Japan), using appropriate fi lters to detect the green, red and 
blue fl uorescence of the FITC, Cy3, and DAPI, respectively. Images were photographed with an 
enhanced digital camera (Spot, Model 130, Diagnostic Instruments, Sterling Heights, MI), cap-
tured to a desktop computer (Compaq Deskpro DPENM P700 CCP, Hewlett Packard Co., Palo 
Alto, CA) and merged. Cells with intranuclear red signal were considered to have originated 
in a male animal; cells with two intranuclear green signals were female-derived. Sections of 
lymph nodes from male and female pigs served as controls. 
Identifi cation of Howell-Jolly bodies in the blood
Blood was drawn into a K2-EDTA tube before SpTx and on a weekly basis thereafter. Blood 
smears were Wright-stained and examined microscopically for Howell-Jolly bodies, which in-
dicate a level of splenic dysfunction (19).
RESULTS
Outcome of spleen transplantation
In Group 1 (n=4), grafts in two untreated recipients were rejected by days 27 and 28 (Table 
1), whereas grafts survived long-term in two treated recipients. The one spleen graft trans-
planted across a MHC class I barrier survived long-term (Table 1). In Group 2 (n=12), grafts in 
two pigs that received either no treatment or pre-Tx cyclophosphamide alone showed acute 
rejection by days 8 and 16, respectively, while two that received thymic irradiation and CyA 
rejected their grafts by days 47 and 62 (Table 1). When whole body irradiation was added to 
the regimen, only one of six pigs rejected its graft (day 61). Our histological study therefore is 
focused on the 7 rejected grafts (n=2 in Group 1; n=5 in Group 2). 
A review of the Table 1 data suggests that, when no or minimal immunosuppressive therapy 
was administered, rejection progressed faster after MHC-mismatched SpTx (Group 2, when 
it occurred in 8 and 16 days) than in MHC-matched minor-mismatched pairs (Group 1, 27 
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or 28 days). Furthermore, greater pre- and post-Tx therapy was required to protect the graft 
from rejection and to induce tolerance in the MHC-mismatched pairs of Group 2 than in the 
MHC-matched pairs of Group 1. When the results of experiments within Group 2 are com-
pared, there was increased graft survival and a greater incidence of tolerance induction when 
conditioning and therapy were increased. Whole body and thymic irradiation combined with 
45-days of CyA prevented spleen rejection in 6 of 7 cases. A regimen that did not contain all 
of these elements resulted in rejection in 4 of 5 cases; in the single case in which rejection did 
not occur, follow-up was limited to 23 days by the death of the recipient from infection. 
Macroscopic appearance of spleen grafts
Within 2 weeks of SpTx, spleens not undergoing rejection were enlarged to twice their normal 
size and demonstrated normal color, a soft texture, good vascular pulsation and bleeding from 
the biopsy site. Long-term surviving grafts became dark purple in color, but remained soft. Some 
capsular fi brosis and adhesions were identifi ed. When rejection was occurring, early changes in-
cluded those in color (from aubergine to yellow-brown), texture (soft to fi rm), arterial pulsation 
(diminished or absent), and a lack of bleeding from biopsy sites. Advanced rejection was usually 
associated with shrinkage in spleen size to less than one-third of that at Tx.
Microscopic appearance of spleen grafts undergoing rejection
Figure 1 illustrates the normal histological appearance of a pig spleen before explantation from 
the donor. Two hours after reperfusion, a slight increase in neutrophils in sinusoids of the red pulp 
was seen (not shown) (16). The speed of development of rejection depended on (a) the extent of 
MHC disparity between donor and recipient and (b) the intensity of the conditioning/immuno-
suppressive therapy administered. Although the speed of development of rejection was variable, 
except for this time sequence, the histopathological features of rejected grafts were similar. 
Initially, a marked expansion of periarteriolar lymphatic sheaths (PALS) of the white pulp by 
PCNA-positive, pleomorphic, large, mitotically-active lymphocytes developed and was asso-
ciated with an increased density of reticulin staining in the PALS, consistent with a reactive 
increase of collagen fi bers in the white pulp (Figure 2). Similarly, increased SMA and vimentin 
staining in the peripheral aspects of the PALS suggested a concomitant vascular proliferation 
or possible angiogenesis. Alternatively, this fi nding may refl ect a proliferation of T cell-zone 
fi broblasts, which are known to express SMA (20). The increase in proliferative activity was 
demonstrated by PCNA staining (Figure 2). 
As necrosis developed, there was a loss of even baseline staining with reticulin, SMA, vimen-
tin, and PCNA (data not shown). More subtle histological changes, which correlated with early, 
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Figure 1. Normal histology of porcine spleen is illustrated with various staining techniques. 
(A) Red pulp is predominant, and white pulp contains a small central artery (arrow), H&E 
(B) Capsule and trabeculae, containing abundant blue-stained collagen, trichrome stain
(C) Scant collagen fi bers (arrow heads) in periarteriolar lymphatic sheaths (PALS), reticulin stain
(D) Smooth muscle cells of trabeculae and of vessels and sinusoids in the white and red pulp express actin, SMA stain
(E) Red pulp, with delicately stained sinusoidal endothelial and/or smooth muscle cells, vimentin stain
(F) Normal cellular proliferative activity in red pulp and lymphoid follicle, with prevalence of staining in a germinal center (arrow), PCNA stain
See addendum for colour version
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Figure 2. Histology associated with expanded PALS (#14867, Group 1, 15 days after SpTx) can be compared to baseline fi ndings seen in Figure 1. 
(A) Marked expansion of PALS around central artery, H&E 
(B) High power view of pleomorphic, atypical lymphoid cells in the PALS, H&E 
(C) Increased density of collagen fi bers in PALS, reticulin stain 
(D) Increased smooth muscle cell staining in red pulp adjacent to PALS, SMA stain 
(E) Similar increase in staining of smooth muscle-like cells and/or endothelial cells (arrowhead) in expanded PALS, vimentin stain 
(F) Increased proliferative activity associated with expanded PALS, PCNA stain 
See addendum for colour version
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Figure 3. Normal histology (A,C,E) is compared with subtle histological changes which are associated with early, focal graft necrosis (B, D, F). 
Normal staining of basement membranes of trabecular cells, PAS stain (A) is degraded in early rejection (B) (#14840, Group 2, 104 days after 
SpTx), PAS stain. The regular network of reticular fi bers of the red pulp (C) is degraded in (D) (#14534, Group 2, 4 days after SpTx), PAS stain. The 
normal (E) and centrally disrupted (F) (#14526, Group 1, 57 days after SpTx) patterns of reticular fi bers are again observed with further staining, 
reticulin stain.
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focal necrosis included a decrease of staining of normally PAS-positive basement membranes 
of trabecular cells and a diminished PAS and reticulin staining of reticular fi bers in the red pulp 
(Figure 3). 
Prior to the appearance of histological features of rejection, there was at least a doubling 
of the TuI when compared to that of baseline (Figure 4A, B). The onset of rejection, ranging 
from focal fi brinoid necrosis of arteriolar walls and sinusoids to diff use liquefactive necrosis, 
was usually associated with variable degrees of hemorrhage (Figure 4C-F). Acute vasculitis 
accompanied the process of necrosis in one graft, and, in another, extramedullary hemato-
poiesis was associated with patchy, liquefactive necrosis (Figure 5A-C). Diff use necrosis was 
the end-result of rejection, and developed as early as day 8 in untreated pigs in Group 2 and 
by day 28 in Group 1. Necrosis was accompanied by an increase in collagen and by either 
the fi rst appearance or an increased density of elastic fi bers in the capsule and trabeculae. 
Replacement fi brosis adjacent to geographic areas of necrosis was seen in the spleen in one 
untreated Group 1 recipient on day 88 and in one treated Group 2 recipient on day 138. These 
areas of fi brous replacement consisted of a variably dense deposition of collagen and a diff use 
population of SMA- and vimentin-positive spindle cells, most of which were PCNA-negative 
(not shown). This end-stage scarring corresponded to shrinkage in allograft size. 
Microscopic appearance of spleen grafts surviving long-term
Eight grafts (Group 1 n=3, Group 2 n=4, and the one MHC class I-mismatched) remained vi-
able 40-367 days after SpTx. Five of them showed atrophy of the white pulp from days 28-160, 
i.e., a decreased number of lymphoid cells, giving the histiocyte-rich sheaths of cells around 
central arteries a pale look on H&E stain. Accompanying the depletion of white pulp was re-
placement of normal red pulp by vacuolated histiocytes and SMA-positive cells, presumably 
smooth muscle cells migrating in from adjacent trabeculae (Figure 5D-F). 
Correlation of histopathology with spleen cell chimerism on fl ow cytometry 
In both Groups, a signifi cant loss of PAA+ cells in the spleen either preceded or occurred con-
comitantly with the development of histological features of rejection. In long-term surviving 
grafts, recipient cells slowly replaced donor cells almost entirely.
Before explantation from the donor and immediately after reperfusion in the recipient, the 
donor spleen demonstrated 96.6 ± 2.0% PAA-positivity (Figure 6), which was comparable to 
the PAA-positivity of leukocytes in the blood of the donor animals (96.2 ± 2.2%). Some PAA- 
recipient cells (~6%) could be seen 30min post-reperfusion. In untreated pigs of Group 1, the 
percentage of donor (PAA+) cells remaining in the spleen had fallen to 0-4% by day 15, being 
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Figure 4. 
A TUNEL index at baseline on the day of SpTx (A) (#14867, Group 1) is increased more than two-fold 15 days after SpTx (B) (#14867, Group 
1) before a subsequent biopsy showed histologic evidence of rejection (arrows mark TUNEL-positive cells). Spleen allograft necrosis varied 
morphologically from focal, fi brinoid necrosis of sinusoidal walls (C) (#14526, Group 1, 57 days after SpTx) (arrow), associated with fi brin thrombi 
in small vessels (D) (#14526, Group 1, 57 days after SpTx) (arrows), to diff use liquefactive necrosis (E) (#14867, Group 1, 28 days after SpTx). 
Necrosis was usually associated with some hemorrhage (F) (#14867, Group 1, 28 days after SpTx).
See addendum for colour version
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Figure 5. 
Other features of late rejection included acute vasculitis accompanying vessel wall necrosis (A) (#14646, Group 2, 28 days after SpTx), and, in 
one graft, extramedullary hematopoiesis (#14832, Group 2, 47 days after SpTx) (B and C). Histological changes associated with prolonged graft 
survival included atrophic white pulp (D) (#15051, Group 2, 57 days after SpTx) (arrow points to a central artery); increased SMA expression in red 
pulp (E) (#14526, Group 1, 160 days after SpTx), SMA stain; and an increase in vacuolated histiocytes (arrows) in red pulp (F) (#14526, Group 1, 
160 days after SpTx).
See addendum for colour version
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Figure 6. 
(A and B) Flow cytometry of a donor (PAA+) spleen (donor to #15410) before explantation, demonstrating the percentage of PAA+cells 
(97.89%) (A), and the profi le of CD3+PAA+ cells (B). (C and D) Flow cytometry of an accepted spleen graft after cessation of CyA (#15051, Group 
2). Replacement with recipient cells is indicated by the presence of PAA- cells. The spleen graft still consists of 49.61% donor cells (C), but some 
CD3+PAA- recipient cells can be seen (D). (E and F) Almost complete repopulation of the spleen graft by recipient cells occurred (#15410, Group 
2, 183 days after SpTx). Only 1.67% of the cells are still of donor origin (E). Virtually all CD3+ cells (F) are recipient type (PAA-).
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replaced by host (PAA-) cells (CD3+, CD8+ and CD16+). In immunosuppressed pigs in Group 
1, the percentage of PAA+ cells remained at >15% on day 29, and at 4% on day 215. The FISH 
technique demonstrated recipient-derived cells populating a gender-mismatched graft (Fig-
ure 7), supporting the fl ow cytometry data.
When necrosis of a graft developed, the overall cellularity of the spleen was markedly dimin-
ished. In untreated recipients in Group 2, PAA+ donor cells were completely replaced by recip-
ient cells within 8 days. In treated Group 2 recipients that eventually rejected their grafts, 30% 
of cells in the graft were PAA+ during CyA therapy but, when rejection occurred 2-3 weeks 
later, all PAA+ cells were rapidly lost from the graft. In Group 2 recipients that did not reject 
their grafts, PAA+ donor cells decreased by about 50% within the fi rst post-Tx month, after 
which the spleen graft was slowly replaced almost entirely with recipient cells, which usually 
occurred within 100 days post-Tx. The chimerism in the spleen graft refl ected the extent of 
lymphoid chimerism in blood (13). 
Presence of Howell-Jolly bodies
After combined native splenectomy and survival of a viable spleen transplant,
Howell-Jolly bodies were never seen in the blood, indicating good splenic graft function. 
When rejection developed, however, Howell-Jolly bodies appeared in the blood within a week 
(Figure 8). 
Figure 7. 
Section of spleen which was transplanted from a female donor into a male recipient (#14840, Group 2, 43 days after SpTx). A notable number of 
recipient-derived cells with Y chromosomes (red signal) has populated the graft at the time of expanded white pulp (day 43), FISH technique, x400.
See addendum for colour version
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DISCUSSION
To our knowledge, this is the fi rst report that describes the histopathology of spleen allograft 
rejection in a large animal model with known MHC barriers. In miniature swine, the course 
of histopathological change in the transplanted spleen varied with respect to the extent of 
donor-recipient MHC-mismatch and the immunosuppressive regimen administered to the re-
cipient. The sequence of histopathologic events was delayed in MHC-matched pairs and in im-
munosuppressed recipients. However, our observation was that common features of rejection 
occurred in minor-mismatched and fully MHC-disparate grafts, but with varying time courses. 
This correlates with the course of rejection in other organ transplants, where the pattern of 
rejection is similar yet the rapidity of its development varies depending on the extent of MHC 
incompatibility between donor and recipient (21). 
An early indicator that rejection was occurring was expansion of white pulp, as described in 
other studies (6,10,22). Correlation with fl ow cytometry indicated that expansion of the white 
pulp was due to infi ltration by recipient cells. Others (6, 22) have attributed the expansion of 
PALS to an increase in the number of donor cells. In our model, this fi nding has not been the 
case, and the lymphoid cellular expansion was recipient-derived. Atrophy of the white pulp, 
on the other hand, perhaps refl ects a “burned out” immune response to the allograft, allowing 
relatively long-term graft survival. 
Figure 8. Red blood cells (arrows) contain Howell-Jolly bodies in a peripheral blood smear of a recipient of a rejected (Grade 3) spleen allograft 
(#15311, Group 2, 75 days after SpTx, two weeks after spleen graft rejection (characterized by coagulative necrosis), Wright stain x640.
See addendum for colour version
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Based on our histologic fi ndings and on data reported by others previously (see below), a 
histologic grading system for acute cellular rejection in spleen allografts is proposed (Table 
2). Focal or multifocal fi brinoid necrosis of sinusoidal and/or arteriolar walls (Grade 1) did 
not preclude long-term graft survival. Expansion of white pulp by large, atypical, and mitoti-
cally-active lymphoid cells (Grade 2) was invariably followed by borderline-severe or severe 
rejection (Grades 3A and B), manifested by focal or diff use coagulative necrosis, respectively. 
The TuI may be a helpful indicator of spleen graft survival; in one untreated Group 2 spleen, 
although the graft looked normal on day 4, the TuI had increased almost 4-fold (12.6 to 40.0) 
from baseline; by day 8, the graft demonstrated diff use necrosis. In future studies, these his-
tological changes may have a predictive signifi cance and aid in the treatment or prevention 
of rejection.
It is unclear why extramedullary hematopoiesis occurred in one of our pig spleen grafts (6,11). 
The spleen is known, however, to be an organ capable of hematopoiesis in certain disease 
states (23,24) and, in other studies, we have observed that the naive spleen has hematopoietic 
stem cell activity (Chapter 7).
In rodents, spleen grafts from untreated PVG rats to untreated AGUS rat recipients were reject-
ed within 2 to 3 weeks (6). The grafts enlarged to six times normal size, and became fi rm and 
white. The circulation through the graft ceased within days. Histologically, a slight expansion 
of the PALS occurred as early as 2 days after SpTx, approximately 50% of the lymphocytes be-
coming enlarged with pyroninophilic cytoplasm (6); the authors do not specify whether these 
lymphocytes were of donor or recipient origin. There was also an increase in the cellularity of 
the red pulp. In the PALS, most of the lymphocytes and large pyroninophilic cells disappeared 
within 7 days, after which the sheaths consisted almost entirely of pale elongated cells (re-
ticular cells, macrophages, fi broblasts), which increased rapidly in number, and multinucleate 
giant cells occasionally appeared. The central arteries of Malpighian corpuscles gradually be-
came surrounded by an enlarging mass of pale tissue which expanded into, and replaced part 
of, the red pulp, at some stages resembling “epithelioid cells” seen in certain forms of chronic 
Table 2 Grading scheme for splenic allograft rejection.
Grade Rejection Histological Features
0 None Normal splenic architecture
1 Mild Focal or multifocal fi brinoid necrosis of sinusoidal and/or arteriolar walls, 
with or without hemorrhage
2 Moderate Expansion of white pulp by large, atypical, and mitotically-active lymphoid 
cells
3A Borderline severe Focal* coagulative necrosis
3B Severe Diff use coagulative necrosis
*Focal is involvement of a small fraction of tissue in a high-power fi eld.
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infl ammation. Red pulp cellularity was gradually diminished and, after 12 days, foci of necrosis 
enlarged and coalesced until the whole spleen became necrotic. 
In large animals, most histological observations have been made in dogs (4,7-12). Multiple 
subcapsular hemorrhages developed, with diff use infi ltration of polymorphonuclear leuko-
cytes into red pulp. Subsequently, generalized hemorrhage was seen, with many pyronino-
philic cells in the red pulp, followed by complete hemorrhagic infarction and necrosis.
In the few human SpTx studies, the histological picture of rejection remains uncertain 
(1,4,5,22,25-28). Within days, the graft may contain an increased number of lymphocytes, 
histiocytes, and reticulum cells. Red pulp congestion, immunoblast proliferation, and intimal 
swelling may develop, with lymphoid expansion predominantly in the marginal zones. Rup-
ture may occur, the spleen showing extensive edema, focal hemorrhage, and cellular deple-
tion in the PALS, with a generalized and massive infi ltrate of large lymphoid cells. Extensive 
necrosis follows. Others have reported that, within 1-2 months, marked fi brosis, focal necrosis, 
and intimal proliferation (causing arterial occlusion) were present and, after 7-9 months, com-
plete atrophy had occurred (5). Raccuglia et al. (27) reported SpTx in a patient with leukemia; 
after almost a year, the graft appeared histologically viable, but showed congestion, diff use 
deposits of hemosiderin and, although lymphatic tissue was abundant, the small follicular 
lymphocytes were decreased. 
The sequence of histopathological events leading to allograft rejection in our study is similar 
to those described in rodents and dogs. With the availability of special staining techniques 
and fl ow cytometry, however, we have been able to detect subtle morphologic changes that 
may help predict the course of the transplanted spleen and the ultimate outcome. Our ob-
servations should prove valuable if SpTx, for the purpose of inducing tolerance, becomes a 
clinical reality.
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ABSTRACT
Background: In rodents, spleen allotransplantation (SpTx) induces tolerance. We investigated 
the induction of chimerism and donor-specifi c unresponsiveness following pig SpTx.
Methods: Thirteen pigs underwent splenectomy (day 0); all received a blood transfusion. In 
11/13 pigs, SpTx was performed across a MHC class I (n=1) or full (n=10) barrier; two control 
pigs received no SpTx. All pigs were monitored for chimerism, and anti-donor immune re-
sponses, including suppressor assays. Four pigs (2 asplenic controls, and 2 with SpTx) under-
went delayed donor-matched kidney Tx without immunosuppression. 
Results: Six of the 11 spleen grafts were lost from rejection (n=5) or splenic vein thrombosis 
(n=1), and 5 remained viable. All 11 SpTx recipients developed multilineage chimerism, but 
chimerism was rapidly lost if the graft failed. Two control pigs showed <6% blood chimerism 
for 4 and 11 days only. Pigs with functioning spleen grafts had multilineage chimerism in 
blood, thymus and bone marrow for at least 2-6 months, without graft-versus-host disease. 
These pigs developed in vitro donor-specifi c hyporesponsiveness and suppression. In 2 pigs 
tolerant to the spleen graft, donor MHC-matched kidney grafts survived for >4 and >7 months 
in the absence of exogenous immunosuppression; in 2 asplenic pigs, kidney grafts were re-
jected on days 4 and 15. 
Conclusions: Successful SpTx can result in hematopoietic cell engraftment and in vitro do-
nor-specifi c unresponsiveness, enabling prolonged survival of subsequent donor-matched 
kidney grafts without immunosuppression.
INTRODUCTION
Immunological tolerance would eliminate the need for, and avoid complications of, chronic 
immunosuppressive drug therapy. Successful spleen allotransplantation (SpTx) in rodents can 
result in specifi c tolerance towards donor-matched organ allografts in the absence of exoge-
nous immunosuppressive therapy (reviewed in (1)). Studies investigating SpTx in large animals 
have been hampered by technical complications and an absence of knowledge of the major 
histocompatibility complex (MHC) of donor or recipient, and have not demonstrated evi-
dence for tolerogenicity, although specifi c tolerance-inducing immunosuppressive regimens 
were not employed. In humans, however, hematopoietic cell chimerism has been reported 
following SpTx (1). Indeed, the era of hematopoietic progenitor cell (HPC) transplantation (Tx) 
began in 1949 when Jacobsen demonstrated that HPCs present in the lead-shielded spleen 
reconstituted the bone marrow (BM) of mice following lethal irradiation (2). The mechanism 
by which the spleen induces tolerance in rodents remains uncertain.
Massachusetts General Hospital partially-inbred, MHC-defi ned miniature swine constitute a 
suitable large animal model in which to investigate the eff ects of SpTx. We have previously 
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reported that SpTx in miniature swine is technically feasible (3), and that, in MHC-matched, 
minor-mismatched donor and recipient pairs, it results in hematopoietic cell chimerism; when 
a 12-day course of cyclosporine was administered to the recipient, tolerance to the trans-
planted spleen could be achieved (3). The induction of tolerance was associated with a longer 
period of mixed chimerism in blood, lymph nodes, and thymus, but this was not permanent, 
and no engraftment in BM was observed.
If a tolerance-inducing protocol is to be practicable for human organ Tx, then it must at least 
be successful in large animal models across a full MHC barrier, since there are diff erences in 
the response to vascularized organ allografts between small and large animal species with 
regard to tolerance induction. Markedly diff erent tissue expression patterns of MHC class II 
antigens between rodents and large animals could account for this discrepancy in response 
to vascularized grafts. These antigens, which are potent stimulators of the T helper pathway in 
the immune response, are notably absent from the vascular endothelial cells of rodents, but 
expressed in all large animals, including humans. In view of this and the potential risk of graft-
versus-host disease (GVHD), it would not seem wise or ethical to initiate a clinical trial of SpTx 
on the basis of rodent studies alone (1).
We have therefore investigated SpTx in miniature swine using an immunosuppressive regi-
men that is mildly myelosuppressive but non-myeloablative.
METHODS
Animals
SpTx and kidney Tx donors and recipients were selected from our herd of partially-inbred, MHC-
defi ned miniature swine (4). Donors were aged 5.1±3.6 months and weighed 31.5±19.0kg, 
recipients 4.9±4.5 months and 30.8±22.4kg. In order to detect donor hematopoietic cells in 
the recipient, donor and recipient pairs were mismatched for the pig allelic antigen (PAA), 
a non-MHC cell surface marker of unknown function (5), donors being PAA+ and recipients 
PAA-. Donors and recipients had a two-haplotype mismatch for both MHC class I and II (‘full 
mismatch’), except for pig 15111, which was matched for MHC class II, but two-haplotype 
mismatched for MHC class I. 
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use of 
Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH publication No. 86-23, revised 1996).
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Surgical procedures
All recipient pigs had intravascular catheters inserted into jugular veins for blood draw and 
drug infusion. The technique of SpTx in miniature swine has been described previously (3). 
All pigs (including control pigs) underwent native splenectomy and received a transfusion of 
donor unirradiated packed red blood cells on day 0 (the day of splenectomy +/- SpTx) (3). The 
technique of kidney Tx has been described previously (6,7), at which time a unilateral right 
nephrectomy was performed. Once good kidney graft function was assured intra-operatively, 
the native contralateral ureter was ligated; native nephrectomy was performed when the kid-
ney graft had shown good function for a prolonged period.
Recipient irradiation 
Whole body (WBI; 100cGy on day -2) and thymic (TI; 700cGy on day -1) irradiation were admin-
istered from a cobalt irradiator (8).
Immunosuppressive / supportive therapy
Cyclosporine (CyA; Sandimmune, generously provided by Novartis Pharmaceutical Corpora-
tion, East Hanover, NJ) was administered as a single daily infusion of 10-30mg/kg i.v. (adjusted 
to maintain a whole blood trough level of 400-800ng/mL) for 12, 28 or 45 days through an 
indwelling catheter, starting on the day of SpTx. All pigs received daily prophylactic enro-
fl oxacin (5mg/kg/d i.v.) and dalteparin (100IU/kg/d subcutaneously) while indwelling venous 
catheters were present.
Monitoring 
Blood cell count, serum chemistry, and CyA levels were determined daily or x3 weekly by rou-
tine methods. Blood was drawn daily to monitor chimerism during the fi rst 2 weeks, and then 
at increasing intervals until chimerism was lost. Spleen rejection was monitored by sequen-
tial biopsies. Kidney rejection was monitored by serum creatinine and by sequential biopsies. 
Monitoring for graft-versus-host-disease (GVHD) included daily inspection of the skin, stools, 
regular determination of liver enzymes, and biopsy of any skin rash.
Histology of spleen and kidney allografts, host BM, thymus, and lymph nodes
Biopsies of the donor spleen were taken before excision from the donor and 2 hours after 
reperfusion on the day of SpTx (day 0). Biopsies of the spleen, mesenteric lymph node, and 
BM were taken approximately on days 14, 28, 45 and 60, and at increasing intervals thereaf-
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ter. The thymus was biopsied on the same days as the BM, except on day 14. Biopsies of the 
spleen and of the donor-matched kidney grafts (on approximate days 18, 30, 60, and 100 or 
on indication) were prepared as described previously (9). Spleen (9) and kidney (10) rejection 
were diagnosed according to standardized grading systems.
Flow cytometry
T cell count in recipient blood
T cell depletion (as a result of irradiation) was assessed by fl ow cytometry between day -3 and 
day 0 (before and after WBI and TI, respectively) by staining with a FITC-conjugated mouse 
anti-pig-CD3 antibody (898H2-6-15, mouse IgG2aK) (11), with F36.7.5 (IgG2a) as a negative 
isotype control. 
Chimerism in donor spleen and in host blood, BM, thymus, and lymph nodes.
The following swine-specifi c antibodies were used to follow the presence of donor cells and 
their phenotypes in the spleen graft, and in recipient blood, lymph node, thymus and BM (12): 
Anti-CD1 (76-7-4, mouse IgG2aK) (13), anti-CD3 (898H2-6-15, mouse IgG2aK) (14), anti-CD4 
(74-12-4, mouse IgG2bK), anti-CD8α (76-2-11, mouse IgG2aK) (15,16), anti-CD9 (1038H-4-6, 
mouse IgMK) (17), anti-CD16 (G7, mouse IgG1), and anti-PAA (1038H-10-9, mouse IgMK) (5). 
Data were acquired using a Becton Dickinson FACScan (Becton Dickinson Biosciences), and 
analyzed with WinList mode analysis software (Verity Software House, Topsham, ME). 
Anti-donor antibodies 
The development of anti-donor antibodies in the serum before and after SpTx and kidney Tx 
was investigated by FACS (18). Both naïve pig serum and pre-Tx serum from each animal were 
used as controls.
Colony-forming unit (CFU) assay of cells from spleen graft and host BM
Single cell suspensions of spleen graft and BM were made, and in vitro progenitor cell assays 
were performed (19-21). 
Polymerase chain reaction (PCR) assay for functional engraftment of donor cells 
in host BM 
These assays were performed as reported previously (22). 
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Fluorescence in situ hybridization (FISH) of spleen biopsies
FISH was performed on gender-mismatched grafts that were either rejected (14840, recipient 
male/donor female) or tolerated (15051, recipient female/donor male), as described (9). Sec-
tions of lymph nodes from male and female pigs served as controls.
Isolation of peripheral blood lymphocytes 
Peripheral blood lymphocytes were isolated from freshly drawn, heparinized whole blood (8), 
and stored at 4ºC until used.
Mixed lymphocyte reaction (MLR) and cell-mediated lympholysis (CML) assays
MLR and CML cocultures, to test for proliferative and cytotoxic responses to alloantigen, re-
spectively, have been described previously (8,16). 
Suppressor CML (sCML) and suppressor- mlr (sMLR) assays
sCML and sMLR assays were performed as described (14,15) in Group B pigs (see below) after 
all exogenous immunosuppressive therapy had been discontinued and when donor-specifi c 
hyporesponsiveness was observed in CML and MLR assays. In Group C pigs, these assays were 
performed at similar time-points, even when no hyporesponsiveness was seen. 
In sCML assays, cells from tolerant or naïve animals were stimulated for 6 days with irradiated 
(2,500cGy) donor or third-party MHC cells (responder and stimulator each at 4×106 cells/mL). 
After one day of rest, the cells were co-cultured with (a) naive unstimulated recipient MHC-
matched responders (0.5mL at 4×106 primed cells/well and 0.5mL at 4×106 naive cells) plus (b) 
the same antigen present in the original stimulation (1mL at 4×106 cells/mL of either donor or 
third-party MHC stimulators). The co-cultures were incubated for 6 days, after which CML was 
measured using standard techniques.
sMLR assays were set up in two phases: In phase 1, the priming phase, cells from tolerant or 
naive animals were stimulated with donor-matched or third-party cells. In phase 2, the co-cul-
ture phase, the putatively activated regulatory cells were co-cultured with recipient-matched 
naive responders, and stimulated with donor-type or third-party PBL stimulators. Briefl y, for 
primary cultures, responder cells at 4×106 cells/mL from either tolerant or naive MHC-matched 
animals were incubated with either donor- or third-party-type cells for 5 days. Secondary co-
cultures were performed as follows: pre-stimulated cells were rested for 24h, and then either 
(i) cultured again with irradiated stimulators (each at 2×106 cells/mL or 4×106 cells/mL to test 
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for a crowding eff ect) or (ii) placed in co-culture with recipient-matched naive cells (each at 
2×106 cells/mL) and stimulator cells (at 4×106 cells/mL) for an additional 5 days. 
Experimental groups (Table 1)
All pigs in all groups underwent native splenectomy and received a transfusion of washed red 
blood cells (~50mL) on day 0 (day of splenectomy +/- SpTx); in those that underwent SpTx, the 
red blood cells were taken from the spleen donor, and in those that underwent splenectomy 
alone, the cells were from a MHC-mismatched donor pig.
Eleven pigs underwent full (n=10) or class 1 (n=1) MHC-mismatched SpTx (day 0), and received 
either no treatment or varying immunosuppressive regimens (Table 1). Six were tested after 
loss of their grafts (Table 1, Group A), and 5 were studied when the graft remained viable (his-
tologically normal) after discontinuation of immunosuppressive therapy and they remained 
unresponsive to the graft (Group B), although 2 of these pigs subsequently needed to be eu-
thanized due to an outbreak of porcine circovirus in the facility (that aff ected other pigs also) 
(Table 1). Two pigs received the identical conditioning and immunosuppressive regimen as 
the majority of pigs in Group B, including blood transfusion, but did not undergo SpTx (Group 
C). A total of 13 pigs were therefore available for study.
To test for the induction of tolerance to other donor-specifi c organs after discontinuation of 
immunosuppressive therapy, kidney Tx (from a donor MHC-matched to the spleen and/or 
blood donor) was performed in 4 pigs, 2 of which were asplenic and 2 of which were toler-
ant to their grafts. Kidney Tx was carried out in pigs from each of Groups A (15733), B (15111, 
15410), and C (15330) two or more months after SpTx (Groups A and B) or after native splenec-
tomy and blood transfusion (Group C). 
Statistics
Statistical diff erences between Groups A, B, and C were determined by the Students’ t test. A 
p-value of <0.05 was considered statistically signifi cant.
RESULTS
Clinical course after SpTx (Table 1)
Six recipients lost their spleen grafts, and constitute Group A (Table 1). Four, that did not re-
ceive the full regimen, rejected their grafts between days 8-62 (9); one pig that rejected its 
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graft (on day 61) after the full regimen (15311) had poor T cell depletion (64% versus an overall 
mean of 75%, Table 1). In the sixth pig (15733), the spleen underwent rupture following com-
pression and thrombosis of the splenic vein, and was excised on day 3, but CyA was continued 
until day 45; this pig developed features of asplenia (see below). 
Table 1. Immunosuppressive therapy and clinical course in pigs in groups A, B and C
Immunosuppression Spleen 
graft 
survival
(days)
% T cell 
depletion
Chimerism 
blood
(days)
In vitro 
DSH (f)
Complication 
(g)Pig # WBI TI CyA(d) Other GVHD
Group A: 
(n=6)
14534 - - 0 - + (e) 8 ND 5 ND -
14646 - + 0 CPP + (e) 16 ND 10 ND -
14832 - + 12 - - 47 ND 32 ND -
14840 - - 28 - + (e) 62 ND 48 ND -
15311(a) + + 45 - - 61 64.5 49 ND -
15733(b) + + 45 - - 3 78.3 50 ND -
Group B: 
(n=5)
15111 (c) - + 12 - - >363 ND 79 Y -
15051 + + 45 - - >59 82.4 >59 Y PCV-2 (59)
15242 + + 45 - - >57 71.4 >57 Y PCV-2 (57)
15410 + + 45 - - >183 77.7 178 Y -
15842 + + 45 - - >100 73.9 >100 Y -
Group C:
(n=2) 
15312 + + 45 - - N/A 72.5 4 N -
15330 + + 45 - - N/A 76.1 11 N -
WBI = whole body irradiation (100cGy on day -2); TI = thymic irradiation (700cGy on day -1); CyA = cyclosporine (administered i.v. as a single 
daily infusion at 10-30mg/kg to maintain a whole blood trough level of 400-800ng/mL for 12-45 days, starting on the day of SpTx); CPP = 
cyclophosphamide (3x 20 mg/kg i.v. on days -5,-4 and -3). ND=not determined; N/A=not applicable.
(a) Poor pre-Tx T cell depletion. 
(b) Spleen graft excised on day 3 for splenic vein thrombosis. 
(c) MHC-Class I-mismatched donor-recipient combination; all others were full MHC-mismatched pairs. 
(d) CyA-treatment in days. 
(e) Mild cutaneous GVHD, from approximately 1-2 weeks post-Tx. 
(f) DSH = donor-specifi c hyporesponsiveness; N=no; Y=yes; 
(g) Complications: PCV-2 = infection with porcine circovirus type 2; fi gures in parentheses indicate day of euthanasia of the pig.
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No rejection occurred in the remaining 5 pigs that had undergone SpTx and in which the full 
course of CyA had been completed (Table 1) (Group B), allowing data to be obtained of un-
responsiveness to the graft in the absence of exogenous immunosuppression. Three of these 
pigs with functioning spleen grafts were followed for prolonged periods (>100 days), but 2 
pigs had to be euthanized on days 57 and 59, respectively, because of an outbreak of porcine 
circovirus type 2 infection. 
The 2 pigs that underwent native splenectomy and a donor blood transfusion (but no SpTx) 
constitute Group C (Table 1). Both pigs developed features of asplenia, namely thrombocyto-
sis (>1,000k/μL) and Howell-Jolly bodies in the blood, but clinically remained well. 
In summary, therefore, we were able to follow 6 pigs that lost their grafts within 2 months 
(Group A), 5 that remained unresponsive to their grafts (3 for >100 days) (Group B), and 2 that 
never received SpTx but did receive immunosuppression and blood transfusion (Group C).
Graft-versus-host-disease (gvhd)
In 3 pigs in Group A, a mild form of transient, self-limiting cutaneous GVHD (lasting from days 
7-13) was observed (Table 1), confi rmed by skin biopsy histology. Although the Group B pigs 
developed higher levels of chimerism, none developed any clinical or histological features of 
GVHD. 
White blood cell, platelet, and T cell counts
In all pigs that received the full regimen (Table 1), there were temporary reductions in white 
blood cell, platelet, and T cell counts during the fi rst month, though the white blood counts 
never fell below 3K/μL. 
Hematopoietic cell chimerism following SpTx
Spleen graft
Splenocytes and leukocytes in the blood of the donor pigs expressed PAA comparably 
(97.0±2.0% vs 96.1±2.2%). Immediately after donor spleen reperfusion, the number of PAA+ 
cells in the spleen decreased by approximately 7-8%, indicating perfusion of the graft by PAA– 
recipient cells. In grafts that were rejected, there was relatively rapid infi ltration of the spleen 
by host cells, and all cells became PAA– (mainly CD3+/CD8+ and CD16+) (9). In nonrejected 
grafts, the number of PAA+ donor cells decreased by approximately 50% within the fi rst month 
after SpTx, after which there was a slower repopulation with PAA– cells. Within 100-150 days, 
donor cells were replaced almost entirely (>98%) by recipient cells (9). 
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Blood 
Multilineage chimerism in pigs that underwent SpTx (Groups A and B) was initially signifi cant-
ly higher than in control pigs (Group C) (Figure 1A-C). In Group A, the signifi cant diff erence 
with Group C was lost after 15-30 days. Chimerism in all lineages remained signifi cantly higher 
in Group B than in Groups A and C until day 100-150. In the 2 control pigs of Group C, a low 
level of chimerism (1.9-5.9%) resulted from the transfusion of donor blood on the day of sple-
nectomy (day 0), but this fell to almost undetectable levels by day 4, and was not measurable 
after day 11; the chimeric cells were mostly CD3+ lymphocytes. In pigs that lost their spleen 
grafts (Group A), chimerism was completely lost a few days after rejection. When the graft was 
not lost, multilineage chimerism in the blood persisted for a prolonged period (Table 1 and 
A B
C D
Figure 1. Average chimerism in the blood per lineage by fl ow cytometry. 
(A) lymphocytes, (B) monocytes, (C) granulocytes. There was a low level of transient chimerism in the pigs of Group C that received the full 
immunosuppressive regimen and blood transfusion only, but no SpTx. Two hours after transfusion of donor packed red blood cells, the maximum 
levels of chimerism documented were lymphocytes 5.9%, monocytes 3.3%, and granulocytes 1.9% (not shown), after which chimerism in 
all lineages fell rapidly. Monocyte and granulocyte chimerism was undetectable by day 5, and lymphoid chimerism was present at levels of 
0.5-1.0% for only 11 days, consisting largely of CD3+ T cells. Group A pigs were chimeric until day 50, by which time most spleen grafts were 
rejected or were undergoing rejection (Table 1). Group A chimerism was signifi cantly higher than Group C until day 15 (granulocytes) and 30 
(lymphocytes and monocytes). Group B pigs had signifi cantly higher chimerism in all lineages compared to Groups A and C at all time points.
(D) At day 50 (5 days after cessation of CyA therapy) signifi cantly greater chimerism in each lineage was seen in Group B compared to Groups A 
(p<0.05) and C (p<0.05). There were no signifi cant diff erences between Groups A and C (p=0.11). 
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Figures 1A-C); donor T cells sometimes made up >50% of the total T cell pool in the absence 
of GVHD. At day 50, signifi cant diff erences in chimerism existed between the 3 Groups; Group 
B had signifi cantly higher chimerism in all lineages than Groups A and C (Figure 1D). 
Bone marrow
In naïve PAA+ pigs, although PAA is expressed on almost all cells in the blood and lymphoid 
tissues (5), it is expressed on only 50-60% of BM cells. If no spleen was transplanted (Group 
C) or after the spleen graft was lost (Group A), there were no PAA+ cells demonstrable in the 
BM. Chimerism (varying from 2.4% to 26.9%) was detectable in 3 of 5 Group B pigs (except 
pig 15111, the class I-mismatched) (Figure 2A) from day 28. Following correction for low ex-
pression of PAA on BM cells in PAA+ pigs, this chimerism can be interpreted as representing 
approximately 5-55% in the PAA– SpTx recipients. Chimerism in BM generally decreased at 
the same rate as in the blood, although it could be sustained at a higher level, presumably 
because the BM stroma off ers an excellent environment for hematopoietic cells to thrive.
Thymus
As TI of 700cGy causes thymic atrophy (8), thymic biopsies were not taken until day 28. No thymic 
chimerism was seen in the Groups A or C pigs, but was documented in 3/5 Group B pigs; donor 
cells contributed between 2.5% and 33% of thymocytes (Figure 2B). A signifi cant proportion of 
small CD1+ immature thymocytes expressed PAA, indicative of donor thymopoiesis (23). Although 
CD1 is also expressed on a subpopulation of peripheral B cells, the majority of the PAA+CD1+ cells 
in the thymus were also CD4+CD8+ (not shown) and therefore were not donor CD1+ B cells circulat-
A B
Figure 2. 
(A) Mean chimerism in the BM in pigs from Groups A, B and C. Only pigs with a viable spleen graft (Group B) demonstrated chimerism in the BM; 
donor cells accounted for 2.4% to 27.0% of the BM cells. (In a naïve PAA+ pig, PAA expression on BM cells is only 50-60%, as opposed to nearly 100% 
expression on cells in the blood). No pig from Group A or C demonstrated chimerism in BM at any time point during follow up (max. 100 days). 
(B) Mean chimerism in the thymus in pigs from Groups A, B and C. Only pigs with a viable spleen graft (Group B) demonstrated chimerism in the 
thymus; donor cells accounted for 1.5% to 33% of the thymocytes. No pig from Group A or C demonstrated chimerism in the thymus at any time 
point during follow up (max. 100 days).
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ing through the thymus. The level of thymic chimerism was consistent with that of myeloid blood 
chimerism, and refl ected the level of HPC engraftment, as observed by others after BM Tx (24). 
When the spleen remained viable, thymic chimerism was slowly lost, as in BM and blood. 
Lymph nodes
Donor cells in the mesenteric lymph nodes could be demonstrated in all pigs with chimerism 
in the blood (except in Group C), but were lost when blood chimerism was lost (not shown); 
the extent of chimerism refl ected the lymphoid chimerism in the blood, the predominant 
donor cell phenotype being CD3+. 
FISH in spleen grafts
The observations made by fl ow cytometry for PAA+ and PAA– cells were confi rmed by FISH in 
2 cases. In the Group A pig 14840 (male), on day 42 the (female) spleen graft that was under-
going rejection consisted largely of male cells (not shown), indicating infi ltration by recipient 
cells. In the Group B pig 15051 (female), FISH of the (male) spleen graft that was not undergo-
ing rejection demonstrated the co-existence of donor (male) and recipient (female) cells on 
day 57, illustrating the dynamic interchange of cells between graft and host.
CFUs from transplanted spleens 
The CFU growth from donor spleen biopsies taken before SpTx were within the normal range 
of CFU growth from naïve pig spleens; primitive progenitor cells with long-term repopulating 
ability were found in naïve spleens at comparable frequencies to those in the BM of the same 
pigs (25). As early as 28 days after SpTx, all spleen grafts lost signifi cant numbers of HPCs, as 
measured by the capacity of spleen cells to give rise to CFUs in vitro. At the time of histologi-
cally-proven rejection, no CFUs were detected (Figure 3A). Viable grafts, however, maintained 
signifi cant numbers of hematopoietic progenitor cells (HPC) (Figure 3B). The data indicate that, 
in viable spleens, the frequencies of HPC were diminished but still present at signifi cant levels. 
Engraftment of donor spleen-derived HPC in host BM 
Only a limited number of pigs (n=5) could be tested by PCR, since the assay required donors 
positive for MHC Class I/C and recipients negative. Pigs that lost their grafts (n=2) showed 
no donor cells in the BM. Colonies from 3 pigs with viable spleen grafts (obtained from CFU 
assays on recipient BM) were tested by PCR and confi rmatory Southern Blot, and all had evi-
dence for engraftment of donor spleen-derived HPC, at least of some lineages (Figure 3C). 
Evidence for engraftment persisted for several weeks to months, though donor HPC activity 
was eventually lost in all cases. 
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CML assays
Within two weeks of graft rejection, the Group A pigs that rejected their grafts demonstrated 
high responses to donor cells (Figure 4A). 
Whereas pre-SpTx, normal anti-donor responses had been observed, all Group B pigs demon-
strated donor-specifi c hyporesponsiveness (Figure 4B), but remained immunocompetent to 
third party cells (Figure 4C). No donor cytotoxic T cell reactivity to host cells was documented 
in these mixed chimeras (Figure 4D). These pigs also showed post-SpTx hyporesponsiveness 
to all stimulator cells that were matched for MHC class I to the spleen donor (not shown), ir-
respective of their MHC Class II matching (to self, donor, or third party). 
CML assays in Group C never showed donor-specifi c hyporesponsiveness (not shown). In pig 
15330, anti-donor reactivity on the day of donor-matched kidney Tx (day 60) was equal to the 
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Figure 3.
(A) CFU growth from spleen grafts over time in a graft that went on to be rejected on day 61 in a pig that had received the full regimen (15311, 
Group A), and (B) a graft that survived long-term (>183 days) in pig 15410 (Group B) that was treated identically. (CFU-GM = CFU-granulocyte-
monocyte; CFU-GEMM = CFU-granulocyte-erythrocyte-macrophage-megakaryocyte; CFU-E = CFU-erythroid; BFU-E = burst-forming unit-
erythroid). 
(C) Southern Blot from recipient BM-derived CFU-DNA (pig 15410 on day 60; Group B), demonstrating the presence of donor-derived colonies 
in all lineages, indicating donor hematopoiesis (functional engraftment). GM = CFU-GM (granulocyte-monocyte); GEMM = CFU-GEMM. 
(granulocyte-erythrocyte-macrophage-megakaryocyte); CFU-E = CFU-erythroid; BFU-E = burst-forming unit-erythroid; CC PBMC = PBMC from 
a miniature swine of SLAcc haplotype (positive control); DD PBMC = PBMC from a miniature swine of SLAdd haplotype (negative control).
GM-1       GM-2     GEMM-2   GEMM-2   CFU E-1   CFUE-2   BFUE-1   BFUE-2   CC PBMC   DD PBMC  
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Figure 4E
Figure 4.
(A) In the two Group A pigs (14534 and 14646), after rejection of the spleen graft (solid lines), an increased anti-donor cytotoxic T cell response 
was documented by CML assays, expressed as percent specifi c lysis (PSL), in comparison with the pre-Tx values (dashed lines). 
(B) Group B recipients became hyporesponsive to donor stimulators in CML assays for at least 6 months after succesful SpTx, whereas there 
was still a cytotoxic T cell response to third party antigens (C), an indicator of immunocompetence. Since these pigs were mixed hematopoietic 
cell chimeras, the donor-anti-self response was tested as well, but remained negative at all time points (D), indicating that the graft was not 
generating a cytotoxic anti-host response. (E) Donor-specifi c hyporesponsiveness in Group B pigs (in time post-Tx) was signifi cantly diff erent 
from Groups A (at all time points) and C (from day 30 onwards).
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day of native splenectomy (day 0), but hyperresponsiveness to the donor developed after 
rejection of the kidney graft (day 4).
Figure 4E illustrates anti-donor cytotoxic lymphocyte reactivity (eff ector:target ratio 100:1) 
from Groups A, B, and C at diff erent time points. Group B pigs had signifi cantly lower percent 
specifi c lysis (PSL) than Group A pigs at all time points post-Tx, and from day 30 post-Tx com-
pared to control pigs (Group C). 
MLR assays
After rejection, in Group A proliferative T cell responses were increased to donor stimulators, 
but not to third party stimulators or self antigens (not shown).
In Group B, as expected, since pig 15111 was a recipient of a MHC class I-mismatched spleen 
graft (and MLR assays mainly refl ect MHC class II reactivity), this pig never demonstrated re-
activity to donor cells on MLR. The other recipients in Group B showed a similar response 
pattern to their CML responses, with evidence for donor-specifi c hyporesponsiveness (Figure 
5A). Donor MHC class II-matched stimulators were also not able to induce a proliferative T cell 
response in the tolerant recipients (not shown). 
Group C pigs remained responsive to donor antigens. Pig 15330 demonstrated increased pro-
liferation to donor stimulators after rejection of a donor-matched kidney graft (not shown). 
sCML and sMLR assays
After discontinuation of immunosuppressive therapy, in the Group B pigs with donor-specifi c 
hyporesponsiveness, sCML (n=5) and sMLR (n=4; not performed in pig 15111) demonstrated 
that cells from these tolerant pigs were able to suppress the cytotoxic and proliferative T cell 
response from a naive recipient-matched pig to donor antigens, but not to third party anti-
gens, at all time-points tested (Figures 5B-E). 
Although Group C pigs did not show hyporesponsiveness to donor cells in primary CML and 
MLR assays, they were tested for suppressive activity at similar time-points to those in Group 
B. No suppression was seen in either sCML or sMLR. In contrast, when mixed with naïve MHC-
matched cells, the anti-donor responses of the pig’s cells appeared somewhat stronger than 
either of them alone (Figures 5F-I). 
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A
Figure 5.
(A) MLR assays from pig 15410 (Group B, SLA ID/IID) at diff erent time points after SpTx. Other Group B pigs behaved similarly. This pig was long-term 
tolerant to the spleen graft, and later had a long-surviving donor-matched kidney Tx in the absence of exogenous immunosuppression. The anti-
donor proliferative T cell response to donor stimulators was very low (although on day 173 some reactivity may have returned), but remained normal 
to third party antigens. The anti-self response was absent, even though the pig had multilineage chimerism in the blood at all time-points. 
B C
Figure 5.
(B) Results of sCML assays from pig 15410 (DD) (Group B) that was tolerant following fully MHC-mismatched SpTx and subsequently received a 
CC kidney graft. Peripheral blood mononuclear cells taken from pig 15410 were unresponsive to CC (donor) antigens (triangles) and were able to 
suppress the anti-CC response from a naïve MHC-matched pig (DD) (diamonds), whereas mononuclear cells from a naïve MHC-matched pig (DD) 
could not suppress this response (squares). As controls, the response of the naïve DD MHC-matched pig was measured using the normal number 
of cells (crosses), but also with 50% of the cells (stars), which is the number of naïve DD cells when co-cultured with the cells of pig 15410. Other 
Group B pigs had similar responses.
(C) sCML assays indicated that suppression was donor-specifi c, as suppression was not seen after stimulation with third party MHC antigens. 
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D E
Figure 5.
(D and E) demonstrate suppression of T cell proliferation to donor antigens in sMLR assays (pig 15410, representative of all Group B pigs). 
Mononuclear cells from 15410 (DD) suppressed the anti-CC response from a naive DD pig in a donor-specifi c manner. 
F G
H I
Figure 5.
(F and G) demonstrate that donor-specifi c suppression was not observed in the Group C pig 15330 (DD), in which there was almost no diff erence 
between anti-donor (JJ) and anti-third party (YUC) reactivity in sCML assays, as well as in sMLR assays (H and I).
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Humoral responses
The 5 rejectors in Group A developed a vigorous anti-donor antibody response (not shown). 
In contrast, in Group B, no anti-donor or anti-self IgM or IgG antibodies were induced (not 
shown). Group C pigs were only exposed to donor antigen on day 0, when they received an 
unirradiated packed red blood cell transfusion. Both pigs remained negative for anti-donor 
antibodies. 
Clinical course after kidney Tx
Four pigs received donor-matched kidney grafts in the absence of exogenous immunosup-
pression. Two asplenic pigs rejected the kidneys on days 15 and 4, respectively (Figure 6). Two 
pigs that were unresponsive to their spleen grafts maintained kidney grafts for >7 and >4 
months, respectively, and in neither was rejection clearly documented.
Kidney graft survival in asplenic pigs (n=2; Groups A and C)
In the Group A pig 15733, that lost its spleen graft from rupture on day 3, CyA was continued 
until day 45, and donor-matched kidney Tx was performed on day 60. The graft was rejected 
by day 15 (serum creatinine 12 mg/dL) (Figure 6); histologically, it showed diff use intersti-
tial edema and focal hemorrhage, diff use infi ltration with mononuclear cells and neutrophils, 
necrotizing glomerulitis with multiple microthrombi, and necrotizing arteritis with endo-
thelialitis, indicating rejection from both humoral and cellular mechanisms (Figure 7E). The 
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Figure 6.
Serum creatinine levels (mg/dL) in the two recipients of a donor-matched kidney allograft after SpTx (15111, 15410 [both Group B], straight 
lines) and in the two ‘control’ asplenic pigs (15733 [Group A], 15330 [Group C], dashed lines). All kidney transplants were performed in the 
absence of exogenous immunosuppression. 
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Figure 7. Histopathology of kidney allografts in two Group B pigs tolerant to their spleen grafts and in two ‘control’ pigs (Groups A and C). Pig 
15111 (tolerant to MHC class I-mismatched spleen graft, Group B); the kidney (MHC-matched to the spleen donor) showed (A) no features of 
rejection after almost 3 months (H&E x160). Pig 15410 (tolerant to full MHC-mismatched spleen graft, Group B); after 129 days the kidney 
showed (B) type 1 acute cellular rejection with an interstitial mononuclear cell infi ltrate, tubulitis, and glomerulopathy in the absence of 
vasculitis (H&E x160); evidence of chronic rejection was manifested by interstitial fi brosis and tubular atrophy, as well as (C and D) occlusive 
arteriopathy; arrows indicate internal elastic lamina (H&E x200 and Verhoeff  elastic stain x 640, respectively). Pig 15733 (Group A, that lost its 
full MHC-mismatched spleen graft from vascular pedicle compression on day 3) developed (E) acute cellular rejection of the kidney graft by day 
15; arrow indicates fi brinoid necrosis of arterial wall (H&E x160). Pig 15330 (Group C) received a kidney graft from a donor MHC-matched to the 
donor of a blood transfusion given on day 0, and developed severe acute cellular and humoral rejection within 4 days, marked by (F) tubular 
necrosis, proteinaceous casts, and interstitial hemorrhage (H&E x320), as well as (G) endothelialitis (arrow) (H&E x200). 
See addendum for colour version
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ligature on the native ureter was released, allowing the pig to survive. During rejection and 
after graftectomy, the pig showed increased MLR and CML responses to its donor, but did not 
develop anti-donor antibody.
In Group C, pig 15330 received a kidney graft (on day 60), that was MHC-matched to the donor 
of the red blood cell transfusion given at the time of native splenectomy (day 0). Although 
there was a good urine output initially, serum creatinine rose quickly to 6.4mg/dL by day 4 
(Figure 6), and the graft showed histologic features of severe cellular and humoral rejection 
(Figure 7F and G). After graft excision, the native ureter was untied; two weeks later, the pig 
showed increased anti-donor responses on CML and MLR, but no anti-donor antibody was 
present in the serum. 
Kidney graft survival in pigs with viable spleen grafts (n=2; Group B)
Pig 15111 received a kidney MHC-matched to the spleen donor on day 139, which survived >7 
months before the pig was euthanized. Although the kidney graft developed hydronephrosis 
due to scarring of the ureter, associated with a rise in serum creatinine to 2.5mg/dL (Figure 6), 
there were no histopathologic features of acute rejection (Figure 7A). 
Pig 15410 received a donor-matched kidney Tx 60 days after SpTx (by which time CyA was 
undetectable in the blood) without further immunosuppression. The serum creatinine was 
stable (<1.8mg/dL) for 60 days (Figure 6). The increase in creatinine to 4.4mg/dL that occurred 
between days 60 and 65 was associated with antibiotic treatment (gentamicin and vancomy-
cin) for a wound infection, after which the creatinine fell spontaneously (to 2.0mg/dL). How-
ever, the creatinine continued to fl uctuate after day 74, and steadily increased after day 100 
to 8.1mg/dL on day 129 (Figure 6). Although the pig remained in good health and continued 
to produce urine, it was euthanized (see Discussion). Microscopic examination showed type I 
acute cellular rejection accompanied by arteriopathy, glomerulopathy, and interstitial fi brosis, 
which was compatible with either chronic rejection or the so-called “de novo collapsing glo-
merulopathy” (26) (Figure 7B-D). No vasculitis was observed in the graft at any time point. On 
the day of euthanasia, this pig still demonstrated in vitro donor-specifi c suppression, and had 
not developed anti-donor antibody. Furthermore, the spleen graft showed normal histologi-
cal appearance.
DISCUSSION
The induction of Tx tolerance remains an ultimate goal in alloTx. One approach suggested by 
rodent studies (1) is off ered by SpTx. The spleen is an organ with considerable HPC activity, 
and successful SpTx across full MHC barriers in miniature swine induces multilineage chime-
rism and engraftment in host BM in the absence of GVHD. The development of mixed chime-
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rism has been associated with Tx tolerance in various animal models and clinical studies (27). 
Since the donor spleen is normally not used in clinical organ Tx, it would be available for Tx 
along with a life-supporting organ, such as a kidney or heart.
Even though the number of experiments is relatively limited, the present report provides the 
fi rst data from a relevant large animal model. This study indicates that, with adequate pre-Tx 
conditioning of the host, SpTx can lead to multilineage chimerism in the blood, and tempo-
rary engraftment of donor HPC in the host BM, associated with the presence of donor cells in 
the thymus and lymph nodes. The chimerism is associated with donor-specifi c unresponsive-
ness and evidence for suppressor activity in vitro, and prolonged donor-specifi c kidney graft 
survival.
In contrast to SpTx between MHC-matched, minor antigen-mismatched miniature swine (3), a 
12 to 28-day course of CyA and TI was insuffi  cient to protect a fully MHC-mismatched spleen 
from rejection and induce a state of tolerance to this organ; the addition of a low dose of WBI 
and a more prolonged course of CyA therapy was required. This regimen, however, was non-
myeloablative, minimally myelosuppressive and well-tolerated. One hundred cGy WBI had the 
benefi t of reducing the host-versus-graft immune response without aff ecting the graft-ver-
sus-host response of the transplanted spleen, thus facilitating a balance in the two responses, 
as emphasized by Bitter-Suermann and others in rodent models of SpTx (1,28). Its eff ects, 
however, can probably be duplicated by pharmacologic agents administered pre-Tx (29). Ev-
enthough WBI depleted host T cells, TI was probably of benefi t in depleting residual T cells in 
the thymus (30) and in creating thymic ‘space’ (31), thus ensuring exposure of maturing thy-
mocytes to donor antigen that would subsequently be recognized as “self”. TI without WBI was 
not able to prevent rejection. Pre-Tx therapy with a T cell-depleting agent that is eff ective in 
pigs, e.g., the pCD3-CRM9 diphtheria immunotoxin (32), which was not available to us for this 
study, might well negate the need for TI for T cell depletion, but whether it would suffi  ce in 
creating “space” for donor cell engraftment in the thymus is unclear. Co-stimulatory blockade 
with an anti-CD154 monoclonal antibody might also replace TI, as evidenced in mice (33,34).
After SpTx, donor cells (including HPC and antigen-presenting cells) emigrate from a viable 
spleen graft into the circulation over a prolonged period of time, and migrate to the host BM 
and thymus, where they engraft. The signifi cance of their presence in host lymph nodes is 
uncertain, but indicates that they have become widely dispersed throughout the host’s lym-
phoid organs. There is a dynamic exchange of immune cells between the graft and the host. 
If the graft is lost, the source of donor HPC is gone, and therefore chimerism and the potential 
for engraftment is lost. It is not clear why chimerism should be slowly lost while the spleen 
graft remains histologically viable. Although we cannot exclude that donor elements would 
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still have been present in the recipient BM (below the detection limits of fl ow cytometry), we 
know that functional engraftment (i.e., donor-derived colonies from BM-CFUs as evidenced by 
PCR and Southern Blot) was eventually lost. Nevertheless, even though no chimerism could 
be detected, the spleen graft remained histologically viable. 
A major complication following any form of HPC Tx, whether it be BM Tx or the Tx of mobilized 
peripheral blood HPC, is GVHD (35,36). This has also been reported after SpTx in some animal 
models and in humans (1,37-43) and, indeed, has been fatal in at least one patient follow-
ing SpTx (42). One striking observation made in the present study of SpTx was the almost 
complete absence of GVHD, despite the presence of large numbers of mature T cells of donor 
origin. Furthermore, there was an absence in CML assays of donor cytotoxic T cell reactivity 
to host cells. Several diff erences between SpTx and HPC Tx may account for this discrepancy. 
First, the spleen releases donor cells into the host circulation over a matter of weeks or months 
rather than as a single infusion. Second, there are diff erences in phenotype between spleen 
and BM HPC that may be of importance in this respect (24).
The in vitro cellular and humoral responses demonstrated that successful SpTx across MHC 
class I or full MHC barriers was associated with in vitro cellular hyporesponsiveness to donor 
antigens and an absence of an antibody response. Tolerance to the transplanted spleen was 
clearly achieved. Suppressor cell assays strongly suggested that the hyporesponsiveness was 
at least partially a result of the development of regulatory cells. (There is also some evidence 
that tolerance induced by SpTx in rodent models is associated with the development of regu-
latory cells (1).) In the absence of a transplanted spleen, the same immunosuppressive regi-
men did not result in hyporesponsiveness and suppression. A detailed analysis of the suppres-
sor mechanism after SpTx would preferably be done in a rodent model in future experiments 
to characterize cells mediating suppression, since in rodents more T cell antigens are charac-
terized than in pigs and monoclonal antibodies to these antigens are commercially available. 
Furthermore, larger numbers of SpTx can be performed in rodents in a relatively short time. 
We cannot completely rule out that the peroperative donor-specifi c red blood cell transfusion 
participated in tolerance induction, since we included it in all of the experiments. However, 
in Groups A and C there was no evidence of persisting donor cells in the recipient circulation 
or donor-specifi c hyporesponsiveness in vitro. Also, pigs in group C rejected the kidney grafts 
that were from the original red blood cell transfusion donor. 
In the limited number of in vivo studies we have been able to carry out to date, in which a 
donor-matched kidney was transplanted in the absence of further immunosuppressive ther-
apy, we demonstrated prolonged survival of the kidney graft but were unable to conclusively 
demonstrate tolerance to the kidney. Neither kidney transplanted into pigs with long-term 
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functioning spleen grafts and in vitro evidence for cellular hyporesponsiveness underwent 
classical rejection, but both showed features of impaired renal function. Whether this was due 
to non-immunological mechanisms leading to glomerulopathy and/or vasculopathy, as pre-
viously described (25, 44-45), to chronic rejection, or to other cause (26), remains uncertain. 
Even though evidence for regulatory cells was present until the day of euthanasia, this may 
not have been suffi  cient to protect against chronic rejection (46). 
Gradual deterioration of kidney graft function has been reported previously in thymectomized 
pigs that became tolerant to their MHC class I-mismatched renal allografts following recovery 
from acute rejection (47). However, in contrast to our study, there was signifi cant anti-donor 
cytotoxic T lymphocyte reactivity in these pigs. Tolerance was confi rmed by the successful 
Tx of a second donor-matched kidney in the absence of immunosuppressive therapy. This 
approach was not available to us in the present case since, on humane grounds, no further 
surgical procedures were undertaken.
Nevertheless, the prolonged survival of these kidneys in the absence of exogenous immu-
nosuppression is remarkable. In previous studies in miniature swine at our center, kidney al-
lografts transplanted across a two-haplotype full MHC barrier, in the absence of any immu-
nosuppressive therapy, uniformly rejected within 10-20 days (48) in contrast to >4 and >7 
months in the present study. From studies on BM Tx, the presence of HPC chimerism alone in 
a full MHC-mismatched donor-recipient combination may not always be suffi  cient to induce 
tolerance to a subsequent donor-matched kidney allograft in the absence of further immu-
nosuppression (49). 
We have not yet performed simultaneous Tx of the spleen and kidney, but we hypothesize 
that tolerance to the kidney graft would be easier to achieve than when kidney Tx is delayed. 
This hypothesis is supported by experience with concurrent renal and BM Tx in pigs (50), non-
human primates (51,52), and humans (53). These regimens, however, have generally involved 
a signifi cant degree of myelosuppression, achieved by either irradiation or intensive cytotoxic 
drug therapy, whereas in several rodent models successful SpTx has been documented to in-
duce tolerance to other donor-specifi c organs without the need for either myelosuppression 
or intensive immunosuppressive therapy (1). 
SpTx-induced chimerism may lead to donor-specifi c hyporesponsiveness by a central mecha-
nism, but our data suggest that peripheral tolerance is also induced; cells from tolerant ani-
mals could suppress CML and MLR anti-donor MHC responses from naïve pigs matched to 
the recipient. No T cell proliferation or cytotoxicity to donor or self antigens in tolerant mixed 
chimeras following SpTx was observed, suggesting that a peripheral regulatory mechanism 
had developed that controlled both recipient anti-donor and donor anti-recipient alloreactiv-
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ity, as previously demonstrated after HPC Tx (54). Furthermore, SpTx may act as a continuous 
donor-specifi c blood transfusion, and this may also be involved in its ‘tolerogenic’ eff ect. 
In summary, following SpTx, donor and recipient hematopoietic elements interact and inter-
change over a long time-period, associated with in vitro and in vivo hyporesponsiveness to-
wards both donor and recipient, and donor-specifi c suppression. SpTx would therefore seem 
worthy of further investigation in suitable large animal models as a clinically-applicable ap-
proach to the induction of tolerance to allografts, and possibly to xenografts (55). 
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ABSTRACT
Objective: We previously observed high levels (>40%) of multilineage hematopoietic cell chi-
merism following SpTx across full MHC barriers in immunosuppressed miniature swine. We 
therefore investigated the spleen as a source of hematopoietic progenitor cells (HPCs). 
Materials and Methods: Specifi c cell surface markers were used to identify HPCs in the 
spleen and bone marrow (BM) of young adult (n=15) and fetal (n=9) miniature swine by fl ow 
cytometry. Hoechst dye-effl  uxing Side Population (SP) cells were analyzed in adult spleen, 
BM and blood for their expression of c-kit. Functional HPC activity of varying repopulation 
potential in vitro was investigated by the ability of spleens and BM to give rise to colony-form-
ing units (CFUs) and cobblestone area-forming cells (CAFCs) in long-term stromal cultures. 
Studies were also carried out on baboon and human spleens and BM. 
Results: Spleen c-kit+ cells co-expressed more lymphoid markers, but equal myeloid markers, 
when compared with BM c-kit+ cells. BM and spleen both contained signifi cant percentages of 
c-kit+ SP cells. Although the frequency of early-forming CFUs in the spleen was only 0.1-1.3% 
of that in the BM, the frequency of CAFCs developing after 8 weeks in culture was comparable 
to that of BM. Secondary CFUs in long-term culture-initiating cell assays confi rmed the pres-
ence of long-term repopulating cells at comparable frequencies in spleen and BM. Similar 
fi ndings were found with regard to baboon and human spleen cells.
Conclusion: The adult spleen is a relatively rich source of very primitive HPCs, possibly HSCs, 
and may be of therapeutic value.
INTRODUCTION
Hematopoietic progenitor cells (HPCs) have been isolated from several mammalian sources, 
including bone marrow (BM), adult blood after cytokine-mobilization of BM cells, umbilical 
cord blood, neonatal blood, and adult liver (1). The potential therapeutic applications for HPCs 
are extensive, and include cell therapies for malignancies, autoimmune diseases, neurological 
disorders, and genetic syndromes (2). Furthermore, in rodents (3), pigs (4,5), dogs (6), nonhu-
man primates (7), and humans (8), the successful transplantation of donor HPCs results in a 
state of hematopoietic cell chimerism in the recipient which, in turn, is associated with the 
induction of tolerance to a donor-specifi c organ. 
Numerous studies in rodent models have demonstrated that successful SpTx can lead to a 
state of tolerance to a subsequently-transplanted donor-specifi c organ without the need for 
exogenous immunosuppression (9). We have recently developed a model of allogeneic SpTx in 
MHC-defi ned miniature swine (10), and have demonstrated that the spleen can be used as an 
eff ective alternative to BM for providing a state of donor-specifi c unresponsiveness (11). Suc-
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cessful SpTx has been associated with the development of a high level (>40%) of multilineage 
hematopoietic cell chimerism in the recipient’s blood, with evidence for engraftment of donor 
cells in the recipient BM, thymus and lymph nodes for at least 2-6 months (11), thus indicating 
the presence of relatively primitive long-term repopulating HPCs in the porcine spleen. 
Recently, it has been reported that the injection of mouse spleen cells into non-obese diabetic 
mice leads to the regeneration of pancreatic islets, believed to be due to the presence of cells in 
the spleen that rapidly diff erentiate into islet and ductal epithelial cells within the pancreas (12). 
We have investigated naïve (not transplanted) pig spleens by fl ow cytometry for the presence 
of side-population (SP) cells and c-kit expression. We also investigated cells that have short-
term colony-forming unit (CFU) potential, and longer repopulating progenitor populations, 
employing an in vitro limiting dilution assay to identify cobblestone area-forming cells (CAF-
Cs) and long-term culture-initiating cells (LTC-ICs) in pig spleens. The results were compared 
with studies in pig BM and blood. Preliminary studies have also been carried out on naïve 
baboon and human spleens.
METHODS
Sources of spleens and BM
Spleens and BM were harvested from ‘adult’ (3-10 months; n=15) and fetal (60-70 days; n=9) 
MHC-defi ned miniature swine (13). All animal care procedures were in accordance with the 
Principles of Laboratory Animal Care formulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Labora-
tory Animal Resources and published by the National Institutes of Health (NIH publication 
No. 86-23, revised 1996). The Subcommittee on Research Animal Care (SRAC) of the Massa-
chusetts General Hospital approved the research protocols. Baboons (n=4, Papio hamadrayas, 
10-15kg) were from the Mannheimer Foundation, Homestead, FL. Human spleens (n=3) and 
BM (n=1) were obtained from deceased male adult organ donors (40-64 years) (through the 
New England Organ Bank, Newton, MA) with family consent. To our knowledge, these organ 
donors did not have any form of blood dyscrasia.
Studies on adult and fetal pig spleens and BM
Phenotypic analysis of HPC by fl ow cytometry
A single cell suspension was made in fl ow cytometry buff er. After red cell lysis, the concen-
tration was adjusted to 1x107cells/mL. Pig immunoglobulin (50μg/1x106cells) was added to 
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avoid nonspecifi c binding. Biotinylated recombinant porcine stem cell factor (pSCF; BioTrans-
plant Inc., Charlestown, MA) followed by phycoerythrin streptavidin (Pharmingen, San Diego, 
CA) staining detected c-kit+ cells. FITC-conjugated antibodies (counterstain) were anti-CD1 
(76-7-4mouse IgG2a/K) (14), anti-CD2 (MSA4mouse IgG2a) (15), anti-CD3 (898H2-6-15mouse 
IgG2a/K) (16), anti-CD4 (74-12-4mouse IgG2b/K) (14), anti-CD5 (BB6-9G12mouse IgG1), 
anti-CD8α (76-2-11mouse IgG2a/K) (17), anti-CD9 (1038H-4-6mouse IgM/K) (18), anti-CD16 
(G7mouse IgG1) (19), anti-CD25 (K231.3B2mouse IgG1), anti-CD45RA (STH267mouse IgG1), 
anti-SWC3 (74-22-15mouse IgG1/K)(20), anti-MHC class I (2-27-3mouse IgG/K), anti-MHC Class 
II (TH16mouse IgG2a), with biotinylated 12.2.2 and FITC 36.7.5 as negative istotype-matched 
controls (to IgM/K, IgG2a, respectively). Data were acquired using Becton Dickinson FACScan 
(San Jose, CA), and analyzed with WinList software (Verity Software House, Topsham, Maine). 
Identifi cation of SP cells and enrichment for c-kit in adult porcine BM and spleen
Mononuclear cells from above-mentioned tissues were stained with Hoechst 33342 accord-
ing to Goodell et al. (21, 22). In brief, cells were suspended at 1x106 nucleated cells/mL in 
Dulbecco’s modifi ed Eagle’s medium (Gibco), with 2% bovine calf serum (Hyclone), 10 mM 
HEPES buff er (Gibco), and 5 μg/mL Hoechst 33342 (Sigma) and incubated at 37°C for 120min. 
Some samples were also stained at 5 x 106 per milliliter cell density in Hank’s balanced salt 
solution containing 2% bovine calf serum for 90 minutes at 37°C with 6.5 μg/ml Hoechst dye 
(Molecular Probes). After the Hoechst staining, cells were pelleted by centrifugation and re-
suspended at 20-40 x 106 cells/mL in cold Hank’s balanced salt solution containing 2% bovine 
calf serum and 10 mM HEPES (HBSS+) for staining with antibodies on ice. Cells were incubated 
with biotinylated pSCF for 20min, washed in excess with HBSS+, and then incubated with phy-
coerythrin streptavidin for 20min before a fi nal wash and resuspension in HBSS+ containing 
2 μg/mL propidium iodide (Sigma). Flow cytometric analysis was performed on a dual-laser 
MoFlo apparatus (Cytomation, Inc. Fort Collins, CO). An argon ultraviolet laser was used to 
excite the Hoechst dye. Fluorescence emission was collected with a 450/20 BP fi lter (Hoechst 
blue) and 630/30 BP fi lter (Hoechst red). A second 488nm laser was used to excite propidium 
iodide and phycoerythrin; emissions were collected with standard fi lters.
CFU assay for the detection of HPC from adult spleen, BM, and blood
The CFU assay was set up as previously described for pig BM (23-25). Single cell suspensions were 
plated at 5 million (spleen) and 50,000 (BM) cells, respectively, in duplicate 35-mm petri dishes 
(Nunc, Naperville, IL) in 1.5mL of Methocult H4230 (Stem Cell Technologies, Vancouver, Canada), 
supplemented with 30% FBS, 25ng/mL pSCF, 2ng/mL rpIL-3 (BioTransplant Inc.), 5ng/mL rpGM-
CSF; BioTransplant Inc.) and 2U/mL rh-erythropoietin (Amgen, Thousand Oaks, CA). As controls, 50 
million blood cells from 2 diff erent pigs were plated. After 10-14 days of incubation (5%CO
2
, 37°C), 
each culture dish was scored using inverted light microscopy and evaluated for CFU-GM, BFU-E, 
CFU-E, and CFU-GEMM. Only colonies containing >50 cells were counted and classifi ed.
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The same techniques were employed with spleen and BM from 9 pig fetuses (50,000 cells 
plated).
CAFC assay by limiting dilution in adult spleen, BM, and blood
CAFC assays were performed with spleen and BM from the same adult pigs (all aged >8 months) 
(spleen n=3, BM n=2) and with blood from 2 diff erent adult donors, as described (26), using por-
cine cytokines (27). A stromal cell line (EUR-FLS-72/1C5A, from Dr Rob Ploemacher, Erasmus MC 
Rotterdam, The Netherlands), derived from day -12 fetal livers of CBA x C57BL/10 F1 mice, was 
used. Stromal cells were cultured in 96-well plates coated with 0.3% porcine gelatin in stromal 
cell line medium, consisting of Iscove’s modifi ed Dulbecco’s medium with glutamax-1 (Gibco, 
Grand Island, NY), supplemented with 0.2% gentamicin (10mg/mL), 10–4mol/L 2-mercaptoetha-
nol, 20% fetal bovine serum, and 0.36% hydrocortisone (0.1mg/mL, Sigma, St Louis, MO) at 37°C, 
5%CO
2
. Spleen and BM cell suspensions to be evaluated for CAFC activity were plated over 9 
dilutions (from 200,000-783 cells) and cultured at 37°C, 5%CO
2
 for 12 weeks in Myelocult H5100 
(Stem Cell Technologies) supplemented with 25ng/mL pSCF, 2ng/mL pIL-3, and hydrocortisone 
(10–6mol/L), fed weekly. The percentage of wells with at least one phase-dark hematopoietic 
clone of >4 cells beneath the stromal layer was determined every two weeks. 
LTC-IC assay by limiting dilution in adult spleen, BM, and blood
The adherent cells (that had been cultured for 12 weeks in the CAFC assay) were recovered 
after trypsin-EDTA (Gibco) digestion for 5min. The content of each well, containing adherent 
and non-adherent cells, was then seeded into 1.5mL CFU media. After 2 weeks, the presence 
of hematopoietic colonies was scored (wells with >2 CFU considered positive). The frequen-
cies and 95% confi dence intervals of CAFC and LTC-IC were computed using the L-calc soft-
ware, version 1.1 (Stem Cell Technologies). 
Studies on adult baboon and human spleens and BM
Phenotypic analysis of HPC by fl ow cytometry
Applying identical procedures for spleen and BM, we stained baboon and human cell suspen-
sions with biotinylated pSCF, FITC-conjugated anti-human CD9 (M-L13mouse IgG1, BD Biosci-
ences, San Diego, CA), and FITC-CD34 (8G12mouse IgG1, BD Biosciences), with appropriate 
controls; pSCF-DNA has 80-90% homology with that of other species (28) and crossreacts with 
human (25) and baboon cells (29).
CFU assays for the detection of HPC
For baboon and human CFU assays, the methylcellulose-based medium contained the rhSCF, 
rhGM-CSF, rhIL-3, rhIL-6, rhG-CSF, and rhEPO (Methocult H 4435; Stem Cell Technologies).
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CAFC and LTC-IC assays
Methods for CAFC and LTC-IC assays were identical to those in pigs, except that Myelocult 
H5100 (Stem Cell Technologies) with 2ng/mL rhIL-3 (R&D systems, Minneapolis, MN), pSCF 
(25ng/mL), and hydrocortisone (10–6mol/L) was used for CAFC cultures. For LTC-IC, the hu-
man/baboon CFU medium was used. 
Statistical methods
Statistical analysis used paired and unpaired t-tests; p values of <0.05 were considered sig-
nifi cant.
RESULTS
Studies on adult and fetal pig spleens and BM
Phenotypes of HPCs in adult and fetal spleen and BM by fl ow cytometry 
-C-kit+ cells
In adult spleen and BM, 5.6±3.1% and 11.1±2.7% of the nucleated cells were c-kit+, respectively 
(P<0.01) (Figure 1A and B). These c-kit+ cells were found predominantly in the monocyte popula-
tion. c-kithigh populations were found in the BM, but were lacking in most spleens. In fetal pigs, 
the mean frequencies of c-kit+ spleen (9.7±3.2%) and BM (10.6±1.8%) cells were similar (P=0.32) 
(Figure 1C and D). Also, c-kithigh populations were detected in both the fetal spleen and BM.
-CD9– and CD9–/c-kit+ cells
In adult pigs, the mean percentages of CD9– cells in spleen (69.6±7.1%) and BM (20.6±5.6%) 
were signifi cantly diff erent (P<0.001) (Figure 1A and B). In contrast, fetal pigs had a signifi cant-
ly higher CD9– cell population in BM (28.5±8.9%) than in spleen (17.3±5.6%) (P<0.01) (Figure 
1c and d). The mean population of CD9–/c-kit+ cells in adult pigs represented 2.1±1.4% and 
4.4±1.4% of spleen and BM cells, respectively (P<0.01) (Figure 1A and B), and in fetal pigs, 
1.5±0.9% and 2.2±0.9%, respectively (P=0.01) (Figure 1C and D). 
-Markers co-expressed by c-kit+ cells
In adult pigs, spleen c-kit+ cells expressed all of the markers investigated, whereas BM c-kit+ cells 
mainly co-expressed CD9, CD16 and SWC3 (Figure 2A). (Pig CD9 and SWC3 resemble Mac-1 and 
Gr-1 expression in mice, and represent markers for the myeloid lineage (30)). There was no sta-
tistical diff erence in the expression of these markers between spleen and BM, but there was for 
the other markers (P<0.05); spleen c-kit+ cells expressed both lymphocytic and myeloid lineage 
Frank Dor BW.indd   148 18-08-2006   15:06:33
149
Primitive hematopoietic cell populations reside in the spleen
C
h
ap
te
r 
7
markers, whereas the BM c-kit+ population was restricted to the myeloid markers. Fetal pig c-kit+ 
cells from spleen and BM did not diff er statistically in their co-expression of other lineage mark-
ers (Figure 2B). In general, fetal BM c-kit+ cells demonstrated similar phenotype to adult BM c-kit+ 
cells, although with rather less co-expression of CD16 and SWC3 (not signifi cant), whereas fetal 
spleen c-kit+ cells had signifi cantly higher co-expression of CD9 (P=0.001). 
Together, these data indicate that porcine BM c-kit+ cells show similar phenotypic properties to 
HPC in other species, e.g., mice, dogs, and primates (23, 31-33). Porcine spleen c-kit+ cells, hith-
erto not described, diff er from porcine BM c-kit+ cells in that they co-express more markers than 
their BM counterparts. Fetal porcine c-kit+ cells are phenotypically similar in spleen and BM, but 
diff er slightly from adult BM c-kit+ cells in that they co-express fewer myeloid markers.
SP cells and co-expression of c-kit
The average percentages of SP cells in BM, spleen, and blood were 0.07%, 0.06%, and 0.06%, 
respectively. SP cells were enriched for c-kit expression in all tissues. In the spleen, 26% of the 
SP cells were c-kit+, compared to 46% in BM, and 12% in blood. Figure 2C-F demonstrates the 
SP in the spleen, and the enrichment for c-kit. Of the total number of mononuclear cells, c-kit+ 
Figure 1. C-kit+ and CD9+ subpopulations of pig spleen and BM. 
Diff erential expression of c-kit (staining with pSCF) and CD9 in adult spleen (A) and BM (B) and in mid-gestational fetal spleen (C) and BM (D). 
Shown are representative data from 15 adult and 9 fetal pigs. 
A
C
B
D
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SP cells were 0.016% in the spleen, 0.032% in BM, and 0.007% in blood. The enrichment for c-
kit was even more pronounced in the “tip” SP cells that exhibit the most effi  cient effl  ux of the 
Hoechst-33342 dye (data not shown).
CFUs in spleen and BM 
CFUs from all hematopoietic lineages were identifi ed in cultures of both spleen and BM cells as 
CFU-GM, BFU-E, CFU-E, and CFU-GEMM (Figure 3A-D). The frequency of CFU per million spleen 
cells plated was 0.1-1.3% of that found in BM from the same pig, with a mean of 0.47% (Table 1A). 
No signifi cant age-related diff erences (between 3-10 months) were observed (not shown). 
CFUs in peripheral blood of adult pigs 
Preliminary experiments had shown that, when blood cells were plated at similar concentra-
tions to spleen cells, CFU growth from blood was too minimal to quantify (Dor 2003, unpub-
lished data). Even when blood was plated at ten times the concentration of spleen cells, CFU 
frequencies in the blood were only 0-4.5% of those in the spleen (Table 1A). 
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Figure 2. 
A-B: Phenotyping of c-kit+ cells in pig spleen and BM
Co-expression of various markers by c-kit+ cells in (A) adult spleen and BM and (B) fetal spleen and BM. (A) c-kit+ cells from adult spleen and BM 
showed similar co-expression of myeloid markers, but c-kit+ cells from adult spleen had greater co-expression of lymphoid markers. (B) Fetal 
spleen and BM c-kit+ cells showed similar co-expression of all markers tested. ND = not determined.
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CFUs in spleen and BM of fetal pigs
Fetal spleen cells were plated at the same concentration as fetal BM, since the spleen is recog-
nized to be a hematopoietic organ in the pig at the gestational stage of 60-70 days (34). The 
frequencies of CFUs in the fetal spleen and BM were similar (Table 1B), but the BM contained 
more CFU-GM than the spleen (P=0.02). A decrease in spleen CFU activity (by 95-99%) and an 
increase in BM CFU activity (by 148-269%) were seen with the transition from fetal to adult life. 
Nonetheless, the adult spleen continued to be a source of HPC.
CAFCs and LTC-ICs in adult blood, spleen, and BM
CAFC assays were used to determine the size of the pool of primitive progenitor populations 
in blood, spleen and BM. Early-appearing CAFCs represent transient repopulating cells equiv-
alent to CFUs, whereas late-appearing CAFCs (day 28-35 in mouse BM and later in human BM) 
are representative of long-term repopulating stem cells (35). Frequencies of CAFC-week 1-4 
in the blood were comparable to those in the pig spleen (Figure 4A), but there was a marked 
reduction in CAFC-week 6 frequency in the blood, after which CAFC were undetectable. The 
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C-F: SP cells and their expression of c-kit in pig spleen
Flow cytometry data of pig spleen. Dead cells were excluded on the basis of propidium iodide staining, and only live cells were analyzed (C). Nearly 
5% of the spleen cells expressed c-kit, as shown above in fi gure 1a (D). Flow cytometry revealed the Hoechst-33342-staining profi le of spleen cells. 
The selected cell population represents the cells that effl  ux the fl uorescent DNA-binding dye, Hoechst 33342, and identifi es a rare, so-called side 
population (SP) (E). The SP cells in the spleen were highly enriched for c-kit (34% in this fi gure), compared to the total spleen cell population (F). 
C
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CFU-GM
CFU-E
Figure 3. CFUs from pig spleen. 
Morphology of colonies in CFUs from adult spleen. Shown are CFU-GM (A, 10x), BFU-E (B, 20x), CFU-E (C, 40x), and CFU-GEMM (D, 20x). 
Table 1A. CFU frequencies in adult pig spleen, BM and blood
 Colony Spleen BM (Spleen as 
% of BM)
Blood (Blood as 
% of spleen)
No. of cells plated (5x106)* (5x104)* (5x107)*
CFU-GM 170.1+/-109.8 130.8+/-54.8 (1.3) 77.0+/-13.0 (4.5)
CFU-GEMM 5.2+/-5.3 19.5+/-16.2 (0.27) 2.0+/-1.0 (3.8)
BFU-E 5.8 +/-6.7 58.3+/-34.7 (0.1) 1.5+/-2.1 (2.6)
CFU-E 4.2+/-4.5 22.3+/-12.3 (0.19) 0 (0)
* Note diff erences in number of cells plated
Table 1B. CFU frequencies in fetal pig spleen and BM (at 60-70 days gestational age)
Colony Spleen BM (Spleen as % of BM)
CFU-GM 35.5+/-13.6 79.8+/-24.5 (45)
CFU-GEMM 8.3+/-4.6 7.3+/-2.1 (114)
BFU-E 30.8+/-6.7 27.5+/-14.3 (112)
CFU-E 22.5+/-10.5 15.0+/-7.5 (150)
BFU-E
CFU-
GEMM
A B
C D
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diff erence in frequency between CAFC-week 4 and CAFC-week 2 was greater in the spleen 
than in the BM from the same naïve pig (Figure 4B and C). Frequencies of CAFC-week 2-8 in 
spleen were consistently 10-fold lower than those in BM. However, frequencies of CAFC-week 
10 and later in spleen and BM approximated each other, indicating that spleen and BM have 
the same frequencies of the very primitive subsets of HPC. This was confi rmed by the com-
parable frequencies of LTC-IC at 12 weeks in cultures of both spleen and BM (Figure 4D). The 
characteristics of CFUs that arose from week-12 CAFC cultures were similar in LTC-IC from 
spleen and BM, and were restricted to colonies of myeloid morphology. The similarities be-
tween the CAFC and LTC-IC endpoints are consistent with the previous report on porcine BM 
populations separated on the basis of c-kit expression (23).
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Figure 4. Frequencies of CAFC from adult pig blood, spleen and BM.
Frequencies (per 105 cells) of CAFC from adult blood (n=2) (A), spleen (n=3) (B) and BM (n=2) (C). Initially, the frequencies in blood and spleen 
were comparable, but from week 4 blood CAFC frequencies decreased until undetectable on week 8, whereas spleen CAFC frequencies were 
present in signifi cant numbers until week 12. During the fi rst 6 weeks of culture, CAFC frequencies in BM were approximately 10-fold higher 
than in spleen, but thereafter CAFC frequencies were similar in spleen and BM (at approximately 1 per 105 cells). Error bars represent 95% CI. 
(D) Frequencies (per 105 cells) of week 12 CAFC and subsequent LTC-IC were comparable in spleen and BM. There were no statistical diff erences 
between spleen and BM. 
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Table 3. CFU frequencies in adult baboon and human spleens in comparison with adult pig spleen
Colony Pig Spleen Baboon 
Spleen
(% of pig 
spleen)
Human 
Spleen
(% of pig spleen)
No. of cells plated (5x106) (5x106) (5x106)
CFU-GM 170.1+/-109.8 29.7+/-2.1 (17) 9.0+/-2.5 (5)
CFU-GEMM 5.2+/-5.3 1.3+/-2.3 (25) 2.5+/-2.7 (48)
BFU-E 5.8+/-6.7 11.0+/-13.1 (190) 37.0+/-12.1 (638)
CFU-E 4.2+/-4.5 4.0+/-3.5 (95) 15.5+/-14.8 (369)
Studies on adult baboon and human spleens and BM
Phenotypes of HPCs by fl ow cytometry
The expression of HPC markers in baboon and human spleen and BM was studied (Table 2). 
There were higher percentages of c-kit+, CD34+, and CD9–/c-kit+ cells in BM than in spleen. The 
percentages were lower than in the pig. 
CFUs in the spleen
Baboon and human spleen cells were plated at the same concentration as porcine spleno-
cytes (5x106cells/3mL CFU media). In comparison with the pig spleen CFU, some diff erences 
were observed in the frequencies of baboon spleen CFU. The baboon spleen had fewer cells 
that gave rise to “white and mixed” colonies, i.e., CFU-GM, CFU-GEMM, whereas the number 
of “red” colonies, i.e., BFU-E, CFU-E, tended to be higher (Table 3). This may refl ect diff erences 
in spleen function between the two species. The human and baboon spleen had comparable 
CFU frequencies (Table 3). 
CAFCs and LTC-ICs in the spleen and BM 
CAFC-week 2 frequencies in spleen and BM were similar (approximately 5 per 105 cells). How-
ever, CAFC-week 4-8 showed decreasing frequencies in both spleen and BM, with only ~0.1 
per 105 cells from week 8. In contrast, frequencies of CAFC-week 6-10 in the spleen were 
slightly higher than in CAFC-week 2-4 (i.e., ~1 per 105cells), and were 10-fold higher than in 
the BM (Figure 5A). LTC-IC from the 12-week CAFC cultures also demonstrated a similar pat-
Table 2. Frequency of HPC markers in baboon and human spleen and BM
Cell population Baboon
spleen
Human
Spleen
Baboon
BM
Human
BM
c-kit+ 2.5% 1.6% 5.6% 5.1%
CD-34+ 1.8% 2.4% 3.4% 3.6%
CD9– 64.4% 72.7% 72.8% 75.6%
CD9–/c-kit+ 0.59% 0.62% 1.6% 1.5%
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tern in frequencies (overlapping 95% confi dence intervals) of cells that were able to give rise 
to colonies (Figure 5B). 
Figure 6 shows the morphology of “cobblestones” from an adult human spleen after 12 weeks 
in culture.
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Figure 5. CAFC and LTC-IC in human spleen and BM.
Frequencies (per 105 cells) of CAFC from adult human spleen and BM (A). During the fi rst six weeks of culture, the frequencies in BM were higher 
than in spleen, but thereafter, frequencies in spleen remained constant, while the BM-CAFC frequency diminished rapidly. 
Frequencies (per 105 cells) of week 12 CAFC and subsequent LTC-IC were comparable in each tissue (B). There were no statistical diff erences 
between spleen and BM.
A. B.
Figure 6. Cobblestone morphology.
 (A&B) Morphology of “cobblestones” from an adult human spleen after 12 weeks in culture (A, 40x; B, 200x).
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DISCUSSION
Hematopoiesis in humans is sustained by a population of pluripotent stem cells that are ca-
pable of self-renewal and diff erentiation into all lineages of functional hematopoietic cells. 
During early embryonic development, these stem cells reside in the yolk sac and the aorta-
gonad-mesonephros region, and later migrate to the liver, spleen and BM (36,37). Adult he-
matopoiesis essentially occurs in the BM, and pluripotent stem cells are rarely detected in 
the circulation. In humans and other higher mammals, the spleen plays an important role in 
blood formation during much of the period of fetal development, but this function rapidly 
decreases after birth, and the spleen is thought not to participate in hematopoiesis in healthy 
individuals (38). 
In contrast, in rodents the spleen continues to be an accessory hematopoietic organ during 
adult life, although its role may largely be limited to erythropoiesis and megakaryocytopoiesis 
(39-41). As early as 1949, Jacobsen (42) clearly demonstrated the ability of hematopoietic cells 
from the shielded spleen to reconstitute lethally-irradiated mice. Recently, Wolber et al. dem-
onstrated that the spleen from adult mice contained low numbers of primitive HPCs capable 
of long-term reconstitution of hematopoiesis in irradiated hosts (43). 
In higher mammals, when hematopoiesis in the BM is failing from e.g. dysplasia or myelofi -
brosis, the spleen can regain its fetal role in exhibiting extramedullary hematopoiesis (44). It 
is unclear whether the spleen regains its hematopoietic function by stimulation of precursor 
cells that are already present in the spleen or by the de novo migration of circulating HPCs to 
the spleen (38,45).
Our own studies indicated that allogeneic SpTx in pigs induced a state of mixed hematopoi-
etic chimerism in the blood and lymphoid tissues of the host, including the thymus, and that 
donor cell engraftment was established in the recipient BM (11). We therefore wished to eval-
uate whether the naïve porcine spleen contains suffi  cient hematopoietic activity to account 
for engraftment in recipients of spleen allografts. Previously, HPCs have been characterized in 
BM and fetal liver of miniature swine (18,24), but not in the spleen.
For fl ow cytometry, the choice of markers specifi c for HPC in the pig is limited. Porcine-specifi c 
CD34 markers, for example, have not yet been developed and antibodies recognizing CD34 in 
other species do not cross-react with pig cells (46). C-kit is the receptor for SCF, and the use of 
biotin-labeled recombinant pSCF has been reported to contain long-term-repopulating he-
matopoietic stem cell (HSC) activity as determined in both the in vitro CAFC assay and in vivo 
engraftment in NOD/SCID mice (23).
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CD9 is associated with cellular activation, and quiescent HPC possibly increase CD9 expres-
sion upon activation. CD9 expression has been shown to be absent on primitive or early por-
cine HPC (47). Lack of expression of CD9 on HPC may be associated with their retention in the 
tissues of their origin (i.e., BM, spleen) (18). In long-term CAFC assays, which are thought to 
test for more primitive cell populations than CFU assays, CD9negative/low activity was enriched 
10-fold relative to CD9high cells (18).
In the present study, no age-related diff erences in phenotype of c-kit+ spleen and BM cells 
were found in the adult population (>3 months old), but there were notable phenotypic dif-
ferences between the adult tissues and mid-gestational fetal tissues. In fetal pigs, c-kit+ cells 
in both spleen and BM co-express a variety of other markers equally, whereas in adult pigs the 
spleen c-kit+ cell population diff ers considerably from that in the BM in co-expression of other 
markers. Expression of c-kit+/CD9– was used as an indicator of pig HPC to compare spleen and 
BM cells; signifi cantly higher numbers of these cells were present in the BM than in spleen. The 
functional relevance of these diff erences on fl ow cytometry remains unclear.
It has previously been shown that murine HSCs can be highly enriched with the use of the 
fl uorescent DNA-binding dye Hoechst 33342 whereby the SP cells can be distinguished by 
their ability to effi  ciently effl  ux the dye (21,22). Hoechst dye effl  ux has also been used to purify 
primitive stem cells from diff erent organisms, tissues, and developmental states (21,48-50). 
Thus, in contrast to many cell-surface markers, Hoechst effl  ux appears to be a physical prop-
erty that correlates with a general state of “stemness” and could potentially identify the HSC 
with the most potent self-renewal activity. 
In pigs, SP cells have previously been demonstrated in BM (18, 21). We demonstrate for the 
fi rst time that the adult pig spleen also contains this population. Parmar et al. recently dem-
onstrated that SP cells of cytokine-mobilized peripheral blood (and not unmodifi ed blood) 
contain HSC activity (51) and that these cells were enriched for c-kit. In our study, spleen SP 
cells were enriched for c-kit (26%), which is more than 2-fold higher than in blood, although 
lower than in BM. A qualitative hierarchy within the SP population may also exist for porcine 
spleen and BM as the expression of c-kit was more pronounced in the “tip” SP fraction, the 
region that is already known to contain the highest frequency of primitive stem cells in the 
mouse bone marrow (21,51-54).
The pig spleen is relatively larger (on average 8g/kg body weight) than the human or baboon 
spleen (on average 2g/kg body weight), which might refl ect diff erent functions. However, the 
present study would suggest that primate spleens appear to harbor HPCs in similar numbers 
to pig spleens. There were slight diff erences in frequencies of CFU-GM (pig>primate), CFU-
GEMM (pig>primate), and BFU-E (primate>pig). The numbers of baboon and human spleens 
that have become available to us to date have been small, and further studies would be ben-
efi cial.
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Total nucleated cell numbers of adult porcine spleen and BM are comparable (2.2x1010 vs. 2.0 
x1010, respectively). These cell numbers were obtained by harvesting all accessible BM and 
whole spleen from adult pigs. Therefore, the relative frequencies allow a 1:1 comparison when 
estimating total progenitor cell numbers in spleen and BM. Unfortunately, we do not have 
data on total cell numbers in fetal porcine or adult human tissue. 
There are very few reports relating to CFU growth from the human spleen. Freedman et al re-
ported that human spleen cells gave rise to multiple hematopoietic colonies only when there 
was evidence for extramedullary hematopoiesis, generally in patients with a malignant or 
other hematological disease (38); however, no spleens from healthy subjects were examined. 
Meytes (55) documented a signifi cant decrease in BFU-E from the blood after splenectomy; 
tissue from the excised spleen contained signifi cant numbers of BFU-E. In deceased organ do-
nors, CFU frequencies from human spleen cells (that had been maintained in liquid nitrogen) 
were 10-20 fold higher than in the present study (56).
Our data clearly demonstrate that the spleen from adult pigs contains a signifi cant number of 
early HPCs in the form of CAFCs and LTC-ICs. The frequency of more primitive CAFC (>8 weeks 
of culture) closely approximated that in the BM. While CAFC-week 6 have been reported to 
correlate with the long-term repopulating ability of hematopoietic cells in NOD/SCID mice 
and in human BM transplants (57,58), extension of such cultures for longer periods, such as 
in our study, may be necessary to identify the most primitive HSC subset (59). In the pres-
ent study, the murine stromal cell line, EUR-FLS-72/1C5A, proved to be important in allowing 
maintenance of the cultures to 12 weeks without the problems of stromal cell detachment 
that are commonly encountered within the fi rst 6 weeks for many other stromal cell lines.
Correlative data between phenotype and function, especially c-kit vs. CAFC/LTC-IC or repopu-
lation in NOD/SCID mice, already exists. LeGuern et al. (23) reported that purifi ed pig c-kit+ BM 
cells were substantially enriched for both CFUs and CAFCs in vitro and their transplantation 
led to improved long-term porcine hematopoiesis in vivo in mice. 
In summary, porcine spleens harbor very early HPCs that can give rise to hematopoietic colo-
nies of diff erent lineages in vitro. It remains unclear whether the HPCs found in the spleen 
actually actively contribute to hematopoiesis in a normal naïve pig or are generally dormant 
and become hematopoietically active when there is an extra demand on blood formation 
that cannot be met by the BM alone. The fact that the frequency of CAFC from spleen and 
BM is comparable only in the week 8-12 cultures supports the theory that the spleen harbors 
HSCs that are generally quiescent. Irradiation or other myeloablative therapy to the host may 
provide a stimulus for HPC in a transplanted spleen to migrate from the graft to the recipient 
BM, as suggested by our own studies (11). The data obtained in the present study correlate 
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well with our in vivo observations that SpTx can lead to multilineage mixed hematopoietic cell 
chimerism in the blood, and engraftment in recipient BM (11). 
Although our observations on primate spleens are preliminary, they suggest that human 
adult spleens are equally a source of early HPCs. The adult spleen may therefore be a valuable 
source of early HPCs, or even HSC, that may prove of clinical use.
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ABSTRACT
The adult spleen is a source of early hematopoietic stem cells (HSC). We therefore studied 
whether culturing spleen or bone marrow (BM) HSC in medium containing 5-azacytidine 
could induce a cardiac phenotype. C-kit-enrichment and -depletion of adult pig spleen and 
BM mononuclear cells was obtained by magnetic bead separation using biotinylated pig stem 
cell factor (SCF; c-kit ligand). Cells were incubated with 5-azacytidine for 24 h, and refreshed 
with 5-azacytidine-free medium every 48 h. Western Blot was used to detect cardiac troponin 
and myosin heavy chains. 
Although 5-azacytidine treatment led to the formation of ball-like cell clusters in both c-kit 
enriched populations, these clusters showed no rhythmic contractions (beating), as observed 
by others. Furthermore, neither cardiac troponin nor myosin was detected in cells derived 
from either source. Our methodology and treatment with 5-azacytidine did not induce car-
diac gene expression in porcine HSC derived from either pig spleen or BM.
INTRODUCTION
Although the presence of hematopoietic stem cells (HSC) is well characterized in the bone 
marrow (BM), we have recently shown that the spleens of pigs, baboons, and humans are 
also sources of early HSC (1). Although CD34 is often used as a marker of the earliest HSC, it 
is also known that, in the sequence of events associated with hematopoietic diff erentiation, 
porcine cells expressing c-kit (c-kit+) contain pluripotent HSC as well (2). Through the use of 
the cobblestone area-forming cell (CAFC) assay, one assay that defi nes the presence of early 
hematopoietic stem cells (3,4), we documented an equal frequency of these earliest stem 
cells in BM and spleen (1). The question was then raised whether these c-kit+ stem cells might 
refl ect an early pluripotent state that could be directed away from hematopoietic fate.
Recent work at understanding the repair of infarcted myocardial tissue and the ability of fetal 
myocardial cells to potentially repair cardiac tissue has generated interest in this fi eld as a po-
tential therapeutic option (5). At the same time, ethical ramifi cations and technical problems 
of fetal tissue acquisition have generated great interest in adult stem cell populations and the 
ability of these cells to dediff erentiate and be directed toward other fates (6-10). Along these 
lines, the ability of 5-azacytidine, a cytosine analog, to induce altered gene expression and in 
vitro cellular rhythmic contractions, associated with a cardiac phenotype, has been well docu-
mented (11-14). Fukuda has demonstrated that regenerative cardiomyocytes can be gener-
ated in the rat from BM stromal cells (MSC) using 5-azacytidine (14), and Tomita et al. (15) have 
demonstrated that porcine heart function improved following the infusion of 5-azacytidine-
treated MSC into infarcted myocardium. 
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In view of the work of Rangappa et al. (16), which demonstrated the ability of adipose-de-
rived rat mesenchymal stem cells to diff erentiate towards cardiac fate, a similar approach was 
applied to the c-kit -expressing HSC from the spleen and BM. The spleen, like the BM, is a 
hematopoietic tissue of mesodermal origin and, as such, may serve as a repository for stem 
cells that retain their plasticity. Recent work by Kodama et al. (17), which showed that injected 
mouse splenocytes contribute to the regeneration of functional pancreatic islet cells, sug-
gests that the transdiff erentiation of splenic cells to an alternate phenotype may, in fact, be 
possible.
Based on the shared embryonic origins of the splenic and BM HSC, and further supported by 
their similar CAFC frequencies at 12 weeks of culture (1), we attempted transformation of c-kit 
expressing HSC from spleen and BM cells toward cardiac fate by an approach that has been 
reported to be successful by others working with mesenchymal stem cells.
MATERIALS AND METHODS
Animals
Four naïve pigs were obtained from the Massachusetts General Hospital herd of partially-
inbred MHC-defi ned miniature swine (aged 3-5 months), whose characteristics have been 
described in detail previously (18). All procedures were in accordance with the Principles of 
Laboratory Animal Care formulated by the National Society for Medical Research and the Guide 
for the Care and Use of Laboratory Animals produced by the Institute of Laboratory Animal Re-
sources and published by the National Institutes of Health (NIH publication No. 86-23, revised 
1996).
Primary culture of porcine c-kit+ cells
Spleen and sternal BM samples were obtained in a sterile fashion from adult pigs immedi-
ately following the administration of an overdose of pentobarbital to induce euthanasia. 
The samples were washed in Hanks Balanced Salt Solution (HBSS) (Gibco, Grand Island, NY), 
and minced in a dish of RPMI 1640 culture medium (Mediatech, Herndon, VA). The resulting 
suspension was passed through a 40-micron fi lter (BD Biosciences, San Jose, CA), diluted 1:1 
with HBSS, and mononuclear cells isolated using a gradient of lymphocyte separation me-
dium (ICN Biomedicals, Aurora, OH). The buff y coats were harvested and residual erythrocytes 
lysed using ACK lysing buff er (Cambrex Bio Science, Walkersville, MD). The cells were resus-
pended in culture medium consisting of RPMI 1640, 15% fetal bovine serum, penicillin (1U/
mL), streptomycin (1mg/mL), gentamicin (0.05mg/mL), amphotericin B (0.34μg/mL) (all from 
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Gibco), Hepes buff er (10mM, Mediatech), and glutamine (2 mM, Gibco). The cells were incu-
bated with 1:40 porcine biotinylated recombinant porcine stem cell factor (pSCF; c-kit ligand) 
(BioTransplant, Charlestown, MA) (2), and then with magnetic cell separation (MACS) anti-
biotin magnetic microbeads (MiltenyiBiotec, Auburn, CA), and separated over MACS LS col-
umns (MiltenyiBiotec) with the negative fraction being retained for use in the c-kit-depleted 
(c-kit–) cultures. The c-kit+ cells were then eluted for use as the HSC. 1x106 cells were removed 
from each population for FACS analysis to evaluate purifi cation of the diff erent populations. 
Both the c-kit+ and c-kit– cell populations for the spleen and BM were counted, and separately 
seeded onto 25-cm2 fl asks at a concentration of 1x106 cells/mL in the same culture medium 
as above. At 24 h, the cells were trypsinized (0.25% trypsin with EDTA, Mediatech) and resus-
pended in the above culture medium. 
Treatment with 5-Azacytidine
Half of the cells from both c-kit+ and c-kit– cultures were transferred from the culture fl asks 
into 6-well plates in culture medium (as described above) with the addition of 5-azacytidine 
(Sigma-Aldrich, St. Louis, MO) at a concentration of 9μM. This was the same concentration 
used in previous experiments in which a cardiac phenotype was observed. The other half was 
cultured in the same manner in the absence of 5-azacytidine. After 24 h incubation with 5-
azacytidine, 40% of the medium was removed from each well, and replaced with fresh culture 
medium without 5-azacytidine. Medium (40%) was again removed and replaced after 36h and 
48h in order to titrate down the concentration of 5-azaycytidine as quickly as possible. Culture 
medium was thereafter changed every 48 h. The cells were observed under an inverted light 
microscope at several time points over 5 weeks.
Phenotypic assessment of cell cultures by fl ow cytometry
Cell suspensions for fl ow cytometry from the BM and spleen were resuspended in fl ow cy-
tometry buff er, consisting of HBSS, 0.1% BSA, and 0.4% sodium azide (diluted 1:1:1). Pig im-
munoglobulin (5 μg/106 cells) was added to prevent nonspecifi c binding. Cells were labeled 
with biotinylated recombinant pSCF; biotinylated 12.2.2 (IgM) and fl uorescein isothiocyanate 
(FITC) 36.7.5 (IgG2a) were used as negative isotype-matched controls. 
Western Blot and visualization
After 5 weeks in culture, cells were removed from the bottom of the plates using 0.25% tryp-
sin with EDTA and lysed at a concentration of 100μL/106 cells using a solubilization buff er, 
consisting of 100mM NaCl, 1.0% SDS, 50mM TEA (pH 7.4), 1mM DTT, 1mM PMSF, and Protease 
Inhibitor Cocktail for use with mammalian cell and tissue extracts 1:1000 (Sigma-Aldrich). The 
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resulting lysates were loaded under reducing conditions onto SDS-PAGE gels (7.5% and 12.5% 
acrylamide for myosin and troponin staining, respectively). The proteins were then transferred 
to nitrocellulose membrane (Hybond C, Amersham Biosciences, Piscataway, NJ) and stained 
with Ponceau Red to assess protein transfer. The nitrocellulose was incubated in blocking buf-
fer (PBS with 10% fetal bovine serum and 0.1% Tween) overnight, washed, and incubated 
for 1 h with either mouse anti-myosin heavy chain (with known pig reactivity) (0.2μg/mL) 
(Biodesign International, Saco, ME) or anti-troponin I (known to have pig reactivity) (0.2μg/
mL) (Novus Biologicals, Littleton, CO) monoclonal antibodies diluted in the same. The mem-
branes were washed in blocking buff er and incubated with HRP-conjugated anti-mouse IgG 
(1:25,000) (Southern Biotechnology Associates, Birmingham, AL). The SuperSignal West Pico 
chemiluminscent substrate kit (Pierce Biotechnology, Rockford, IL) was used to develop the 
blots. 
RESULTS
c-Kit purity by MACS cell separation
The isolation of c-kit+ populations from the BM was substantially more effi  cient than that from 
the spleen tissue (Table 1). Following cell separation, in the BM, there was a signifi cant diff er-
ence in mean c-kit expression between the populations: 66.01%±14.67% c-kit+ cells in the en-
riched population, and 3.31%±1.76% in the depleted population (p=0.01). In the spleen, the 
separation came close to, but did not achieve, statistical signifi cance; enriched cultures con-
tained a mean of 19.98%±7.07% c-kit+ cells, and depleted samples contained 3.44%±1.06% 
c-kit+ cells (p=0.05). When BM and spleen were compared, there was no statistical diff erence 
between the respective c-kit-enriched populations (p=0.07) or the respective c-kit-depleted 
populations (p=0.93).
Growth and morphology of cultures prior to 5-azacytidine treatment
Following separation, there was a gross diff erence in the overall morphology of the cells from 
the two tissues. BM c-kit+ isolates had cells that were larger and well rounded compared to 
splenic c-kit+ isolates, where the cells were much smaller and had more variation in shape 
(Figure 1). In the c-kit– cultures, the BM cells were somewhat smaller than in the correspond-
ing c-kit+ BM cells, but still remained well rounded. Morphologically, splenic c-kit– cultures 
were not as distinct from splenic c-kit+ cells as in the BM. Both splenic populations were of the 
same relative size, and featured variation in cell morphology that included both smaller, well-
rounded cells, and other more spindle-shaped cells.
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Eff ects of 5-azacytidine treatment
Bone marrow
Regardless of exposure to 5-azacytidine, there were substantial morphological variations be-
tween the samples (Table 2). In only one of the three 5-azacytidine-exposed, c-kit -enriched 
BM samples were multinucleated fusion bodies visualized, that resembled those observed 
by Taylor and Jones (13) or Rangappa et al. (16). In this single culture, at one week there were 
several separate foci of fi broblast or triangle-like morphology. This growth continued through 
Table 1. Enrichment of c-kit hematopoietic stem cells in porcine bone marrow and spleen
Tissue Trial  %c-kit %c-kit  %c-kit
unseparated1 enriched2 depleted3
Bone Marrow 1* 20.38 81.84 5.34
2 7.36 52.88 2.34
3 8.06 63.31 2.28
Mean 11.93 66.01 3.32
Standard Deviation 7.32 14.67 1.75
Spleen 1 4.99 12.1 2.77
2* 4.49 25.79 2.89
3 8.79 22.04 4.67
Mean 6.09 19.98 3.44
Standard Deviation 2.35 7.07 1.06
1 % c-kit unseparated = % c-kit+ cells prior to separation over column
2 % c-kit enriched = % c-kit+ cells in enriched cultures
3 % c-kit-depleted = % c-kit+ cells in depleted cultures
* indicates those samples that showed multinucleate ball masses
A B
Figure 1. BM and spleen c-kit-enriched cultures. 
One day after separation over a magnetic column, BM c-kit-enriched cultures show larger and more rounded cells (A) compared to spleen c-kit-
enriched cultures (B).
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week 2, with the joining of separate fi broblastic foci and the presence of multinucleated 
masses by day 23 (Figure 2A). The masses continued to grow in size until day 29, when they 
assumed a constant size without further change in morphology. These masses ranged from 
1 to 9 per well, and were only present in foci with high fi broblastic activity. At no point over 
the 5 weeks of culture was either rhythmic or nonrhythmic beating observed in any of the 
structures. 
The other two 5-azacytidine-exposed, c-kit-enriched BM samples showed similar fi broblastic 
activity through week 2, but there was no subsequent evidence of multinucleated masses. 
A growth pattern without multinucleated masses was consistently observed in each of the 
c-kit-depleted cultures exposed to 5-azacytidine in addition to both groups of cultures that 
were not exposed to 5-azacytidine at any time (Figure 2B). Growth in cultures not exposed to 
5-azacytidine was relatively decreased, with some cultures showing foci of growth that did 
not join with neighboring colonies.
Spleen
In the spleen, there was considerably greater variation (Table 2). Multinucleated cell masses 
similar to those seen in the BM were visualized in only one culture that was enriched for c-kit 
and exposed to 5-azacytidine. The observed changes followed a similar time course to that in 
the corresponding BM culture (Figure 2C). Of the other two c-kit -enriched samples exposed 
to 5-azacytidine, however, fi broblastic activity was present in only one. The other culture re-
mained static with cells fi xed to the bottom of the well, but with no visible sign of cellular 
extensions (Figure 2D). This same growth was observed in the cultures that were exposed 
to 5-azacytidine and depleted of c-kit, as well as in each of the cultures that were neither 
Table 2. Relationship between exposure to 5-azacytidine and morphology
Source of Cells c-kit 5-azacytidine Morphology of Cells
(3 samples in each group)
Bone Marrow enriched + 1 with fusion bodies, 2 with fi broblastic activity but no fusion bodies
depleted + 3 with fi broblastic activity but no fusion bodies
enriched - 3 with comparatively decreased fi broblastic activity; no fusion 
bodies
 depleted - 3 with comparatively decreased fi broblastic activity; no fusion 
bodies
Spleen enriched + 1 with fusion bodies
1 with fi broblastic activity and no fusion bodies
1 stagnant with no growth
depleted + 3 stagnant with no growth 
enriched - 3 stagnant with no growth
depleted - with strong fi broblastic-like growth, but no fusion bodies 
2 stagnant with no growth 
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exposed nor enriched. In the c-kit-depleted populations that were not exposed to 5-azacyti-
dine, strong fi broblastic activity was present in only one sample, which displayed the same 
clustered cell masses as in the c-kit -enriched population. 
Western Blot analysis
Analysis by SDS-PAGE did not detect the presence of either cardiac troponin I or cardiac myo-
sin heavy chain in any of the cultures generated, regardless of exposure to 5-azacytidine. In 
those single BM and spleen cultures that showed multinucleated cell masses, expression of 
these proteins was again negative. Control samples of freshly processed porcine cardiac tis-
sue were used as positive controls for the myosin heavy chain and troponin antibodies; fresh 
splenic tissue was used as a negative control in each gel (Figure 3). Extended exposures of 
each blot were done in order to detect low-level expression of either myosin  or troponin, but 
no signals were observed in any of the samples (data not shown).
Figure 2. BM and spleen c-kit-enriched populations showed various morphologies at day 21 following exposure to 5-azacytidine. 
(A) c-Kit enriched BM culture, exposed to 5-azacytidine, showing a multinucleate fusion body 
(B) c-Kit enriched BM culture, exposed to 5-azacytidine, showing fi broblastic growth, but no fusion bodies 
(C) c-Kit enriched spleen culture, exposed to 5-azacytidine, showing a multinucleate fusion body similar to that in (A) 
(D) c-Kit enriched spleen culture, exposed to 5-azacytidine, showing stagnation, with no growth or fi broblastic activity
A
C
B
D
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DISCUSSION
The ability of 5-azacytidine to induce novel gene expression has been documented by several 
diff erent groups over the last few decades (11-16). Although Constantinides et al. (11), were 
the fi rst to describe the appearance of multinucleated striated muscle cells in non-myeloblast 
precursors following 5-azacytidine treatment, it was Makino et al. (19) who fi rst described 
the appearance of cardiomyocytes from immortalized BM stromal cells in 1999. Because it 
was necessary for cell lines to be immortalized for this conversion, any clinical utility of this 
methodology remained questionable. However, soon after this, Tomita et al. (20) reported 
that MSC in a primary culture were also capable of achieving this phenotype, and Rangappa et 
al. (16) have recently reported that mesenchymal stem cells derived from fatty tissue in rats as-
sume a rhythmic beat consistent with cardiac phenotype following exposure to 5-azacytidine. 
However, there is some confl ict in the literature, as Liu et al. (21) have reported an inability to 
reproduce these results in rat primary BM stromal cell cultures. Their work suggested that, un-
less the cell line was immortalized, a cardiac phenotype was not achievable. The present study 
was an attempt to add further experience by assessing the utility of 5-azacytidine to infl uence 
the fate of porcine pluripotent HSC.
Figure 3.  Absence of expression of troponin I or myosin in BM or spleen cultures on Western Blot. 
BM and spleen stained for troponin ( a , b ); BM and spleen stained for myosin ( c , d ). 
1 = Molecular marker; 2 = cardiomyocytes (control); 3 = BM c-kit enriched + 5-azacytidine, 4 = BM c-kit depleted + 5-azacytidine; 5 = spleen 
c-kit enriched, no 5-azacytidine; 6 = spleen c-kit depleted, no 5-azacytidine; 7 = homogenized spleen (control). Lanes 2 and 7 are positive and 
negative control, respectively.
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Based on our previous work, it was known that a small fraction of c-kit+ cells that were also 
CD9–, and therefore non-mobilized, were present in the spleen (1). The work of Le Guern et al. 
(2), which showed that c-kit+ was a marker for HSC, and that this cell population displays early 
engraftment capacity, lead us to believe that these cells might be very early stem cells pres-
ent in the spleen. Indeed, CAFC assays indicated that the earliest stem cells in the spleen were 
present at an equal frequency to those in the BM, raising the question of whether this popu-
lation, or another splenic cell population, may have the same potential as the HSC and MSC 
described above. It was a central premise to our study whether enrichment for c-kit would 
improve the conversion of HSC to cardiac phenotype, if this were at all achievable. 
Although CD34 is a widely-used marker for HSC in rodents and humans, there is not yet a com-
mercially-available anti-CD34 antibody for pigs. However, c-kit+ expression is known to have 
a strong correlation with stem cell activity, and can therefore reliably be used as a stem cell 
marker in pigs (1,2). By using both BM and spleen as sources of HSC, it has been possible to 
compare the results, not only between these two sources, but also between splenic HSC and 
the MSC described by others (16,19-21). If such an increase in effi  cacy had been seen, there 
would have been some argument for including c-kit as a possible marker for increased plastic-
ity and potential conversion to cardiomyocytes. If c-kit expression were unrelated to pheno-
type conversion, there would have been similar frequency of cardiac conversion regardless 
of the enrichment status, provided that the cells were still exposed to 5-azacytidine. If this 
were the case, it was hypothesized that separation over a magnetic column would not aff ect 
the results. However, it should be noted, that we were unable to achieve the same effi  cacy in 
separation in the spleen as in the BM, despite the same methodology. This may result from 
the fact that, although spleen cells express c-kit, they do not express c-kithigh as do the HSC of 
the BM (1). This distinction may be one cause for the diff erence in purity of the cells obtained 
from the MACS columns. Although the eff ect of this variation remains uncertain, we believed 
that it was more important to maintain an identical, standardized separation protocol for both 
tissues. Thus, we included any cells expressing c-kit, whether c-kithigh or c-kitlow, in the c-kit+ 
group, and only those cells failing to express any c-kit at all in the c-kit- group.
Our results were consistent with the observations of Liu et al (21). Although we observed a 
similar fi broblastic growth pattern to Rangappa et al. (16), our cultured cells not only failed to 
beat, they also failed to express cardiac-specifi c proteins at any level. The gross appearance 
of the multinucleate structures in one BM and one spleen from separate animals was most 
consistent with the formation of chondrocyte structures fi rst described by Taylor and Jones 
(13). As noted by Chacko et al. (22) and Benya et al. (23), however, the chondrocyte pheno-
type in culture is quite unstable and degrades with subculture. As a result, it was impossible 
to better analyze the composition of these structures. We do not exclude the possibility that 
the multinucleate masses we observed may have been foci of cell types other than cardiac 
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cells. In view of our interest in applying the successful approach of other scientists working 
with 5-azacytidine and cardiac transformation, our experiments focused only on determining 
the presence of cardiac-specifi c troponin and myosin. However, the infrequent and seemingly 
random appearance of the multinucleate structures in our work attests to the argument by Liu 
et al. (21) that genetic reprogramming by 5-azacytidine may be nonspecifi c. Because it is a cy-
tosine analogue, and appears to work by altering gene methylation (24), it is more feasible to 
hypothesize a sequence of random gene activation than specifi c cardiac gene potentiation.
The basis for the discrepancy between our results and those of some others (11-13,14-16) is 
diffi  cult to assess. Since we did not carry out a ‘control’ experiment in an attempt to confi rm 
that, following exposure to 5-azacytidine, porcine MSC can diff erentiate into cardiomyocytes, 
or compare porcine HSC with their murine counterparts, the negative result we obtained 
could be associated with technical discrepancies or failures. For example, the particular cul-
ture conditions we employed may not have been appropriate for porcine cells. Furthermore, 
our lack of better ‘control’ experiments is explained by the considerably low cell yield associat-
ed with the purifi cation and separation procedures; this aff orded us only enough cells to carry 
out the ‘experimental’ segment of our protocol. Increasing the number of experiments would 
not have addressed this problem, as the issue was one of low cell yield following separation 
and not necessarily variation between the samples of each tissue examined. A fi nal possibility 
is that, although we were not able to confi rm troponin and myosin expression in these cells at 
the 5-week point, other cardiac proteins, such as Nk2.5 or alpha-actinin, may have been pres-
ent at other time points during the experiment. As the scope of our study was limited by the 
commercial availability of porcine markers for these proteins, we were not able to invesitgate 
for their presence. As this was an initial study into the “plasticity” of splenic HSC, we restricted 
our Western blot analysis to those cardiac proteins described by others and did not attempt 
detection of proteins that may be expressed by bone, cartilage, or endothelial cells. These 
limitations can only be resolved by further investigations, possibly on a larger scale. 
The goal of our work was not to defi nitively answer the question of HSC plasticity in a porcine 
model, but rather to stimulate new thinking with regard to an alternative source of adult stem 
cells for transdiff erentiation studies, namely the adult spleen. One other important diff erence 
that may account for variability in results is the donor species. Although Tomita et al. (15) 
assessed porcine myocardial function following infarction and the subsequent infusion of 5-
azacytidine-treated MSC, the majority of in vitro studies have been in rodent species. Pig BM 
and splenic cells may not have the same pluripotency or transforming capabilities as those 
in lower mammals. It is also possible that, in the pig and higher mammals, culture by the 
method we utilized may drive the cells into a state of senescence, and therefore less suscep-
tible to the eff ects of 5-azacytidine. Additionally, if 5-azacytidine requires a certain state of 
cellular interaction, enrichment or depletion of c-kit+ stem cells may be detrimental to the 
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intercellular contact or cytokine-mediated microenvironment that may be necessary. The en-
richment of c-kit+ cells by MACS may have resulted in the removal or destruction of critical 
cellular components through specifi c or non-specifi c binding to the column; however, the 
lack of correlation between fi broblastic growth states and individual c-kit concentrations sug-
gests another mechanisms may be at work. Finally, only one concentration of 5-azacytidine 
(9μM) was tested, based upon previous reports that this concentration was the most eff ective 
at inducing cardiac phenotype (16). As our cells were plated at a higher density than that pre-
viously reported (16), the concentration of 5-azacytidine may not have been suffi  cient. While 
the absence of any clear cardiomyocyte phenotype is consistent with the failure to detect 
either myosin or troponin by Western Blot, it is also possible that this technique may not have 
been sensitive enough to distinguish expression of these proteins by a small subpopulation 
of cells.
Our study does not preclude the ability of BM and splenic cells to be transformed towards 
cardiac phenotype. It does, however, suggest that our methodology for the enrichment or 
depletion of c-kit+ stem cells does not effi  ciently aff ect this process.
CONCLUSIONS
Treatment with 5-azacytidine of cultures derived from the porcine BM and spleen led to an 
unpredictable pattern of growth. Regardless of exposure to 5-azacytidine, fi broblastic activity 
was present to varying extent among separate populations of c-kit+ and c-kit– populations. 
Although there were some ball-like formations in both BM and spleen c-kit+ populations that 
were similar to those observed by others, these cell clusters showed no sign of in vitro beat-
ing. Furthermore, neither cardiac troponin nor myosin heavy chain were detected by Western 
blot in cells derived from either source. These results suggest that, using the protocol we em-
ployed, MACS of c-kit+ stem cells and treatment with 5-azacytidine is not an effi  cient means 
of inducing cardiac gene expression in porcine HSC derived from either BM or spleen.
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In several rodent models spleen allotransplantation has been shown to be associated with do-
nor-specifi c tolerance to allo-antigens (1). To study the tolerogenic capacity of the spleen in a 
systematic manner in large animals with known MHC barriers, we have developed an allogeneic 
spleen transplantation (SpTx) model in MHC-defi ned miniature swine (2). One of the goals of 
investigating SpTx as a potential for tolerance induction was its extrapolation to xenoTx. 
In our allogeneic SpTx experiments, we have observed that all recipients develop hemato-
poietic cell chimerism in the blood. Across full MHC barriers, when recipients were treated 
with 100cGy of whole body irradiation, 700cGy thymic irradiation, and a 45-day course of 
cyclosporine, multilineage chimerism was present in the blood and lymphoid tissues, and in 
some cases resulted in engraftment of donor cells in recipient bone marrow (BM). This was 
associated with in vitro donor-specifi c hyporesponsiveness in mixed leukocyte reaction (MLR) 
and cell-mediated lympholysis (CML) assays. Long-term survivors demonstrated evidence for 
donor-specifi c regulatory T cell activity, since peripheral blood mononuclear cells from these 
pigs contained a cell population that was able to suppress anti-donor responses of cells from 
naïve recipient-MHC-matched pigs in suppressor-CML and -MLR assays (Chapter 6). 
We have performed xenogeneic pig SpTx in two baboons, in the fi rst of which we established 
that the surgical technique used in our pig alloTx model was also feasible in the pig-to-ba-
boon model. The second baboon (B221) also received donor-specifi c BM Tx 4 hours later. We 
here report our observations in B221 and compare them with those in a baboon (B219) that 
received BM Tx only (with no SpTx). 
Both baboons were conditioned with a fairly complex regimen based on the pig-to-baboon 
BM Tx regimen reported previously (3,4). Both donor pigs were miniature swine bred by nu-
clear transfer/embryo transfer with greatly reduced expression of α1,3-galactosyltransferase 
RNA, associated with reduced levels of Galα1-3Gal (Gal) when compared with wild-type swine; 
some Gal was detectable by fl ow cytometry on hematopoietic cells. No measures were taken 
to deplete natural anti-Gal antibodies, but complement depletion was performed using cobra 
venom factor, which was administered for the fi rst 21 days. 
SpTx was carried out in B221 in the abdomen using the previously-described technique (2). BM 
was harvested from the donor pigs and prepared for infusion into the baboon as previously 
described (5). BM cells (1.33 and 0.8 x 109/kg, respectively, in B221 and B219) were infused intra-
venously without untoward eff ect (in B221 four hours after SpTx). Blood was drawn at intervals 
to determine the extent of hematopoietic cell chimerism by fl ow cytometry. 
The maximum percentage of pig cells (using a ‘pan-pig’ antibody) in the blood of B221 was 
16.8% (2 hours after SpTx), but only 1.9 % in B219 (on day 2) (Figure 1), and the duration of 
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pig cell macrochimerism was 12 days in B221 compared to only 5 days in B219. In B221, the 
absolute number of pig cells was 689/μL after SpTx and 876/μL after BM Tx (Figure 2) (2 hours 
after SpTx and BM Tx, respectively); in contrast, in B219 the peak absolute number of pig cells 
2 hours after the BM Tx was 85/μL (Figure 2). In both cases, loss of chimerism was most likely 
related to phagocytosis of pig cells by host macrophages (3,6). 
In B221, two hours after SpTx, multilineage chimerism was present (Figure 3A), but two hours 
later (before BM Tx) no pig cells were detectable in the blood. Two hours after BM Tx these 
percentages were similar (Figure 3B). The phenotypes of the cells released by the spleen graft 
were diff erent from those detected after BM Tx; after SpTx, more pig lymphoid cells in the T 
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Figure 1. 
Percentage and duration of pig cell macrochimerism (detected by fl ow cytometry) in B221 that underwent pig SpTx followed 4 hours later by 
donor-specifi c BM Tx, and in B219, that underwent pig BM Tx only.
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Figure 2.
Absolute number of pig cells detected in the recipient’s blood following pig spleen + BM Tx (B221) or BM Tx alone (B219).
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Figure 3.
Multilineage pig cell chimerism detected by fl ow cytometry in the blood of B221 two hours after initial SpTx (A) and after subsequent BM Tx (B).
0
2
4
6
8
10
12
14
CD
1
CD
3
CD
4
CD
8
CD
9
CD
16
SW
C3
%
 o
f w
ho
le
 b
lo
od
After SpTx
After BMTx
Figure 4.
Phenotypes of pig cells after SpTx (black bars) and BMTx (white bars). Following SpTx, more pig lymphoid cells in the T cell lineage (expressing 
either CD1+, CD3+, CD4+, or CD8+) could be detected. After BMTx, there was a higher number of myeloid (CD16+, SWC3+) cells. SWC3 is a marker 
for the porcine myeloid lineage.
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cell lineage (expressing either CD1+, CD3+, CD4+, or CD8+) could be detected than after BM 
Tx, when there was a higher number of myeloid (CD16+, SWC3+) cells (Figure 4). (Pig SWC3 
expression resembles that of Mac-1 and Gr-1 in mice, and represents a marker for the myeloid 
lineage (7)). 
Biopsy of the spleen graft was performed on day 18, when it was found to be rejected (8), 
which was most likely due to anti-Gal antibody-mediated injury (since the histologic picture 
resembled antibody-mediated rejection but no anti-nonGal antibody could be detected in 
the blood). 
To our knowledge, this is the fi rst report of SpTx in a discordant pig-to-baboon xenoTx model. 
As in allogeneic SpTx, multilineage hematopoietic cell chimerism could be detected early af-
ter reperfusion of the spleen graft. The level of chimerism was comparable to that seen after 
the subsequent BM Tx. The level and duration of chimerism were greater when the spleen was 
transplanted in addition to the BM. The cells released from the spleen were diff erent in phe-
notype from those after BM Tx, which correlated well with the phenotypes of hematopoietic 
stem cells identifi ed in naïve spleens and BM (9). A relatively large population of CD3+ T cells 
was detected after SpTx, but no features of graft-versus-host disease were observed during 
follow-up, an observation that correlates well with that of Eguchi et al. in the pig-to-mouse 
model (10). 
The adult pig spleen is a relatively rich source of hematopoietic progenitor cells (9). In an al-
logeneic setting, the transplanted spleen releases progenitor cells into the recipient’s blood, 
from which they reach the lymphoid tissues (lymph nodes, thymus) and engraft in the BM. 
Based on previous studies in the pig-to-baboon model using either cytokine-mobilized pe-
ripheral blood progenitor cell Tx from Gal-positive miniature swine (3) or BM from α1,3-ga-
lactosyltransferase gene-knockout miniature swine (4), we conclude that there is a need for 
a proper microenvironment for pig cell engraftment in the baboon. SpTx from the BM donor 
potentially provides an additional source of stem cells but also hematopoietic stroma that 
may facilitate seeding of pig BM cells and support hematopoiesis. Further studies of com-
bined spleen and BM Tx, using α1,3-galactosyltransferase gene-knockout pigs, would seem 
worthwhile. 
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ABSTRACT
Background: Post-transplant lymphoproliferative disease (PTLD) is an important complica-
tion of immunosuppression after transplantation (Tx). We have performed spleen transplanta-
tion (SpTx) in miniature swine across full major histocompatibility complex barriers in order 
to study the tolerogenic eff ect of the spleen. We describe the development of PTLD after al-
logeneic SpTx. 
Methods: Recipient pigs were immunosuppressed with whole body irradiation (100cGy), thy-
mic irradiation (700cGy), and cyclosporine given intravenously daily to maintain a trough level 
of 400-800ng/mL for 45 days. Native splenectomy and SpTx were performed on day 0. Two 
control pigs received the immunosuppressive regimen and underwent native splenectomy, 
but did not undergo SpTx. 
Results: After SpTx, 2 of 7 pigs developed PTLD (29%) on days 30 and 32, respectively. One 
pig developed a malignant proliferation of host-type B-lymphocytes, whereas the other had 
proliferation of donor-type B-lymphocytes. The 2 pigs that developed PTLD had signifi cantly 
greater T cell depletion on the day of SpTx with higher trough levels of cyclosporine in the fi rst 
week after transplantation than similarly treated pigs that did not develop PTLD and control 
animals. Early changes associated with PTLD included increased PLHV-1 viral loads in blood 
and tissues, increased numbers of leukocytes, B-(CD3-CD16-) cells, and total serum IgM. These 
changes occurred prior to the development of clinical features of PTLD. 
Conclusions: PTLD can occur after allogeneic SpTx in swine. This model may provide a useful 
system for studies of the pathogenesis of PTLD.
INTRODUCTION
One of the major complications in patients with organ transplants receiving immunosup-
pressive therapy is an increased risk of malignant disease, particularly lymphoid tumors. Post-
transplant lymphoproliferative disease (PTLD) comprises a heterogeneous group of lymphoid 
proliferations, usually of B-cell origin, that are associated with ineff ective T cell function and 
exogenous immunosuppression. A strong correlation has been reported between B-cell neo-
plasms developing in immunosuppressed patients and the presence of the B-lymphotropic 
gammaherpesvirus, Epstein-Barr virus (1). 
In miniature swine, PTLD has been described most commonly after allogeneic hematopoi-
etic cell transplantation (Tx) (2), but has also been reported after liver Tx (3) and kidney Tx 
(Huang CA, unpublished data). Because of the clinical importance of PTLD, our laboratory has 
characterized this complication in more detail in the pig model (2,4). As in humans, a lym-
photropic gammaherpesvirus, porcine lymphotropic herpesvirus-1 (PLHV-1), has been found 
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to play a major role in the pathogenesis of PTLD (2,4,5). Risk factors for PTLD identifi ed after 
hematopoietic cell transplantation include T-cell depletion, the degree of histocompatibility 
mismatch, and the intensity of PLHV-1 infection (4).
SpTx has been performed in miniature swine to examine the ability of the spleen to induce 
a state of tolerance (6, 7). We describe for the fi rst time the occurrence of PTLD in miniature 
swine after SpTx across a full major histocompatibility complex (MHC) barrier.
MATERIALS AND METHODS
Animals
Transplant donors and recipients were selected from our herd of partially-inbred, MHC-de-
fi ned miniature swine (8). Donors (n=7, 3.4±1.2 months of age, weighing 22.7±9.6 kg), and re-
cipients (n=7, 3.0±0.9 months, weighing 18.9±8.8 kg) were fully MHC-mismatched. To be able 
to study hematopoietic cell chimerism, donor and recipient pairs were also mismatched for 
the pig allelic antigen (PAA), a non-MHC cell-surface marker of no known function (9), donors 
being PAA+ and recipients PAA-.
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use of 
Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH Publication No. 86-23, revised 1996).
Spleen transplantation
The technique of heterotopic SpTx in miniature swine has been described in detail previously (7). 
Recipient pretransplant conditioning and immunosuppressive treatment
The recipients received a low dose of whole body irradiation (WBI; 100 cGy on day -2), which 
is non-myeloablative (Chapter 6), and thymic irradiation (700 cGy on day -1) from a cobalt irra-
diator (10). Cyclosporine (CyA; Sandimmune, generously provided by Novartis Pharmaceutical 
Corporation, East Hanover, NJ) was administered intravenously (iv) as a single daily infusion at 
a dose of 10-30 mg/kg (adjusted to maintain a whole blood trough level of 400-800 ng/mL) for 
45 days, beginning on the day of SpTx (day 0), through an indwelling catheter in the neck. CyA 
levels were determined by a fl uorescence polarization immunoassay (Abbott Laboratories, 
Dallas, TX), which measured the parent compound, but not metabolites. 
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Control experiments
As controls, two pigs (#15312, #15330) underwent the identical immunosuppressive regimen, 
but no spleen was transplanted.
Supportive therapy and monitoring 
Supportive therapy consisted of daily prophylactic enrofl oxacin and dalteparin (6). Blood cell 
count, serum chemistry, and CyA levels were determined daily. Monitoring for graft-versus-
host-disease included daily inspection of the skin and stools, and daily determination of liver 
enzymes. In case of a skin rash, punch biopsies were taken from aff ected and non-aff ected 
skin for histological examination. Serum lactate dehydrogenase (LDH) was followed routinely 
as a potential marker of spleen graft rejection. 
Flow cytometry
Flow cytometry was performed twice weekly to monitor the level of hematopoietic cell chi-
merism. T cell depletion was assessed by fl ow cytometry before the immunosuppressive regi-
men was initiated on day-3 and on the day of the SpTx (day 0), and the number of circulating 
CD3+ T cells in the recipient’s blood was subsequently determined at frequent intervals. In 
one case (#15446), B-cell proliferation in the blood was monitored, and fl ow cytometry was 
used to determine the phenotype of the cells involved in the PTLD. Monoclonal antibodies 
used included: Anti-CD1 (76-7-4, mouse IgG2aK) (11), anti-CD3 (898H2-6-15, mouse IgG2aK) 
(12), anti-CD4 (74-12-4, mouse IgG2bK), anti-CD5 (9G12 (BB6-9G12), mouse IgG1) (13), anti-
CD8α (76-2-11, mouse IgG2aK), anti-CD9 (1038H-4-6, mouse IgM/K), anti-CD16 (G7, mouse 
IgG1), anti-PAA (1038H-10-9, mouse IgMK) (9), anti-Igμ (5C9, IgG1/K), and anti-Igĸ (K139.3E1, 
mouse IgG2a). Staining of blood and tissue cell suspensions was achieved as previously de-
scribed (14). Data were analyzed using WinList mode analysis software (Verity Software House, 
Topsham, ME). 
Enzyme-linked immunosorbent assay (ELISA) to assess level of total IgM in 
spleen transplantation recipients 
Ninety-six-well fl at-bottomed Nunc maxisorp ELISA plates (Nalge-Nunc International, Roch-
ester, NY) were coated with 5 μg/mL of purifi ed porcine IgM (PPIgM) (Rockland, Gillbertsville, 
PA) in carbonate-bicarbonate buff er (Sigma-Aldrich, St. Louis, MO) overnight at 4oC. Plates 
were washed three times with PBS containing 0.1% Tween 20 (Sigma-Aldrich). Non-specifi c 
binding sites were subsequently blocked with 1% bovine serum albumin (BSA; Fisher Scien-
tifi c, Hampton, NH) in PBS for one hour at room temperature. Serially-diluted porcine IgM 
Frank Dor BW.indd   192 18-08-2006   15:08:51
193
PTLD after spleen transplantation in miniature swine
C
h
ap
te
r 
9
standards (100-0.14μg/mL) were included on each plate. The test sera were serially diluted 
such that at least two points from each could be extrapolated to the linear part of the stan-
dard curve. Both the standards and the serum samples were tested in triplicate. To initiate the 
competition, the IgM standards and the diluted sera were incubated for one hour at room 
temperature with HRP-conjugated goat anti-porcine IgM (Serotec Oxford, UK) in an uncoated 
ELISA plate that had been blocked as previously described. Both the standards and the se-
rum samples were tested in triplicate. The competition reaction was then transferred to the 
blocked, porcine IgM-coated plate and incubated for 60 min at room temperature. The plates 
were developed using O-phenylenediamine (Sigma-Aldrich) at 0.9mg/mL in phosphate-ci-
trate buff er with urea hydrogen peroxide (Sigma-Aldrich) for 20 min at room temperature. The 
reaction was stopped with the addition of 2N sulfuric acid (Fisher Scientitfi c). Plates were read 
on a microplate reader (Molecular Devices, Menlo, Calif.) at 490 nm. 
Polymerase chain reaction (PCR) to identify porcine lymphotropic herpesvirus-1 
(PLHV-1) 
DNA extraction 
Blood samples were taken before SpTx and weekly thereafter. Peripheral blood mononuclear 
cells were isolated from blood by density gradient sedimentation using histopaque-1077 (Sig-
ma-Aldrich, St. Louis, MO). Tissue samples were snap frozen at the time of biopsy or necropsy. 
DNA was isolated using the Purgene DNA Isolation Kit (Purgene, Minneapolis, MN). Tissue 
DNA was quantifi ed by the Hoechst dye fl uorescence assay on a DNA fl uorometer (Hoefer 
Scientifi c Instruments, San Francisco, CA). 
Quantitative real-time PCR
Target DNA sequences were quantifi ed by real-time PCR using the ABI PRISM 7700 Sequence 
Detection System (Perkin-Elmer, Foster City, CA), as described previously (15). In brief, se-
quence-specifi c primers and probes were generated for each gene target using Primer Express 
software (Perkin-Elmer). PCR conditions were identical for all assays. Each PCR reaction mix 
consisted of target DNA, 900 nM primers, 200 nM probe, TaqMan Universal PCR 2x MasterMix 
(Applied Biosystems, Branchburg, NJ) containing the passive reference dye ROX (6-carboxy-
x-rhodamine) in a 50μL fi nal reaction volume loaded into a 96-well plate. The PCR conditions 
were as follows: an initial cycle at 50ºC for 2 min, 95ºC for 10 min, 50 cycles of denaturation 
at 95ºC for 15 sec, and annealing/extension at 60ºC for 1 min. Under these conditions, target 
DNA was detected with a linear dynamic range from 100 to 106 copies (data not shown). The 
threshold cycle or C
t
 values of PCR amplifi cation of the standards were used to generate a 
standard curve for quantifi cation of target DNA. Samples from which reproducible amplifi ca-
tion signals were detected at levels below the lowest standard quantifi cation limit are referred 
to as +/- or “below 6 copies”, with 6 being the lower limit of quantitative detection.
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Measurement of porcine lymphotropic herpesvirus type-1 (PLHV-1) DNA 
Primers and probe for PLHV-1 were derived from the PLHV-1 polymerase gene and were as 
follows: PLHV-1 sense: 5-AAG GTG ACA TGC AAT GCT GTG-3; antisense: 5-TGC AAT CTT GAG 
ACA GGG CA-3; probe: 5’ 6FAM-TGG GTT CAC TGG TGT TGC ATC TGG TAT G-TAMRA 3’ (16-18). 
Reverse primer and probe were specifi c for PLHV-1 by blast analysis, while the forward primer 
was able to detect PLHV-1 and 2. Sequencing of the product amplifi ed by the conventional 
primers confi rmed the specifi city for PLHV-1. No cross-reactivity was detectable with porcine 
cytomegalovirus in in vivo tissues samples and in DNA preparations derived from in vitro cyto-
megalovirus-infected cell cultures, both with known high copy numbers of cytomegalovirus. 
The quantitative detection limit for this assay was 6 copies per reaction. Results were expressed 
as copy number of PLHV-1 per 104 pig MHC class I molecules or 5 x 103 cell equivalents.
Measurement of species-specifi c porcine DNA 
Pig MHC class I gene (pig MHCC1) primers and probe were developed as internal controls for 
porcine cellular DNA (15, 19). Primers and probe were derived from the pig MHCC1 gene and 
were as follows: MHCC1 sense: 5’-GCC CTG GGC TTC TAC CCT AA-3’; antisense: 5’-TCT CAG GGT 
GAG TGG CTC CT-3’; probe: 5’ 6FAM-CCA GGA CCA GAG CCA GGA CAT GGA GCT CGT-TAMRA 
3’. Quantitative sensitivity was 3 copies per reaction. In the peripheral blood mononuclear cell 
samples, the number of cells was quantifi ed as one cell per two copies of MHCC1. PLHV-1 copy 
numbers were calculated per 5 x 103 mononuclear cells. In tissues, MHCC1 served as internal 
control for the input total DNA amount.
Microscopic examination of tissues
Tissue samples were fi xed in 10% formalin and subsequently embedded in paraffi  n, or frozen 
and stored at -80°C. Five-micron histologic sections were cut from paraffi  n blocks, stained 
with hematoxylin and eosin and studied by light microscopy. 
RESULTS
Hematopoietic cell chimerism 
All recipients of SpTx developed multilineage mixed hematopoietic cell chimerism after re-
perfusion of the spleen graft, whereas the control pigs had only very low and transient chime-
rism, mostly restricted to CD3+ T cells, resulting from blood transfusions during the splenec-
tomy procedure. Details of hematopoietic cell chimerism following SpTx have been reported 
in Chapter 6. There was no signifi cant diff erence in initial levels of chimerism in pigs without 
and with PTLD.
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Incidence of PTLD
Of the 7 SpTx recipients treated with the same immunosuppressive regimen, 2 (29%) pigs 
developed PTLD; in one (#15399), the PTLD developed from native (recipient) B-cells and, in 
the other (#15446), from donor B-cells. PTLD was not observed in the two control pigs that 
received the identical immunosuppressive regimen without SpTx.
Clinical course of pigs with PTLD 
Laboratory abnormalities associated with PTLD were detected before clinical features of dis-
ease became apparent in two pigs (#15399 and #15446) that developed PTLD (days 30 and 
32), (Table 1). An increased viral load of PLHV-1 in the blood was detected by 14 days af-
ter transplantation, followed by B-cell proliferation (by fl ow cytometry day 28) in the blood 
and on routine LN biopsy. The pig with recipient-type PTLD (#15399) demonstrated a decline 
in lymphoid chimerism, while the pig with donor-type B-cell proliferation (#15446) had in-
creased lymphoid chimerism. These changes in lymphoid chimerism preceded increases in 
WBC, which began 29-31 days after SpTx (Figure 1A). There were no signs of infection and 
surveillance blood cultures remained negative. 
Increased levels of serum total IgM were detected before or accompanying clinical signs of 
PTLD. The increase in total serum IgM levels in both animals coincided with B-cell expansion. 
In #15399, the maximum IgM level (57 mg/mL) was more than 17-fold higher than the upper 
Table 1. Time-course of events in the development of PTLD in two pigs with spleen allografts 
Day Pig #15399 Pig #15446
7
14 PLHV-1 upregulation in blood PLHV-1 upregulation in blood
21
27 Increase in total serum IgM B-cell proliferation in blood
28 PLHV-1 upregulation in LN B-cell proliferation in LN
atypical lymphoid proliferation LN
29 Increase in WBC count PLHV-1 upregulation in LN
30 Clinical features detected; CyA stopped Increase in WBC count
32 Palpable LN Clinical features detected; CyA stopped
Increase in total serum IgM
34 Palpable LN
35 Euthanized for respiratory diffi  culty
37 Atypical lymphoid proliferation LN
Euthanized for respiratory diffi  culty
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limit of the normal level (0.2-3.2 mg/mL, Bajwa JA et al, unpublished data), and in #15446, IgM 
was 13.3 mg/mL, more than 4-fold higher than the upper normal limit (Figure 1B).
Clinical features of systemic illness included loss of appetite, lethargy, and weight loss in both 
aff ected animals. Within two days, enlarged lymph nodes could be easily palpated, those in 
the pre-femoral region being most accessible and the easiest to examine. Although CyA treat-
ment was discontinued when suspicion of PTLD arose, in both cases the disease progressed 
rapidly to respiratory failure associated with obstructive enlargement of the tonsils and com-
pression of the trachea by enlarged lymph nodes in the neck and mediastinum, necessitating 
euthanasia of both animals. 
Both pigs demonstrated signifi cant rises in total bilirubin and lactate dehydrogenase (LDH) in 
the serum, concomitant with the onset of clinical disease. The LDH levels at the time of clinical 
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Figure 1. 
In this fi gure, the open boxes indicate pig #15399, the closed diamonds pig #15446. The circle represents the day that clinical features became 
apparent. (A) White blood cell counts of the two pigs with PTLD. Both pigs had signifi cant increases in leukocytes that began just prior to the 
recognition of clinical features of PTLD. (B) Serum total IgM levels in the 2 pigs that developed PTLD. The upper limit of normal in pigs is 3.2 mg/
mL, represented by the dashed line. The increase in serum IgM preceded clinical features in pig #15399 by 3 days. (C) Serum total bilirubin levels 
in the two pigs with PTLD. Both pigs demonstrated intrahepatic cholestasis due to liver involvement of PTLD, which was confi rmed by histological 
examination (Figure 5). In #15446, the increase in bilirubin began before clinical features were obvious.
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onset were 1469 U/L and 1137 U/L (2.9 and 2.3-fold higher than normal level). Total bilirubin 
levels were 0.5 and 1.54 mg/dL at the time of clinical appearance of PTLD rising to 1.42 and 
2.33 mg/dL by the day of sacrifi ce (fi gure 1C). 
At necropsy, both animals had massive enlargement of the lymph nodes, including the tonsils 
(with advanced necrosis in one case) and the lymph nodes of the abdomen (Figure 2A), me-
diastinum, neck, and groin. The spleen grafts (Figure 2B) were also involved in the lymphoid 
proliferation, particularly in the pig with the recipient-type PTLD (#15399) that also had two 
distinct solid hepatic tumors, each with a diameter of 1cm. 
T cell depletion
Although T cells were not depleted specifi cally, following whole body and thymic irradiation, 
all 9 pigs showed a signifi cant decrease in the absolute number of T cells. The two pigs that 
went on to develop PTLD had signifi cantly greater T cell depletion (90.6%) than unaff ected 
animals (70.6%) (p=0.019) (data not shown). Recovery of T-cells was similar in both aff ected 
and unaff ected animals with the absolute T cell counts increasing over 14 days to >1500/mm3 
(data not shown). 
Cyclosporine dosage and levels
Despite adjusting of the CyA dosage on a daily basis, the two pigs that developed PTLD had 
signifi cantly higher CyA levels in the fi rst week after SpTx (p=0.001) (Figure 2C). CyA levels also 
increased, despite a reduction in dosage or cessation of therapy, when the clinical features of 
PTLD developed. This resulted in overall higher CyA trough levels in the pigs with PTLD over 
the course of the experiment (p<0.001) (Figure 2D). Renal function remained normal in both 
pigs. 
Flow cytometry 
In the animal that developed donor-type PTLD (#15446), B-cell proliferation in the blood be-
gan on day 27 before any clinical features of PTLD were obvious (day 32) (Figure 2E). Figure 
3 shows fl ow cytometry from lymphoid tissues taken on day 28 (day of spleen and lymph 
node (LN) biopsies) and day 37 (day of euthanasia) in #15446. On day 28, 40% of LN cells were 
donor B-cells (CD3-CD16-PAA+), but recipient CD3-CD16-PAA- B-cells were still present (32 %) 
(Figure 3A). By the day of euthanasia (day 37), donor B-cells made up almost 75% of the total 
cellular LN content. In the BM (Figure 3B), engraftment of donor (PAA+) cells was observed on 
day 28, with approximately 2% being donor B-cells. However, by day 37, almost 54% of BM 
cells were of donor origin, of which 66% were B-cells (of note, in a normal PAA+ pig, only 50-
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Figure 2. 
(A) Macroscopic appearance of mesenteric lymph nodes in pig #15399 at necropsy (day 35). (B) Spleen graft of pig #15399 on day 35 (necropsy) 
with a distinct lymphomatous nodule. (C) Mean CyA trough levels were signifi cantly higher in the fi rst week after spleen Tx in the 2 pigs that 
developed PTLD compared with the 7 pigs that did not (p=0.001), even though CyA dosages were adjusted on the basis of the daily CyA trough 
levels. (D) Similarly, pigs that developed PTLD had signifi cantly higher CyA trough levels during the entire course of therapy than the pigs that 
did not develop PTLD (p<0.001). This resulted partly from the fact that CyA trough levels increased despite reduction in dosage or even complete 
withdrawal when PTLD became clinically apparent. (E) Absolute numbers of donor B-cells (CD3-CD16-PAA+) in the blood of the recipient that 
developed donor-type PTLD (#15446). The expansion of the donor B-cell pool in the recipient blood was clear before clinical features of PTLD 
developed. (PAA+ is a cell surface marker of no known function, expressed on all donor cells).
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60% of BM cells express PAA (9)). The spleen graft (of PAA+ origin) had a high B-cell content on 
day 28 (almost 50%), and a PAA+ B-cell content of 63% on day 37 (Figure 3C). 
Phenotyping of PTLD cells
Previous studies confi rmed the CD3-CD16- peripheral blood cells to be B-cells based on sur-
face and cytoplasmic Igμ and Igĸ staining (2). 
In the current series, CD3-CD16- PTLD cells in the blood did not express any of the porcine 
B-cell markers CD1, Igμ and Igĸ. However, in LN and bone marrow samples, low levels of ex-
pression of Igμ chains, but not Igĸ and CD1 could be seen in the clonally-expanded B-cell pool 
(not shown). 
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Day 28
Day 37
A. Lymph Node B. Bone Marrow C. Spleen Graft
40.16 19.52
32.81 7.52
74.28 11.22
6.88 7.82
1.91 4.62
33.66 59.81
35.55 18.30
7.17 38.88
63.22 22.09
49.62 36.99
5.02 49.62
0.70 13.99
Figure 3. Flow cytometry of lymphoid tissues on day 28 and day 37 (necropsy) from pig #15446 that developed donor-type PTLD. 
(A) In the LN (top), a distinct population of donor B-cells (CD3-CD16-PAA+) could be seen on day 29, making up 40% of the total cells. At 
necropsy (day 37), this percentage was increased to almost 75% (bottom). 
(B) The bone marrow biopsy on day 29 (top) revealed the presence of some donor cells (~6.5%), but only approximately 2% donor B-cells, 
which was not uncommon after SpTx. However, on the day of necropsy (day 37) (bottom), there was an unusually large number of donor B-cells, 
making up 35% of the total. 
(C) The spleen graft (which was from a PAA+ animal) contained a large number of donor B-cells on day 29 (top). This number increased and 
made up almost 2/3 of the total spleen cells at the time of necropsy (day 37) (bottom). 
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PLHV-1 activation in blood and tissues 
Both pigs with PTLD had a signifi cant increase in copy numbers of viral DNA in the blood, 
beginning 2 weeks after SpTx, 2 weeks before the onset of clinical signs of PTLD (Figure 3D). 
In addition, biopsies from LN from both animals also revealed high copy numbers of PLHV-1 
DNA (not shown). All tissues obtained at necropsy revealed high PLHV-1 DNA content (Figure 
3E). In the pig with the donor-type PTLD (#15446), the spleen graft had high copy numbers of 
PLHV-1. The control pigs and the 5 other SpTx recipients did not develop an increase in PLHV-1 
viral load in the blood or in tissue samples taken at biopsy and necropsy. 
Histopathology
In pig #15399, histological examination of protocol biopsies of mesenteric LN and spleen graft 
revealed features of PTLD on day 28 (two days before clinical features were detected). In the 
Figure 3.
(D) Copy numbers of PLHV-1 in recipient blood after SpTx in two pigs with PTLD. Approximately two weeks before the onset of clinical features of 
PTLD, both animals demonstrated signifi cant copy numbers of PLHV-1. 
(E) Tissues taken at necropsy revealed very high PLHV-1 copy numbers per 10,000 MHC-Class I copy numbers.
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spleen, white pulp expansion (Figure 4A) with some cellular atypia was observed, although 
few mitotic fi gures were seen (Figure 4B). The red pulp had an abundance of lymphocytes. 
The mesenteric LN taken on the same day contained atypical lymphocytes and plasma cells 
(Figure 4C). Tingible body macrophages marked a high degree of cell turnover. At necropsy 
on day 35, the above fi ndings were more pronounced in both tissues; in the spleen graft, the 
white pulp expansion was massive (Figure 4D), with sheets of atypical cells (Figure 4E). Many 
mitoses were noted. Few normal lymphocytes were found. In the LN (Figure 4F), the atypia 
and mitotic activity were pronounced as well. The liver, which contained macroscopically 
distinct tumors, had evidence of PTLD histologically (Figure 5A). The tonsil, that was macro-
scopically aff ected, demonstrated sheets of atypical cells and necrosis (not shown). The bone 
marrow was clearly involved (Figure 5B), and malignant cells fi lled most of the space of the 
hematopoietic microenvironment.
Figure 4. Histologic changes in the morphology of spleen and LN in pig #15399 on post-operative days 29 (A-C) and 35 (D-F). 
A moderate increase in size of a Malpighian corpuscle in the spleen (A), H&E x50, was associated with mild cellular atypia (B), H&E, x400. A 
mesenteric LN showed mild cellular atypia (C), H&E, x400. The spleen later showed a marked increase in size of a Malpighian corpuscle (D), H&E, 
x50 (arrow), associated with marked cellular atypia and mitotic activity, (E), H&E x400 (arrows point to mitoses). A LN showed marked cellular 
atypia and mitotic activity (arrows point to mitoses), (F), H&E x400.
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In pig #15446, protocol biopsies on day 28 (4 days before clinical onset of PTLD), no diagnostic 
abnormality of either spleen graft or LN could be observed. Necropsy on day 37 revealed iden-
tical histopathological features of PTLD in LN (with necrosis), spleen graft, tonsils (not shown) 
as well as in liver and BM (Figure 5C&D) as in #15399. In neither pig did the lungs demonstrate 
any atypical cells. 
DISCUSSION
To our knowledge, this is the fi rst report that describes PTLD after SpTx. PTLD has been de-
scribed in miniature swine after hematopoietic cell Tx (2), in 3 cases after liver Tx (3), and there 
has been a single case after kidney Tx (Huang CA, unpublished data). PTLD or lymphoma has 
developed in only one solid organ (kidney) transplant recipient in the several hundred min-
iature swine receiving kidney, heart or lung allografts at our center. The incidence of PTLD in 
miniature swine undergoing hematopoietic cell Tx has been reported to be as high as 28% (4), 
with a greater incidence (42%) in animals receiving a full two-haplotype MHC-mismatched 
transplant. In pigs with PTLD that did not receive WBI, the incidence of donor-type was 7.7 % 
and host-type 92.3 %. In current studies with BMTx using a preparative regimen including 100 
cGy WBI 1 out of 8 pigs developed PTLD of donor-type (Cina RA, personal communication). In 
six pigs receiving 300 cGy WBI, none developed PTLD. Cho et al. defi ned risk factors in the de-
velopment of PTLD in a series of 47 miniature swine (4); a greater initial T cell depletion, wide 
Figure 5. Tumor involved extra-splenic and extra-nodal tissues in both animals on post-operative day 35. 
In pig #15399, tumor infi ltrated both liver (A), H&E, x100 (arrow points to discreet margin of tumor and normal liver), and bone marrow (B), H&E 
x100. Similarly, in pig #15446, liver (C), H&E x200 (arrow points to discreet margin of tumor and normal liver), and bone marrow (D) showed 
tumor infi ltration.
Frank Dor BW.indd   202 18-08-2006   15:09:05
203
PTLD after spleen transplantation in miniature swine
C
h
ap
te
r 
9
MHC-disparity between recipient and donor, a greater intensity of immunosuppression, and 
the presence of PLHV-1 infection contributed to the development of PTLD. 
In the present small series, PTLD developed in 2 of 7 pigs (29%) that underwent two-haplo-
type MHC-mismatched SpTx. Myelosuppressive host conditioning, including WBI, results in a 
reduction of the host B-cell pool, which may contribute to a reduction in the prevalence of 
host-type PTLD. However, following SpTx, one of the two pigs developed a host-type PTLD. 
Host-type PTLD is more often seen in human organ transplant recipients, probably because 
the lymphoid system remains of host-type, whereas that of recipients of hematopoietic cell Tx 
is generally converted to donor-type, as shown in previous studies at our center when whole 
body irradiation was used in the preparative regimen (2). In mixed chimeras without myeloab-
lation, however, host- or donor-type PTLD may be seen, with a predominance of host-type 
PTLD, presumably because recipient B-cell precursors are more prevalent at the time of origin 
of the disease than are the corresponding donor elements. Following SpTx, the recipients de-
veloped a high level of mixed hematopoietic cell chimerism (Chapter 6), and therefore PTLD 
would appear to be able to arise from donor or recipient cells. 
The clinical picture of PTLD in our two cases resembled that reported previously (2,4). Loss of 
appetite, lethargy, and weight loss were predominant features. Within days, lymphadenopa-
thy was evident. Even though CyA therapy was discontinued as soon as suspicion of PTLD 
arose, the disease progressed rapidly to respiratory failure, necessitating euthanasia. 
An important observation was that an increase in PLHV-1 DNA copy numbers in the blood 
was apparent well before clinical features of PTLD became apparent, as described by Cho et al. 
(4); no such increase was seen in pigs that did not develop PTLD, although copy numbers of 
PLHV-1 were present at low numbers in the blood. In addition, in pigs with PTLD, a high copy 
number of PLHV-1 was present in a LN, which remained macroscopically and histologically 
normal, 2-3 days before clinical features developed. Flow cytometry of this node revealed 
B-cell expansion; shortly thereafter, B-cell proliferation was detected in the blood. This may 
be of clinical diagnostic relevance, since the detection of viral replication in the blood would 
appear to be the fi rst indication of the disease. Clinically, intensive and frequent monitoring 
for Epstein-Barr virus may therefore reveal early PTLD that may be reversible. 
Another new fi nding was the disproportionate rise in serum IgM levels in the pigs with PTLD. 
To our knowledge, this is the fi rst time that this phenomenon has been described in rela-
tion to PTLD. Other changes that occurred before clinical signs appeared were an increase in 
white blood cell count, a relatively sudden increase or decrease in lymphoid chimerism, B-cell 
proliferation, and histological evidence of atypical lymphoid proliferation in a LN on protocol 
biopsy. A marked increase in CyA level (without a change in dosage) accompanied the devel-
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opment of clinical features of PTLD; a recipient’s lack of ability to metabolize CyA rapidly may 
be a factor in the development of PTLD. 
In clinical cases of PTLD, a reduction or cessation of immunosuppressive therapy has been 
suggested as a means of reversing PTLD (20, 21). However, when the serum lactate dehydro-
genase has risen >2.5 times above the upper limit of normal, or when organ dysfunction is 
present, or when the disease has spread to multiple visceral sites, a response to a reduction 
in therapy has been unlikely (22). Successful cessation or reduction of immunosuppression 
has led to recovery of only 3 of 9 pigs aff ected with PTLD in our laboratory (2). In our two af-
fected animals, the serum lactate dehydrogenase at the time of clinical onset was 1448 U/L 
and 1137 U/L (2.9 and 2.3-fold higher than normal level), respectively. Lymphadenopathy was 
present throughout the body, and organ dysfunction developed rapidly. Based on these risk 
factors for unresponsiveness, there was no reasonable likelihood of preventing death in these 
2 animals. 
Although the number of pigs in our study was small, our observations correlate with those of 
Cho et al (4) in that a greater extent of T cell depletion in the recipient appeared to be a factor 
that contributed to disease development. Clinically, PTLD is more common in patients treated 
with T cell-depleting regimens, such as those including anti-thymocyte globulin and OKT3 
(23-27). Increased T cell depletion in association with the presence of PLHV-1 would appear to 
be combined risk factors for disease development. Irradiation (WBI and thymic) is a known ac-
tivator of latent herpes viral infection (28) and may further impair T cell function and immune 
surveillance (4). Furthermore, low-dose WBI (100 cGy and less) may cause mutations in B-cells 
that ultimately develop into malignancies. 
In summary, this study provides evidence for the occurrence of PTLD after Tx of allogeneic 
spleens in miniature swine receiving a relatively modest immunosuppressive regimen. SpTx 
off ers a promising strategy to induce Tx tolerance (6). However, the risk of over-immunosup-
pression in the induction phase of tolerance clearly needs to be emphasized. This model may 
provide a useful system for studies of the pathogenesis of PTLD.
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MINIABSTRACT
This paper summarizes experience with spleen transplantation in a pre-clinical large animal 
model with an emphasis on the potential of the spleen to induce immunological tolerance.
ABSTRACT
Objective: To summarize experience with allogeneic spleen transplantation (SpTx) in swine.
Summary Background Data: Successful SpTx in rodent models has been demonstrated to 
induce a state of donor-specifi c tolerance. The relevance of this phenomenon remains to be 
demonstrated in large animal models and in humans.
Methods: SpTx has been carried out in miniature swine across known MHC antigen barriers. 
Tolerance to the spleen could be obtained by a nonmyeloablative conditioning regimen and 
cyclosporine, allowing in vitro investigation of the mechanism of tolerance induction and in 
vivo investigation of whether tolerance to a second donor-specifi c organ had been achieved. 
Naïve pig spleens were studied as a source of hematopoietic stem cells.
Results: Survival of the spleen was associated with prolonged periods (months) of hemato-
poietic cell chimerism and with the induction of in vitro donor-specifi c cellular unresponsive-
ness, with evidence for suppression by regulatory cells. No or minimal features of graft-versus-
host disease were observed. In two cases (MHC class I- or full-mismatched), the subsequent 
transplantation of a kidney (MHC-matched to the spleen donor) without exogenous immu-
nosuppression resulted in prolonged kidney survival (months), but eventual failure despite 
viability of the spleen and in vitro donor-specifi c unreponsiveness; evidence for donor-specifi c 
tolerance was therefore inconclusive. As a source of hematopoietic stem cells, immunologi-
cally-naïve adult pig spleens were found to be equivalent to bone marrow.
Conclusions: Allogeneic SpTx may be a means of achieving donor-specifi c tolerance. The na-
ïve adult spleen is a relatively rich source of hematopoietic stem cells.
INTRODUCTION
The spleen, although not fully understood, has a number of functions as a secondary lym-
phoid organ, a blood fi lter, storage for platelets and red blood cells, and as a hematopoietic 
organ (1-5). 
In general, absence of the spleen may result in a higher risk of certain bacterial infections, 
and also by mycobacteria, viruses, and parasites, now generally termed ”overwhelming post-
splenectomy infections” (6-8). Furthermore, decreased levels of IgM (9-11), increased platelet 
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counts (4), and the presence of abnormal red blood cells in the blood (7, 12) are phenomena 
typically seen after splenectomy (Chapter 1). 
There are numerous reports in the literature indicating that successful spleen transplanta-
tion (SpTx) in some rodent models can lead to the development of donor-specifi c immuno-
logical tolerance (reviewed in 13). Tolerance allows for long-term survival of the spleen in the 
absence of exogenous immunosuppression, and also the successful transplantation of other 
organs from the spleen donor without the need for further therapy. 
In large animals and humans, however, although SpTx has been carried out on a number of 
occasions, there is no conclusive evidence that it is capable of inducing tolerance either to 
itself or to other donor-specifi c organs (13). However, there is evidence that a state of he-
matopoietic cell chimerism exists after SpTx, at least for some weeks (14-16). Furthermore, 
graft-versus-host disease has been documented after SpTx, and in one clinical case proved 
fatal (15), indicating that the transplanted spleen can initiate an immune response against the 
host (Chapter 3). 
The absence of conclusive evidence for tolerance induction in large animal models is probably 
related to the fact that in none of the studies carried out was knowledge available of the major 
histocompatibility complex (MHC) of either donor or recipient known, and the immunosup-
pressive regimens administered were not aimed at the induction of tolerance. Furthermore, 
most of these studies were performed several decades ago when only limited immunosup-
pressive agents and laboratory techniques for the assessment of tolerance could be used. 
The major aim of our studies was to examine whether the spleen can induce tolerance in a 
large animal model across known MHC barriers (further aims are described in Chapter 2). The 
MHC-defi ned MGH miniature swine have been used for almost 30 years in transplantation 
research and were considered a suitable model in which to study the spleen’s capacity to 
induce tolerance.
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use of 
Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH publication No. 86-23, revised 1996).
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SURGICAL TECHNIQUE OF SPLEEN TRANSPLANTATION IN MINIATURE SWINE
The surgical technique has been described previously (17 and Chapter 4) and involved taking 
a long donor vascular pedicle of splenic artery and celiac axis to its origin from the aorta and 
of splenic vein to its junction with the portal vein. Carrel patches of aorta and portal vein were 
taken with the donor spleen to facilitate implantation in the host. The recipient procedure 
involved end-to-side anastomoses of the donor aortic cuff  to the recipient abdominal aorta 
and of the donor portal venous cuff  to the recipient inferior vena cava. A number of potential 
surgical complications have been experienced, particularly kinking, twisting or compression 
of the vascular pedicle, leading to either splenic vein thrombosis (with resulting engorgement 
or even rupture of the spleen) or splenic artery thrombosis (leading to ischemic necrosis). 
In all of the studies performed in MHC-defi ned miniature swine (18), the donor has been posi-
tive for the pig allelic antigen (PAA) and the recipient negative for this antigen; the pig allelic 
antigen is a marker of unknown function, but allows detection of donor hematopoietic cells in 
the host (19). Whenever SpTx was performed, a native splenectomy was carried out. In view of 
the considerable volume of blood required to reperfuse the pig spleen (which is approximate-
ly four times the size of the human spleen in relation to body weight, i.e., 8g/kg in comparison 
to 2g/kg) a transfusion of donor red blood cells was given immediately prior to reperfusion. In 
control experiments, native splenectomy was performed and a donor red blood cell transfu-
sion was given, but SpTx was not carried out. 
EXPERIENCE IN MHCMATCHED, MINOR ANTIGENMISMATCHED SPLEEN 
TRANSPLANTATION IN MINIATURE SWINE CHAPTER 4
Four such transplants were performed to establish the surgical technique and to study donor 
spleen survival in donor-recipient combinations with minor antigen diff erences only. When no 
immunosuppressive therapy was given to the host, rejection of the spleen developed within 
approximately one month. The major histopathological features of the rejected spleen were 
multifocal hemorrhage, fi brinoid necrosis and vessel wall necrosis. Recipient cells (CD3+/CD8+ 
and CD16+ cells) rapidly invaded the graft, and loss of function of the spleen was associated 
with the presence of Howell-Jolly bodies in the blood (Chapter 5). 
When a 12-day course of cyclosporine (CyA) was administered to the host (days 0-11) with or 
without augmentation of immunosuppression by pretransplant thymic irradiation (700cGy on 
day -1), the spleen was not rejected, and the histological appearance of the spleen remained 
normal for >200 days, despite the fact that there was a slow replacement of donor cells in the 
spleen by recipient cells (Figure 1A-C). 
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In all cases, mixed hematopoietic cell chimerism was detected in the host, i.e., PAA-positive 
donor cells were found circulating in the blood. Chimerism was lost rapidly when rejection 
developed, but was maintained for approximately two months when rejection did not devel-
op. In addition, in one non-rejector, chimerism in the thymus was observed at multiple time 
points. The period of chimerism in the blood correlated to some extent with the replacement 
of PAA-positive cells in the transplanted spleen by host cells. 
This small experience established the surgical technique and demonstrated that tolerance 
could be induced to the spleen, and was associated with transient chimerism in blood and 
thymus. 
EXPERIENCE IN MHC CLASS IMISMATCHED SPLEEN TRANSPLANTATION IN 
MINIATURE SWINE CHAPTER 6
One transplant was performed, the recipient receiving pretransplant thymic irradiation (700 
cGy on day -1) and a 12-day course of CyA. Again, multilineage chimerism was detected in the 
blood for approximately three months, and replacement of donor cells by recipient cells took 
place in the spleen graft during this period. 
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Figure 1. Flow cytometry data of a spleen graft at diff erent time points. All spleen grafts were derived from PAA+ donors and transplanted into 
PAA– recipients. 
(A) Pre-Tx, 98% of the spleen cells expressed PAA. 
(B) On day 60 after SpTx, the spleen graft consisted of approximately 50% PAA+ cells (donor-type). This indicates that 50% of the cells in the 
spleen graft were of recipient-type at this stage. 
(C) By 150 days after SpTx, PAA+ cells (donor-type) in the spleen had largely been replaced by PAA– cells (recipient-type). This indicates a near-
complete (99%) repopulation of the spleen graft by recipient cells.
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Cell-mediated lympholysis (CML) assays, that refl ect cytotoxic T lymphocyte anti-donor reac-
tivity across the Class I barrier, demonstrated that the host-versus-donor response was lost 
during the fi rst month after SpTx, and there was a virtual absence of response for the next 
10 months during the remainder of the experiment. This indicated that successful SpTx had 
induced a state of donor-specifi c hyporesponsiveness, since the response of the host to third-
party cells remained vigorous. Further in vitro studies indicated that a state of endogenous ac-
tive suppression had developed; when recipient cells were mixed with donor-type cells from a 
naïve donor, the host cells suppressed the immune response of naïve recipient-matched cells 
in suppressor-CML assays, indicating the presence of regulatory cells in the spleen recipient 
(20).
Interestingly, even during the period of hematopoietic cell chimerism, no donor-versus-host 
response was detected in CML assays. This correlated well with the clinical absence of graft-
versus-host-disease (GVHD). 
In the recipient, fl ow cytometry did not indicate donor cells in the host bone marrow (BM) or 
thymus, and there was no evidence by polymerase chain reaction (PCR) on colony-forming 
unit (CFU) assays for donor hematopoietic cells that had engrafted in the BM. Our conclusion 
therefore was that the hyporesponsiveness that had developed was due to the induction of 
peripheral, rather than central, tolerance. 
Four and a half months after SpTx, a donor-matched kidney was transplanted into the host 
without any exogenous immunosuppressive therapy. This kidney was followed for a further 
7.5 months (approximately one year after SpTx) at which time spleen histology remained pris-
tine and kidney histology showed some interstitial fi brosis, but no features of acute cellular 
rejection. However, during this period, the serum creatinine had risen to 2.5mg/dL during a 
period of hydronephrosis due to ureteral scarring that had been corrected surgically. [In the 
absence of exogenous immunosuppression, a MHC Class I-mismatched kidney transplant sur-
vives in a naïve miniature swine for approximately 14 days (21), and a MHC Class I-mismatched 
heart transplant for 8 days (22).] Altogether, in vivo donor-specifi c tolerance correlated well 
with the in vitro tests that indicated donor-specifi c hyporesponsiveness. 
EXPERIENCE WITH FULL MHCMISMATCHED SPLEEN TRANSPLANTATION IN 
MINIATURE SWINE CHAPTER 6
Fourteen such studies have been performed (details in Chapter 6). The regimen of a 12-day 
course of CyA and pretransplant thymic irradiation was found to be inadequate to induce 
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a state of tolerance to the transplanted spleen in this model (12). Long-term survival of the 
spleen graft was only obtained when the regimen consisted of pretransplant thymic irradia-
tion (day -1), a 45-day course of CyA (rather than a 12-day course), and the addition of whole 
body irradiation (100 cGy on day -2). The combined dose of whole body and thymic irradia-
tion was insuffi  cient to cause myeloablation, as evidenced by normal white blood cell counts 
throughout the post-SpTx period and only marginally reduced platelet counts, which recov-
ered within three weeks. 
When this full regimen was applied, rejection of the spleen developed in only one of 9 experi-
ments; the cause for failure in this one case was uncertain. When the full regimen was not ap-
plied, but the host was either untreated or received only elements of this regimen, 4 of 5 grafts 
rejected (within 15 days after cessation of CyA) and the remaining animal died of infection on 
day 23 (while still on CyA) before rejection had occurred. In pigs that had undergone success-
ful SpTx, there were recipient deaths from post-transplantation lymphoproliferative disease 
(associated with abnormally high levels of CyA) (23 and Chapter 9) and infection (due to an 
outbreak of circovirus in the pig facility). 
The full regimen was associated with the prolonged presence of donor cells in the histologi-
cally normal spleen, which were slowly replaced by recipient cells over a period of 100-150 
days. Spleen graft survival was also associated with the development of multilineage chi-
merism in the blood, particularly of T cells, with lesser chimerism of B cells, monocytes and 
granulocytes. In several recipients, donor T cells outnumbered host T cells (Figure 2A), yet 
no features of GVHD (e.g., skin rash, diarrhea, hepatic dysfunction) were seen. Multilineage 
chimerism was slowly lost, particularly after cessation of CyA therapy, but could persist for 
>6 months. In three pigs, a rapid increase in granulocyte and monocyte chimerism was seen 
during the fourth week to levels >50%, although lymphocyte chimerism was maintained at 
<20%. 
Chimerism (generally of 3-15%) was also detected in the thymus in 6 of the 9 recipient pigs 
from one month after SpTx, with evidence for donor thymopoiesis. In one recipient it even 
rose to a maximum of approximately 30% by day 57 (Figure 2B). In the same 6 pigs, donor 
cells represented up to 25% of the BM cells. In this respect, it should be noted that, in PAA-
positive pigs, only 50-60% of BM cells carry this marker (19), and therefore the actual number 
of donor cells in the BM following SpTx may be considerably more than the 25% measured 
by fl ow cytometry. True engraftment was confi rmed by PCR and subsequent Southern Blot 
analysis on DNA derived from colony-forming units from recipient BM, which indicated donor 
hematopoiesis. Our observations were that engraftment in the BM was more likely to occur 
when T cell depletion had been particularly good.
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As with the Class I-mismatched experiment, anti-donor reactivity on CML was lost within the 
fi rst few weeks following successful SpTx, and the host remained unresponsive to donor cells 
thereafter, whereas it retained full reactivity against third-party cells. Mixed leukocyte reac-
tion (MLR) assays (MHC Class II-restricted T cell responses) determined that recipients were 
hyporesponsive to donor-specifi c or donor-matched cells. Suppressor CML and MLR assays 
clearly documented active suppression in the host, which was again donor-specifi c, indicative 
of the presence of regulatory cells. 
In fully MHC-mismatched donor-recipient combinations, anti-donor antibodies were found 
only in those recipients that did not receive the full immunosuppressive protocol and rejected 
the spleen graft.
A donor-matched kidney transplant was performed on day 60 (by which time no CyA could 
be detected in the blood) in one spleen recipient that demonstrated in vitro hyporesponsive-
ness to the donor, without any immunosuppressive drug therapy. This graft functioned for >4 
months, although there was a steady rise in serum creatinine, which was 8.1mg/dL at the time 
the animal was euthanized. The kidney graft showed fi brotic changes with some vasculopathy 
and glomerulopathy, and a cellular infi ltrate (similar to that seen on previous biopsies), but no 
endothelialitis. The exact cause of graft failure remains uncertain. 
The histology of the spleen graft revealed no rejection. Nevertheless, although in vitro evi-
dence for tolerance existed and the spleen graft was not rejected, a state of in vivo tolerance 
could not be confi rmed. [Graft survival for a period of >4 months is in marked contrast to 
51%
10 1 10 2 10 3 10 4
CD3 -->
10
1
10
2
10
3
10
4
PA
A
 --
>
10 1 10 2 10 3 10 4
PAA -->
0
10
20
30
40
N
um
be
r
30.6%
A B
Figure 2. 
(A) Flow cytometry data of peripheral blood of a SpTx recipient during CyA therapy. Donor T cells (CD3+PAA+) are circled. Donor T cells frequently 
made up approximately 50% of the T cell pool (in the absence of GVHD). 
(B) Flow cytometry data of thymus in a SpTx recipient, at 57 days after SpTx. Donor-derived cells made up approximately 31% of the T cells in the 
thymus at this point.
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kidney graft survival across a full MHC barrier in the absence of immunosuppression in a naïve 
pig, which is rarely more than 10-20 days (24).] 
For comparison, two pigs received the full immunosuppressive regimen, including native 
splenectomy and red blood cell transfusion, but without SpTx. Although temporary chime-
rism (due to white cell contamination of the red cell transfusate) was seen in these two control 
animals, it was at a very low level (maximum 5.9%) and was lost within 11 days (Figure 3A). 
There was no evidence of the development of in vitro hyporesponsiveness on either MLR or 
CML assays (data not shown). In one case, a subsequent kidney transplant from a pig MHC-
matched to the red blood cell donor (performed on day 60) was rejected in an accelerated 
manner with evidence for both cellular and humoral rejection within four days (Figure 3B). 
After the kidney transplant had been excised, hyperresponsiveness to donor cells was seen 
on both CML and MLR assays. It therefore appeared that the regimen alone was insuffi  cient to 
develop hyporesponsiveness. 
INVESTIGATION OF NAÏVE PIG SPLEENS FOR HEMATOPOIETIC PROGENITOR 
CELLS CHAPTER 7
In view of the clear development of multilineage hematopoietic cell chimerism following 
SpTx, with subsequent engraftment in recipient BM, we investigated the naïve spleen as a 
source of hematopoietic progenitor cells (HPC), and compared this source with the BM from 
the same pig (Chapter 7).
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Figure 3.
(A) Peripheral blood chimerism of a control pig that received the full immunosuppressive regimen and a blood transfusion, but no SpTx. By day 
11, no chimerism is present.
(B) Histology of the kidney graft (matched to the blood donor, fully MHC-mismatched with the recipient) in a control pig. By day 4 after KTx, 
severe rejection can be seen (H&E 200x). Interstitial hemorrhage, severe cellular infi ltration, and endothelialitis point to both cellular and 
humoral rejection. 
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The fetal spleen, even in higher mammals, is a major contributor to hematopoiesis (5). How-
ever, under normal circumstances, this function of the spleen is lost before birth. In the adult 
pig, nonhuman primate or human, the spleen can become an hematopoietic organ (extra-
medullary hematopoiesis), but only when there is diminished or absent BM hematopoietic 
activity, for example in BM aplasia or myelofi brosis (25, 26). 
In rodents, however, the spleen continues to be a major source of HPC. Indeed, the fi rst dem-
onstration of successful restoration of the hematopoietic system was carried out by shielding 
the spleen from lethal whole body irradiation by Jacobsen in 1949 (27); this seminal study 
demonstrated that the spleen was a source of HPC that, through engraftment in the aplastic 
BM, could restore full hematopoiesis to the rodent. 
C-kit is an essential marker of long-term-repopulating HPC with early engraftment capacity 
(28). The fetal pig spleen and BM are rich sources of c-kit+ cells. By adult life, however, the pig 
spleen is a source of far fewer c-kit+ cells than the BM, particularly of cells that are c-kithigh on 
fl ow cytometry (Figure 4). 
In mice and humans, it has been demonstrated that side population (SP) cells are highly en-
riched in hematopoietic stem cells (HSC) (29-31). We demonstrated for the fi rst time that in 
the adult pig spleen, SP cells are enriched for c-kit, as well as in BM (32). It may therefore be 
concluded that HSC in the adult spleen reside in the c-kit+ SP compartment. 
Culture of adult pig spleen cells demonstrated them to be a source of HPC of all forms of CFU. 
However, the frequency of CFU from the adult spleen was approximately only 0.5% of that 
from the adult BM. The fact that the CFU activity of HPC in the spleen was not solely due to the 
presence of blood in the spleen was confi rmed by the observation that CFU from pig blood 
were only 0 - 4.5% of those in the spleen.
The ability of either spleen or BM to produce CFU indicates the presence of HPC, but these are 
believed to be at a relatively late stage of diff erentiation (33). The cobblestone area-forming 
cell (CAFC) assay indicates the presence of hematopoietic stem cells (HSC) (33,34). When the 
capacity of the spleen to develop CAFC was compared with that of the BM, the frequency of 
these cells was initially approximately 10-fold higher in the BM. However, after 8 weeks of 
culture, CAFC frequencies in spleen and BM were equal, indicating that HSC (that provide the 
ability for long-term cell culture) were equal in number in the spleen and BM. When spleen 
CAFCs were re-plated in the so-called long-term culture-initiating cell assay, colonies were 
found at much the same frequency, indicating that these HSC had the ability to form colonies 
after prolonged culture (32). 
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HEMATOPOIETIC PROGENITOR CELLS CHAPTER 7
As the pig spleen is approximately four times the size of the spleen in the baboon or human in 
relation to body weight, it is possible that this ability to produce HPC was specifi c for the pig 
spleen and not for the baboon or human spleen. We therefore carried out a limited number of 
studies on naïve human and baboon spleens, which indicated that they also contain HPC that 
could produce CFU of all lineages. CAFC were also present in the human spleen at the same or 
even greater frequency than in the BM of the same donor. Long-term culture-initiating cells 
could also be demonstrated from human spleen CAFC (32).
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Figure 4. Flow cytometry data of spleen and adult bone marrow (BM) (A+B, respectively), and fetal spleen and BM (C+D, respectively). 
Stem cell factor (SCF) is a marker for c-kit+ cells, expressed on hematopoietic progenitor cells (HPC). CD9 is a marker for the myeloid lineage, 
CD9– cells have been shown to be more primitive cells. Cells that are both CD9– and c-kit+ are primitive HPC. Each quadrant within fi gure A,B,C 
and D represents a specifi c sub-type (e.g. CD9-/c-kit+), from which the percentage of the total amount of cells is given in each corner. 
In adult spleen and BM (A+B, respectively), c-kit+ cells made up 5.6% and 11.1%, respectively. The spleen (A) lacked c-kithigh populations (within 
the rectangles). 
In fetal spleen and BM (C+D, respectively), c-kit+ cells made up 6.9% and 11.7%, respectively, and both BM and spleen contained c-kithigh 
populations (within the rectangles). 
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We conclude that the adult spleen is a source of HPC (32), which correlates well with the ob-
servations made in our SpTx studies. Since the spleen in mammals is not an active participant 
in adult hematopoiesis, it is not surprising that relatively low frequencies of HPC were found in 
comparison with the BM, but it is surprising that more undiff erentiated earlier HSC are found 
at comparable frequencies in spleen and BM. There is evidence from studies of others (35-38) 
that the adult spleen may be a source of other types of stem cells in addition to HSC.
DISCUSSION 
After SpTx, there is a dynamic exchange of cells between the host and the donor tissues. Do-
nor cells can be found in the host blood circulation, BM and thymus, as well as other lym-
phoid organs (e.g., lymph nodes), whereas recipient cells slowly repopulate the donor spleen 
(12,20). 
This hematopoietic cell chimerism is associated with clear in vitro evidence of donor-specifi c 
unresponsiveness, that might be due to the development of regulatory cells that developed 
in both tolerant MHC-class I-mismatched and fully MHC-mismatched SpTx recipients. We have 
addressed the question whether the unresponsiveness observed after SpTx was truly donor-
specifi c and not due to a “bystander” eff ect, in which regulatory T cells, activated by donor-
antigen, suppress immune responses in an antigen-nonspecifi c manner. In diff erent in vitro 
analyses with cells from unresponsive SpTx recipients, there was no evidence for “bystander 
suppression”. Therefore, it seems unlikely that bystander suppression played a role in our in 
vivo experiments.
In the fully MHC-mismatched SpTx recipients, there was evidence for both central and periph-
eral tolerance mechanisms. However, macrochimerism slowly decreased in all recipients, even 
when engraftment in the BM had occurred. Evidence for regulatory mechanisms persisted in 
all animals. 
Recipients of long-term surviving spleen grafts receiving the full immunosuppressive regi-
men did not develop anti-donor antibodies. Although we did not investigate this phenom-
enon specifi cally, it suggests the possibility that SpTx also induces antibody-mediated unre-
sponsiveness.
The spleen is known to be a source of immature and other subtypes of dendritic cells (39-
41) that would be released into the circulation and may be important in mediating tolerance 
(42,43). A distinct subpopulation of immature dendritic cells has been identifi ed in the spleen 
with limited T cell stimulation capacity (44). By releasing cells into the recipient circulation 
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over a number of weeks, SpTx may also have the same eff ect as a prolonged donor-specifi c 
blood transfusion, and may induce hyporesponsiveness through a similar mechanism. How-
ever, the mechanisms by which donor-specifi c blood transfusion (DSBT) promotes organ al-
lograft acceptance are still largely unclear (45), although mainly peripheral mechanisms have 
been described. It has been demonstrated in a number of rodent models that, early after 
DSBT, alloantigen-specifi c regulatory T cells are present in secondary lymphoid organs, where 
they gradually expand, and can be found in the graft as early as 2 weeks after Tx (46). In large 
animal models, the benefi cial eff ect of DSBT has also been shown (47-49), although there 
were no full MHC-mismatches in these studies. Other studies showed no benefi cial eff ect of 
DSBT (50,51). The disadvantages of DSBT include immunization against alloantigens in 50% of 
the cases, which could jeopardize a subsequent organ transplant (49), transfusion-associated 
GVHD (52), a rare but often lethal complication (occurring in 90% of the reported cases), infec-
tions (53), and malignancies (49). Potential advantages of SpTx over DSBT are (i) both central 
and peripheral mechanisms are involved in tolerance induction through SpTx, (ii) donor cells 
are released continuously in the recipient’s circulation after SpTx rather than in one or two 
“bolus” transfusions (which could prevent GVHD and facilitate donor-recipient immune inter-
action), (iii) SpTx provides a stroma for APC-T cell interaction, and (iv) SpTx seems to be more 
eff ective in preventing an anti-donor antibody response than DSBT (20,50,51). 
Relatively high levels of chimerism were documented after successful SpTx, particularly of T 
cells, and notably in the absence of any features of GVHD. Why GVHD was not seen in these ex-
periments, whereas it is not uncommon after MHC-mismatched BM Tx in large animals (54,55) 
(and in humans) remains uncertain, but there are several diff erences that may account for this. 
First, the spleen releases donor cells into the host circulation over a matter of weeks or months 
rather than as a single infusion as occurs with BM Tx. Second, the diff erences in phenotype 
between spleen and BM HPC may be of importance in this respect. Third, regulatory T cells are 
known to control graft-versus-host reactions (56); the regulatory T cells induced by SpTx may 
be more eff ective in controlling GVHD compared to these induced by BMTx.
SpTx may also be compared to intestinal Tx, because of the large load of lymphoid tissue 
that is transplanted. Chimerism has been described after intestinal Tx, though this is usually 
limited to microchimerism, in contrast to SpTx. The level of chimerism positively correlates 
with graft survival (57). However, microchimerism is transient, unless a concomitant BMTx is 
performed, leading to macrochimerism and engraftment of donor BM cells (58). In contrast to 
SpTx, GVHD was noted in 4.7-6.5% of intestinal Tx recipients (59). An important complication 
of intestinal Tx, besides infection and GVHD, is PTLD (60), the incidence of which has been re-
ported to be higher after intestinal Tx than after any other organ transplants (61). There are no 
reports that intestinal Tx induces donor-specifi c tolerance. It does not seem realistic to believe 
that intestinal Tx will be used clinically for the purpose of inducing Tx tolerance.
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Interestingly, in a recent report on multivisceral Tx, it was indicated that multivisceral grafts 
seem to facilitate survival of organs, suggesting that this procedure off ers a degree of immu-
nologic advantage (62). The authors concluded that this advantage could at least partly be 
attributed to the inclusion of the spleen in the graft (62).
Another organ that has the potential to induce tolerance is the thymus, the major site of self-
nonself discrimination in the immune system. Two diff erent immunologic events would allow 
a vascularized thymic graft to induce tolerance. The fi rst mechanism involves thymic stromal 
cells, and possibly dendritic cells, in the vascularized thymic graft that may induce central tol-
erance after Tx by achieving deletion or anergy of T cells reactive to the donor haplotype. The 
second potential mechanism involves thymic emigrants from the vascularized thymic graft, 
which could be responsible for the induction of tolerance by means of a peripheral mecha-
nism of regulation that leads to the silencing of alloreactive cells (63). Disadvantages of thy-
mus Tx are its applicability only in the pediatric and adolescent population (since the thymus 
involutes with adolescence) (64), the need for host thymectomy to successfully induce toler-
ance (65), and the technically challenging nature of the surgical procedure (64,66). 
Based on the studies described in this dissertation, allogeneic SpTx deserves further investi-
gation as a potential means of achieving donor-specifi c immunological tolerance. Since the 
spleen is commonly discarded (except for tissue-typing purposes) from deceased human or-
gan donors, it is readily available for Tx along with any other organ, such as the kidney or 
heart. If indeed it is proved that the spleen can induce a state of tolerance to the kidney or 
heart, allowing the patient to be weaned from all exogenous immunosuppressive drug ther-
apy (with its concomitant side eff ects and complications), this would be a signifi cant advance 
in organ Tx. The potential of SpTx in the induction of tolerance following xenoTx has also been 
considered (67) (Chapter 8). 
Our limited studies on the presence of HPC and HSC in the spleen indicate that the human 
spleen, like its pig counterpart, is an equal source of these cells. This suggests that SpTx in 
humans might be associated with the same outcome as in pigs.
ACKNOWLEDGEMENTS
We acknowledge and thank our many colleagues, research fellows and technicians, largely at 
the Transplantation Biology Research Center at the Massachusetts General Hospital/Harvard 
Medical School, Boston, USA, who contributed to the studies summarized in this manuscript. 
Frank Dor BW.indd   222 18-08-2006   15:09:54
223
Summary and general discussion
C
h
ap
te
r 
10
REFERENCES
 1. Timens W. The human spleen and the immune system: not just another lymphoid organ. Res Im-
munol 1991; 142: 316-20.
 2. Timens W, Leemans R. Splenic autotransplantation and the immune system: adequate testing re-
quired for evaluarion of eff ect. Ann Surg 1992; 215:256-260.
 3. Kopp WC. The immune functions of the spleen. In: Bowdler AJ, ed. The spleen. London: Chapman 
and Hall Medical; 1990; 103-26.
 4. Sills RH. Splenic function: physiology and splenic hypofunction. Crit Rev Oncol Hematol 1987; 7: 
1-36.
 5. Christensen JL, Wright DE, Wagers AJ, et al. Circulation and chemotaxis of fetal hematopoietic 
stem cells. PLoS Biol 2004 Mar;2:E75.
 6. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus 
perceived risks. Br J Surg 1991; 78: 1031-8.
 7. Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infec-
tion--an update. Crit Care Med 1999;27:836-842.
 8. Bohnsack JF, Brown EJ. The role of the spleen in resistance to infection. Annu Rev Med 1986; 37: 
49-59.
 9. Koren A, Haasz R, Tiatler A, et al. Serum immunoglobulin levels in children after splenectomy. A 
prospective study. Am J Dis Child 1984;138:53-55.
 10. Constantoulakis M, Trichopoulos D, Avgoustaki O, et al. Serum immunoglobulin concentrations be-
fore and after splenectomy in patients with homozygous -thalassemia. J Clin Pathol 1978;31:546-
550.
 11. Durig M, Landmann RM, Harder F. Lymphocyte subsets in human peripheral blood after splenec-
tomy and autotransplantation of splenic tissue. J Lab Clin Med 1984;104:110-115.
 12. Dor FJMF, Gollackner B, Kuwaki K, et al. Histopathology of spleen allograft rejection in miniature 
swine. Int J Exp Pathol 2005; 86:57-66. 
 13. Dor FJMF, Gollackner B, Cooper DKC. Can spleen transplantation induce tolerance? A review of the 
literature. Transplant Int 2003;16:451-460. 
 14. Groth CG, Bergström K, Collste L. Immunologic and plasma protein studies in a splenic homograft 
recipient. Clin Exp Immunol 1972; 10: 359-365. 
 15. Booster MH, Wijnen RM, van Hooff  JP, et al. The role of the spleen in pancreas transplantation. 
Transplantation 1993; 56: 1098-1102. 
 16. Deierhoi MH, Sollinger HW, Bozdech MJ, et al.. Lethal graft-versus-host disease in a recipient of a 
pancreas-spleen transplant. Transplantation 1986; 41: 544-546.
 17. Gollackner B, Dor FJMF, Knosalla C, et al. Spleen transplantation in miniature swine. Surgical tech-
nique and initial results in MHC-matched pairs. Transplantation 2003;75:1799-1806. 
 18. Sachs DH. MHC homozygous miniature swine. In: Swindle MM, Moody DC, Phillips LD, eds. Swine 
as Models in Biomedical Research. Ames: Iowa State University Press; 1992: 3-15. 
 19. Fuchimoto Y, Huang CA, Shimizu A, et al. An allelic non-histocompatibility antigen with wide tis-
sue distribution as a marker for chimerism in pigs. Tissue Antigens 1999; 54: 43-52. 
 20. Dor FJMF, Tseng Y-L, Kuwaki K, et al. Immunological unresponsiveness in chimeric miniature swine 
following MHC-mismatched spleen transplantation. Transplantation 2005;80:1791-1804. 
 21. Rosengard BR, Ojikutu CA, Guzzetta PC, et al. Induction of specifi c tolerance to class I-disparate 
renal allografts in miniature swine with cyclosporine. Transplantation 1992;54:490-497.
 22. Madsen JC, Yamada K, Allan JS, et al. Transplantation tolerance prevents cardiac allograft vascu-
lopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation 
1998;65:304-313. 
 23. Dor FJMF, Doucette KE, Mueller NJ, et al. Post-transplant lymphoproliferative disease after alloge-
neic transplantation of the spleen in minaiture swine. Transplantation 2004;78:286-291. 
Frank Dor BW.indd   223 18-08-2006   15:09:54
Chapter 10
224
 24. Gianello PR, Sachs DH. Eff ect of major histocompatibility complex matching on the development 
of tolerance to primarily vascularized renal allografts: a study in miniature swine. Hum Immunol 
1996;50:1-10. 
 25. Kraus MD, Bartlett NL, Fleming MD, et al.. Splenic pathology in meylodysplasia: a report of 13 cases 
with clinical correlation. Am J Surg Pathol 1998;22:1255-1266.
 26. Thiele J, Kvasnicka HM, Czieslick C. CD34+ progenitor cells in idiopathic (primary) myelofi brosis: a 
comparative quantifi cation between spleen and bone marrow tissue. Ann Hematol 2002;81:86-
89.
 27. Jacobsen LO, Marks EK, Rolson NJ, et al. The eff ect of spleen protection on mortality following ex-
irradiation. J Laborat Clin M 1949; 34: 1538-1543. 
 28. LeGuern AC, Giovino MA, Abe M, et al.Stem cell activity of porcine c-kit+ hematopoietic cells. Exp 
Hematol 2003;31:833-40. 
 29. Goodell MA, Rosenzweig M, Kim H, et al. Dye ef.ux studies suggest that hematopoietic stem cells 
expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 
1337–1345.
 30. Parmar K, Burdick D, Ethier M, et al. Murine side population cells contain cobblestone area-forming 
cell activity in mobilized blood. Stem Cells Dev 2005;14:452-61.
 31. Banu N, Fabian A, Mulligan RC. Functional studies of human bone marrow derived side population 
cells. Blood (ASH Annual Meeting Abstracts) 2004; 104: Abstract 3221.
 32. Dor FJMF, Ramirez ML, Parmar K, et al. Primitive hematopoietic progenitor cell populations reside 
in the spleen: studies in the pig, baboon, and human. Exp Hematol 2006. In Press.
 33. Coulombel L. Identifi cation of hematopoietic stem/progenitor cells: strength and drawbacks of 
functional assays. Oncogene 2004;23:7210-22. 
 34. Hao QL, Thiemann FT, Petersen D, et al.. Extended long-term culture reveals a highly quiescent and 
primitive human hematopoietic progenitor population. Blood 1996;88:3306-3313. 
 35. Kodama S, Huhtreiber W, Fujimura S, et al. Islet regeneration during the reversal of autoimmune 
diabetes in NOD mice. Science 2003;302: 1223-1227. 
 36. Kodama S, Faustman DL. Routes to regenerating islet cells: stem cells and other biological thera-
pies for type 1 diabetes. Pediatr Diabetes 2004 Dec;5 Suppl 2:38-44. 
 37. Kodama S, Davis M, Faustman DL. Regenerative medicine: a radical reappraisal of the spleen. 
Trends Mol Med 2005; 11:271-6. 
 38.  Di Gioacchino G, Di Campli C, Zocco MA, et al. Transdiff erentiation of stem cells in pancreatic cells: 
state of the art. Transplant Proc 2005;37:2662-3.
 39.  Buckley PJ. Phenotypic subpopulations of macrophages and dendritic cells in human spleen. 
Scanning Microsc 1991;5:147--57; discussion 157-8. 
 40.  McIlroy D, Troadec C, Grassi F, et al. Investigation of human spleen  dendritic cell phenotype and 
distribution reveals evidence of in vivo activation in a subset of organ donors. Blood 2001;97:3470-
3477. 
 41. Voisine C, Hubert FX, Trinite B, et al.Two phenotypically distinct subsets of spleen dendritic cells in 
rats exhibit diff erent cytokine production and T cell stimulatory activity. J Immunol 2002;169:2284-
91. 
 42. Jonuleit H, Schmitt E, Schuler Get al.. Induction of interleukin 10-producing, nonproliferating 
CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature hu-
man dendritic cells. J Exp Med 2000;192:1213-1222.
 43. Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have 
captured apoptotic cells. J Exp Med 2000;191: 411-416.
 44. Quah B, Ni K, O’Neill HC. In vitro hematopoiesis produces a distinct class of immature dendritic cells 
from spleen progenitors with limited T cell stimulation capacity. Int Immunol 2004;16:567-77.
 45.  Kitade H, Kawai M, Rutgeerts O, et al. Early presence of regulatory cells in transplanted rats ren-
dered tolerant by donor-specifi c blood transfusion. J Immunol 2005;175:4963-4970.
Frank Dor BW.indd   224 18-08-2006   15:09:55
225
Summary and general discussion
C
h
ap
te
r 
10
 46.  Obertop H, Jeekel J, Vriesendorp HM, MacDicken I, Westbroek DL. The eff ect of donor blood on 
renal allograft survival in DLA tissue typed beagle littermates. Transplantation 1975; 20:49-52. 
 47.  van Es AA, Marquet RL, van Rood JJ, Kalff  MW, Balner H. Blood transfusions induce prolonged al-
lograft survival in rhesus monkeys. Lancet 1977;5:1506-1509.
 48.  Hoerbelt R, Johnston DR, Shoji T, et al. Combination treatment with donor-specifi c transfusions 
and cyclosporine A induces long-term survival of cardiac allografts in miniature swine. Transplan-
tation 2005;80:1275-1282.
 49. Meryman HT. Transfusion-induced alloimmunization and immunosuppression and the eff ects of 
leukocyte depletion. Transf Med Rev 1989;3:180-193.
 50. Xu H, Montgomery SP, Preston EH, et al. Studies investigating pretransplant donor-specifi c blood 
transfusion, rapamycin, and the CD154-specifi c antibody IDEC-131 in a nonhuman primate model 
of skin allotransplantation. J Immunol 2003;170:2776-2782.
 51. Ringers J, Haanstra KG, Kroczek RA, et al. Blockade of CD40-CD154 at the time of donor-specifi c 
blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates. 
Transplantation 2002;73:862-866.
 52. Anderson KC. Transfusion-associated graft-versus-host-disease. N Engl J Med 1990;323:315-321.
 53. Tartter PI. Blood transfusion and postoperative infections. Transfusion 1989;29:456-459.
 54. Storb R, Deeg HJ, Raff  R, et al. Prevention of graft-versus-host disease. Studies in a canine model. 
Ann N Y Acad Sci 1995;770:149-64. 
 55. Kozlowski T, Sablinski T, Basker M, et al. Decreased graft-versus-host disease after haplotype mis-
matched bone marrow allografts in miniature swine following interleukin-2 treatment. Bone Mar-
row Transplant 2000;25:47-52. 
 56. Trenado A, Charlotte F, Fisson S et al. Recipient-type specifi c CD4+CD25+ regulatory T cells favor 
immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leu-
kemia. J Clin Invest 2003;112:1688-1696.
 57. Fujishiro J, Tahara K, Inoue S, et al. Immunologic benefi ts of longer graft in rat allogeneic small 
bowel transplantation. Transplantation 2005;79:190-195.
 58. Nakao A, Toyokawa H, Kimizuka K, et al. Simultaneous bone marrow and intestine transplanta-
tion promotes marrow-derived hematopoietic stem cell engraftment and chimerism.  Blood 
2006;108:1413-1420.
 59. Mazariegos G. Abu-Elmagd K, Jaff e R, et al. Graft versus host disease in intestinal transplantation. 
Am J Transplant 2004;4:1459-1456.
 60. Dijkstra G, Rings EH, Bijleveld CM, et al. Intestinal transplantation in The Netherlands: First experi-
ence and future perspectives. Scand J Gastroenterol Suppl 2006;243:39-45.
 61. Reyes J, Green M, Bueno J, et al. Epstein Barr virus associated posttransplant lymphoproliferative 
disease after intestinal transplantation. Transplant Proc 1996;28:2768-2769.
 62. Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 
2005;242:480-493.
 63. Kamano C, Vagefi  PA, Kumagai N, et al. Vascularized thymic lobe transplantation in miniature 
swine: thymopoiesis and tolerance induction across fully MHC-mismatched barriers. Proc Natl 
Acad Sci U S A 2004;101:3827-32.
 64. Johnston DR, Muniappan A, Hoerbelt R, Guenther DA, Shoji T, Houser SL, Sachs DH, Madsen 
JC. Heart and en-bloc thymus transplantation in miniature swine. J Thorac Cardiovasc Surg 
2005;130:554-559.
 65. Nobori S, Samelson-Jones E, Shimizu A, et al. Long-term acceptance of fully allogeneic cardiac grafts 
by cotransplantation of vascularized thymus in miniature swine. Transplantation 2006;81:26-35.
 66. LaMattina JC, Kumagai N, Barth RN, et al. Vascularized thymic lobe transplantation in miniature swine: 
I. Vascularized thymic lobe allografts support thymopoiesis. Transplantation 2002;73:826-831.
 67. Dor FJMF, Tseng YL, Kuwaki K, et al. Pig spleen transplantation induces transient hematopoietic 
cell chimerism in baboons. Xenotransplantation 2004;11:298-300.
Frank Dor BW.indd   225 18-08-2006   15:09:55
Frank Dor BW.indd   226 18-08-2006   15:09:56
Summary in Dutch
11
Frank Dor BW.indd   227 18-08-2006   15:10:10
Frank Dor BW.indd   228 18-08-2006   15:10:25
229
Summary in Dutch
C
h
ap
te
r 
11
ONDERZOEK GERELATEERD AAN DE INDUCTIE VAN IMMUNOLOGISCHE 
TOLERANTIE DOOR MIDDEL VAN MILTTRANSPLANTATIE IN 
MINIATUURVARKENS
Het ultieme doel in klinische transplantatie is het bereiken van donor-specifi eke immunolo-
gische tolerantie ten opzichte van het getransplanteerde orgaan zonder dat continue immu-
nosuppressieve therapie noodzakelijk is. Namelijk, getransplanteerde organen zouden dan 
langdurig kunnen overleven zonder dat de patiënt de risico’s en complicaties van farmacolo-
gische immunosuppressieve therapie ondervindt. Het transplanteren van de milt wordt in dit 
proefschrift onderzocht als methode om immunologische tolerantie te induceren. 
In hoofdstuk 1 van dit proefschrift wordt een uitgebreide introductie gegeven over de milt. 
Vanuit de medische geschiedenis wordt met name duidelijk dat de functie(s) van de milt lang-
durig onbekend is (zijn) geweest, en het orgaan met mystiek werd omhuld. Er wordt een over-
zicht gegeven van de huidige inzichten betreff ende de embryologie, anatomie, histologie, 
en fysiologie van de milt, waarbij specifi eke aspecten van de varkensmilt worden uitgelicht. 
Daarna volgt een aantal paragrafen over transplantatie-immunologie, waarin met name aan-
dacht is voor het begrip “transplantatie-tolerantie”. Ter afsluiting van de introductie wordt de 
lezer geïnformeerd over het miniatuurvarkensmodel, met name in relatie tot transplantatie-
studies.
Hoofdstuk 2 verwoordt puntsgewijs de doelstellingen van het onderzoek:
1. het ontwikkelen van een pre-klinisch groot proefdiermodel voor milttransplantatie.
2. het bepalen van histologische kenmerken van afstoting (rejectie) van milttransplantaten in 
het miniatuurvarken. 
3. door middel van milttransplantaties in het miniatuurvarken in verschillende donor-ont-
vangercombinaties (Major Histocompatibility Complex (MHC)- gematched, MHC-klasse I 
mismatch, volledige MHC mismatch) zal worden gepoogd om langdurig gemengd hema-
topoietisch chimerisme te induceren, en worden onderzocht of milttransplantatie leidt tot 
donor-specifi eke non-responsiviteit en langdurige overleving van het milttransplantaat. 
Tevens zal worden onderzocht welk immunosuppressieve regime het meest succesvol is 
om immunologische tolerantie te bewerkstelligen. 
4. het onderzoeken of succesvolle MHC-gemismatchte milttransplantatie (met of zonder 
inductie van gemengd hematopoietisch chimerisme en/of cellulaire non-responsiviteit) 
tolerogeen is, zodat vervolgens een niertransplantaat dat MHC-gematcht is aan de donor 
kan overleven zonder dat de ontvanger immunosuppressiva krijgt. Tevens zal worden on-
derzocht welk mechanisme aan deze tolerantie of non-responsiviteit ten grondslag ligt.
5. het onderzoeken van de milt als bron van hematopoietische voorlopercellen of stamcel-
len.
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6. het onderzoeken of milttransplantatie ook een rol kan spelen bij tolerantie-inductie in xe-
notransplantatie (transplantatie tussen verschillende soorten), in een varken-naar-baviaan 
transplantatiemodel.
7. het identifi ceren en beschrijven van mogelijke nadelen van milttransplantatie en/of het 
immunosuppressieve regime.
Hoofdstuk 3 is een review van bestaande literatuur met als hoofdvraag: kan de milt tole-
rantie induceren? In diverse knaagdiermodellen is overtuigend bewijs gevonden voor een 
tolerogeen eff ect door een getransplanteerde milt onder verschillende omstandigheden. In 
meerdere studies wordt beschreven dat er een balans kan worden verkregen tussen host-
versus-graft (ontvanger-versus-transplantaat) en graft-versus-host (transplantaat-versus-ont-
vanger) reacties na milttransplantatie, hetgeen leidt tot lange-termijns overleving van zowel 
de getransplanteerde milt als een tweede donor-specifi ek orgaan. De inductie van tolerantie 
zou gepaard gaan met het ontwikkelen van regulatoire T cellen. Echter, in grote proefdieren 
en mensen is geen defi nitief bewijs verkregen dat milttransplantatie tolerantie kan induceren. 
De meeste studies beschrijven dat de getransplanteerde milt, zoals ieder ander orgaantrans-
plantaat, wordt afgestoten. Echter, deze studies zijn alle sterk verouderd. Tevens is in geen 
van de studies gebruik gemaakt van een model waarvan de transplantatie-antigenen, het 
MHC, bij donor en ontvanger bekend zijn. Ook is in geen van de beschreven onderzoeken 
gebruik gemaakt van immunosuppressieve strategieën die gericht zijn op het induceren van 
tolerantie, waarover de laatste jaren veel kennis is vergaard. Enkele studies die klinische milt-
transplantatie beschrijven (van mens naar mens) demonstreren dat na milttransplantatie he-
matopoietisch chimerisme kan optreden, en een sterke graft-versus-host reactie teweeg kan 
brengen, die zelfs tot dodelijke graft-versus-host-disease kan leiden. Dit toont aan dat de milt 
in ieder geval de potentie heeft om de gebruikelijke afstotingsreactie van een ontvanger van 
een orgaantransplantaat tegen te werken.
De voordelen van immunologische tolerantie bij ontvangers van een orgaantransplantaat, 
zeker in vergelijking met chronische farmacologische immunosuppressie, zijn aanzienlijk. 
Derhalve lijkt het zinvol om, voordat eventuele klinische studies worden geïnitieerd, milt-
transplantatie te bestuderen in een groot proefdiermodel, zoals het Massachusetts General 
Hospital MHC-gedefi nieerde miniatuurvarken, waarmee een aanzienlijke ervaring is opge-
bouwd in transplantatie-onderzoek. 
In hoofdstuk 4 wordt de chirurgische techniek van milttransplantatie in het varken beschre-
ven. Aanvankelijk werd een techniek gebruikt, waarbij de donormilt werd geëxcideerd en de 
suprapancreatische arteria lienalis end-to-side werd geanastomoseerd op de infrarenale ab-
dominale aorta van de ontvanger en de miltvene op de infrarenale vena cava inferior. Echter, 
de diameter van de miltvaten in de donorvarkens was klein (<3 mm), waardoor er stenotische 
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en/of trombotische complicaties optraden ter hoogte van de anastomose. Daarom ontwik-
kelden we een techniek waarbij in de donor de miltarterie en truncus coeliacus werden vrij-
geprepareerd tot aan de aorta teneinde een Carrel patch van de aorta te kunnen uitnemen. 
De miltvene werd tot aan de confl uens met de v. mesenterica superior vrijgeprepareerd zodat 
een cuff  van de vena porta kon worden geïncludeerd. De donormilt werd geëxcideerd, ge-
wogen en vervolgens op ijs geplaatst. De milt werd via de arterie gespoeld met preserva-
tievloeistof totdat de veneuze effl  ux helder was. Bij alle ontvangers werd een splenectomie 
verricht, waarna de donormilt werd geïmplanteerd door middel van end-to-side anastomose 
tussen de cuff  van donoraorta en abdominale aorta van de ontvanger. De vena porta cuff  
werd end-to side op de vena cava inferior geanastomoseerd. Reperfusie van het milttrans-
plantaat resulteerde in een hematocriet-daling van 25%. Derhalve werd een transfusie van 
donor-erythrocyten gegeven. Het milttransplantaat werd aan de oppervlakte van de darmen 
gepositioneerd ter voorkoming van “kinking” van de vaatsteel. 
De introductie van deze nieuwe chirurgische techniek leidde tot 4 succesvolle MHC-gematch-
te milttransplantaties, waarvan in dit hoofdstuk de resultaten worden beschreven. Twee van 
de vier ontvangers kregen geen immunosuppressie. Rejectie van het milttransplantaat trad 
op na 28-29 dagen. De histologische kenmerken daarvan worden in hoofdstuk 5 beschreven. 
De overige twee ontvangers kregen 12 dagen cyclosporine A (en één tevens 700cGy thymus-
bestraling op dag-1); afstoting van de milt werd niet waargenomen. Alle ontvangers van een 
milttransplantaat vertoonden gemengd hematopoietisch chimerisme gedurende circa drie 
weken. Degenen die waren behandeld met cyclosporine A hadden signifi cant langere perio-
des van chimerisme, tot twee maanden. Tevens was er sprake van thymus-chimerisme in de 
ontvanger die thymusbestraling had ondergaan en 12 dagen cyclosporine A had gekregen.
We concludeerden dat milttransplantatie in het varken technisch mogelijk is, en dat lange-ter-
mijnsoverleving van MHC-gematche milttransplantaten wordt gefaciliteerd door een kortdu-
rende cyclosporine A behandeling, die tevens leidt tot langdurig gemengd hematopoietisch 
chimerisme. Additionele thymusbestraling faciliteert chimerisme van de thymus. 
In hoofdstuk 5 rapporteren we de histopathologie van milttransplantaat-rejectie in het eer-
der beschreven miniatuurvarkensmodel, na een overzicht te hebben gegeven van eerdere 
studies waarin afstoting van milttransplantaten wordt beschreven. 
Van 17 tot dan toe verrichte milttransplantaties in ons varkensmodel trad afstoting op in 2 
milttransplantaten in onbehandelde MHC-gematchte (minor antigen-gemismatcht) ontvan-
gers (Groep 1) en in 5 transplantaten in volledig MHC-gemismatchte ontvangers (Groep 2), 
van wie 1 ontvanger onbehandeld was en 4 immunosuppressieve therapie hadden onder-
gaan. Na biopsie en/of necropsie werd weefsel van het transplantaat met diverse kleuringen 
bewerkt, gekleurd met immunohistochemische markers, en werden er TUNEL assays uitge-
voerd.
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In beide groepen konden overeenkomende kenmerken van transplantaatafstoting worden 
waargenomen, maar deze traden op verschillende momenten in de tijd op. Necrose trad al op 
dag 8 op in groep 2, en pas op dag 28 in groep 1, variërend van focale fi brinoïde necrose van 
de vaatwand van arteriolen en sinusoïden tot aan diff use necrose, meestal geassocieerd met 
bloeding. Andere kenmerken van rejectie zijn onder anderen: expansie van de witte pulpa 
door atypische cellen, verminderde aankleuring van basaalmembranen en reticulaire vezels. 
Een verdubbeling van de TUNEL index ging vooraf aan histologisch waarneembare afstoting. 
Tevens kunnen binnen een week na afstoting van het milttransplantaat (mits natieve splenec-
tomie is uitgevoerd) Howell-Jolly bodies worden waargenomen in een bloeduitstrijkje. 
Op basis van deze studie hebben we histologische richtlijnen opgesteld om acute rejectie van 
allogene milttransplantaten (waarvan donor en ontvanger MHC bekend is) te kunnen diag-
nosticeren, en wellicht te kunnen voorspellen (zie tabel hieronder).
Graad Rejectie Histologische Kenmerken
0 geen Normale architectuur van de milt
1 mild Focale of multifocale fi brinoïde necrose van wanden van sinusoïden en/of arteriolen, met of 
zonder bloeding   
2 matig Expansie van witte pulpa door grote, atypische, en mitotisch-actieve lymphoïde cellen
3A matig-ernstig Focale coagulatieve necrose
3B ernstig Diff use coagulatieve necrose
De meeste milttransplantaten die langdurig overleefden vertoonden histologisch het beeld 
van atrofi e van de witte pulpa gedurende de eerste 5 maanden. De (overigens normale) rode 
pulpa werd gedeeltelijk vervangen door gevacuoliseerde histiocyten en gladde spiercellen.
In hoofdstuk 6 wordt de inductie van gemengd hematopoietisch chimerisme en donor-spe-
cifi eke non-responsiviteit na milttransplantatie beschreven. Bij 13 varkens werd een splenec-
tomie (dag 0) uitgevoerd; allen kregen een transfusie van donor erythrocyten, waarna direct 
een milttransplantatie werd uitgevoerd met een MHC-klasse I mismatch (n=1) of volledige 
MHC-mismatch (n=10); twee varkens dienden als controle en kregen geen milttransplantaat. 
Alle varkens werden intensief gemonitord voor chimerisme en anti-donor immuunresponses. 
Zes van de 11 milttransplantaten gingen verloren door rejectie (n=5) of trombose van de milt-
vene. Vijf transplantaten overleefden langdurig. Alle 11 ontvangers van een donormilt ont-
wikkelden gemengd hematopoietisch chimerisme, dat spoedig verloren ging bij transplan-
taatfalen. De 2 controledieren vertoonden kortdurend (<11 dagen) laaggradig chimerisme in 
het bloed. Varkens met functionerende milttransplantaten hadden multilineair chimerisme 
in bloed, thymus en beenmerg gedurende tenminste 2-6 maanden (met bewijs voor engraft-
ment in beenmerg), zonder graft-versus-host-disease. Deze ontvangers ontwikkelden in vitro 
donor-specifi eke non-responsiviteit en suppressie.
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In 2 ontvangers van een succesvol milttransplantaat werd van een donor MHC-gematcht var-
ken een nier getransplanteerd zonder enige vorm van exogene immunosuppressie. Tevens 
werd in 2 controledieren, die geen milttransplantatie hadden ondergaan, maar wel het gehele 
immunosuppressieve regime, inclusief splenectomie en bloedtransfusie, een niertransplan-
tatie uitgevoerd van een varken MHC-gematcht aan de bloeddonor. Ook deze dieren kregen 
geen verdere immunusuppressie. In 2 tolerante varkens overleefden de donor-gematchte 
niertransplantaten >4 en >7 maanden zonder exogene immunosuppressie. In 2 controledie-
ren werden deze niertransplantaten afgestoten na 4 respectievelijk 15 dagen. Wij concluderen 
dat succesvolle milttransplantatie kan resulteren in engraftment van hematopoietische cellen 
van de donor en in vitro donor-specifi eke non-responsiviteit, zodat vervolgens niertransplan-
taten gematcht aan de oorspronkelijke donor kunnen overleven zonder dat de ontvanger 
opnieuw immunosuppressiva krijgt.
Hoofdstuk 7 
Aangezien we eerder, zoals in hoofdstuk 6 beschreven, langdurig gemengd hematopoietisch 
chimerisme (>40%) observeerden na volledig MHC gemismatchte milttransplantatie, werd de 
milt onderzocht als een bron van hematopoietische voorlopercellen (progenitors). Met be-
hulp van specifi eke celoppervlakte-markers werden hematopoietische progenitors in de milt 
en beenmerg van jong-volwassen (n=15) en foetale (n=9) miniatuurvarkens geïdentifi ceerd 
met behulp van fl owcytometrie. De zogenaamde “Side Population Cells”, waaronder zich mo-
gelijk stamcellen bevinden, scheiden een speciale fl uorescerende stof (Hoechst33342) uit, 
waardoor ze een verlaagde fl uorescentie hebben, werden geanalyseerd in volwassen milt, 
beenmerg, en bloed. Met name werd bekeken in welke mate zij de stamcelmarker c-kit tot 
expressie brachten. De c-kit+ cellen in de milt hadden meer co-expressie van lymfoïde markers 
dan c-kit+ beenmergcellen, maar een gelijke co-expressie van myeloïde markers. Zowel de 
“Side Population Cells” in het beenmerg als in de milt bevatten een signifi cante hoeveelheid 
c-kit+ cellen. 
Functionele hematopoietische progenitor activiteit van de milt en het beenmerg werd in vitro 
onderzocht door middel van de “colony forming unit (CFU)” assays en “cobblestone area-for-
ming cell (CAFC)” assays in lange-termijnkweken. 
Hoewel de frequentie van vroege CFUs in de milt slechts 0.1-1.3% was van de frequentie in het 
beenmerg, was de frequentie van CAFCs die zich na 8 weken in kweek vormden vergelijkbaar 
met de frequentie in het beenmerg. Secundaire CFUs in zogenaamde “long-term culture-initi-
ating cell assays” bevestigden de aanwezigheid van cellen met lange-termijn repopulatie-ca-
paciteit, in vergelijkbare frequenties in milt en beenmerg. Tevens werden studies uitgevoerd 
met miltweefsel en beenmerg van bavianen en mensen, waarin vergelijkbare resultaten wer-
den geboekt als in het varken. Concluderend is deze studie de eerste die aantoont dat de 
milt een relatief rijke bron van zeer primitieve hematopoietische voorlopercellen is, mogelijk 
stamcellen, die van therapeutische waarde zouden kunnen zijn in de toekomst. 
Frank Dor BW.indd   233 18-08-2006   15:10:28
Chapter 11
234
Hoofdstuk 7 appendix
Aangezien we al eerder in hoofdstuk 7 hebben beschreven dat de volwassen milt een bron 
is van primitieve hematopoietische voorlopercellen (mogelijk stamcellen), initieerden we een 
studie waarin we onderzochten of hematopoietische voorlopercellen uit milt- en beenmerg 
door middel van behandeling met 5-azacytidine (een cytosine-analoog) konden diff erentië-
ren in cardiomyocyten, zoals eerder door anderen beschreven is voor beenmergcellen. Daar-
toe werden van volwassen varkens mononucleaire milt-en beenmergcellen verrijkt met c-kit 
danwel gedepleteerd voor c-kit door “magnetic bead separation” met varkens-stamcelfactor 
(=c-kit ligand). Hierna werden de cellen geïncubeerd met 5-azacytidine gedurende 24 uur, 
waarna het kweekmedium elke 48 uur werd ververst met 5-azacytidine-vrij medium. De mor-
fologie van de cellen werd microscopisch gedurende 5 weken regelmatig beoordeeld. Met 
behulp van de Western Blot techniek werd de expressie van cardiaal troponine en myosine 
gedetecteerd.
Hoewel 5-azacytidine behandeling leidde tot morfologische veranderingen in beide c-kit-ver-
rijkte populaties, namelijk het ontstaan van balvormige celclusters, werden er geen ritmische 
contracties (zoals het kloppen van het hart) waargenomen, in tegenstelling tot eerdere be-
vindingen van anderen. Verder werd noch troponine, noch myosine gedetecteerd in milt-of 
beenmergcelkweken. 
Concluderend leidde onze behandeling van hematopoietische voorlopercellen vanuit milt of 
beenmerg met 5-azacytidine niet tot de inductie van hartspecifi eke genexpressie.
Hoofdstuk 8 beschrijft de resultaten van de eerste xenogene milttransplantaties in een var-
ken-naar-baviaan model. Eén van de doelstellingen bij het aanvangen van de studies naar 
de potentie van de milt om tolerantie te induceren was het onderzoeken van de mogelijke 
extrapolatie van de techniek naar xenotransplantatie. Xenogene varkensmilttransplantatie 
werd uitgevoerd in twee bavianen, waarvan we de eerste transplantatie met name hebben 
gebruikt om de chirurgische techniek zoals in hoofdstuk 4 beschreven te valideren in het 
varken-naar-baviaan model. De tweede baviaan (B221) kreeg 4 uur na de varkensmilttrans-
plantatie ook een beenmergtransplantatie van dezelfde donor. We rapporteren in dit hoofd-
stuk onze observaties in deze baviaan en vergelijken deze met een baviaan die alleen een 
beenmergtransplantatie van een varken had ondergaan (B219).
Beide bavianen werden geconditioneerd met een vrij complex immunosuppressief regime 
gebaseerd op het varken-naar-baviaan-beenmergtransplantatiemodel. De beide brondiervar-
kens waren miniatuurvarkens met sterk verlaagde expressie van het xeno-antigen, Galα1-3Gal 
(Gal). Er werden geen maatregelen getroff en om natuurlijk-voorkomde anti-Gal antistoff en te 
depleteren, wel werd het complement gedepleteerd met behulp van cobra venom factor.
We onderzochten het optreden van gemengd hematopoietisch chimerisme na xenogene 
milt- en beenmergtransplantatie. In B221 was er 2 uur na de milttransplantatie multilineair 
chimerisme in het bloed (16.8%), echter 2 uur erna (voor beenmergtransplantatie) waren er 
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geen varkenscellen meer detecteerbaar. Twee uur na de beenmergtransplantatie was het per-
centage chimerisme vergelijkbaar, hoewel de phenotypes van de varkenscellen in het bloed 
van de baviaan na milttransplantatie verschilden van die na beenmergtransplantatie. Het 
maximale percentage chimerisme in B219 was slechts 1.9% (op dag 2). De duur van het ma-
crochimerisme in B221 was 12 dagen, in B219 5 dagen. Een biopt van het milttransplantaat op 
dag 18 vertoonde het beeld van rejectie, waarschijnlijk anti-Gal antistof-gemedieerd.
Concluderend kon, net als na allogene milttransplantatie, hematopoietisch chimerisme wor-
den gedetecteerd na xenogene milttransplantatie, in vergelijkbare percentages als na de 
hierop volgende beenmergtransplantatie. In vergelijking met een baviaan die alleen een 
beenmergtransplantatie kreeg, waren er meer en landuriger varkenscellen in de circulatie van 
de baviaan met milt- en beenmergtransplantatie. Er trad geen graft-versus-host-disease op. 
Mede gebaseerd op eerdere studies naar varken-naar-baviaan beenmergtransplantatie con-
cluderen we dat er een geschikte micro-omgeving nodig is voor varkenscellen om te kunnen 
engraften in een baviaan. De milt van de beenmergdonor biedt een extra bron van hemato-
poietische cellen, maar ook een stroma, noodzakelijk voor hematopoiese.
Hoofdstuk 9
Post-transplant lymphoproliferative disease (PTLD) is een belangrijke complicatie van immu-
nosuppressie na transplantatie. PTLD omvat een heterogene groep van lymfoïde proliferaties, 
meestal van B-cel origine, die geassocieerd zijn met ineff ectieve T cel functie en exogene im-
munosuppressie. Er is een sterke correlatie gerapporteerd tussen B cel neoplasma’s in pa-
tiënten die immunosuppressiva ontvangen en de aanwezigheid van het B-lymfotroop gam-
maherpersvirus, Epstein-Barr virus. In het miniatuurvarken is PTLD beschreven na allogene 
beenmergtransplantatie, maar ook na lever- en niertransplantatie. Vanwege de klinische rele-
vantie van PTLD is het fenomeen uitvoerig in het varken bestudeerd. Zoals in mensen, speelt 
een lymfotroop gammaherpesvirus, het “porcine lymphotropic herpesvirus-1” (PLHV-1) een 
belangrijke rol in de pathogenese van PTLD. Eerder gedefi nieerde risicofactoren voor PTLD 
na beenmergtransplantatie in het varken zijn: T cel-depletie, de mate van MHC mismatch, en 
de intensiteit van PLHV-1 infectie. In dit hoofdstuk beschrijven we het optreden van PTLD in 2 
van de 7 (29%) ontvangers van een milttransplantaat (op dag 30 en 32) die hetzelfde immuno-
suppressieve regime hadden ondergaan, namelijk totale lichaamsbestraling (100 cGy op dag 
-2), thymusbestraling (700 cGy op dag -1), en cyclosporine intraveneus gedurende 45 dagen. 
Twee controledieren kregen dezelfde immunosuppressie, maar geen milttransplantatie. 
In één geval betrof de PTLD een maligne proliferatie van ontvanger-type B-lymfocyten, in 
het andere geval een proliferatie van donor-type B-lymfocyten. In de twee varkens met PTLD 
bleek er een signifi cant betere T cel-depletie te bestaan op de dag van de milttransplantatie 
(na totale lichaamsbestraling en thymusbestraling), en hogere cyclosporine waarden (trough 
levels) in het bloed in de eerste week na transplantatie dan gelijkbehandelde varkens die 
geen PTLD ontwikkelden en controles. Vroegtijdige veranderingen geassocieerd met PTLD 
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waren: toegenomen hoeveelheden PLHV-1 in bloed en weefsels, leukocytose, toename van 
aantal B cellen en verhoogd serum IgM. Deze veranderingen gingen vooraf aan de klinische 
verschijnselen van PTLD. Het staken van immunosuppressie leidde niet tot verbetering. 
Concluderend is dit de eerste studie die het optreden van PTLD na allogene milttransplantatie 
beschrijft in miniatuurvarkens die relatief milde immunosuppressie kregen. Hoewel milttrans-
plantatie een veelbelovende strategie is om transplantatietolerantie te induceren, benadruk-
ken we de risico’s van over-immunosuppressie in de inductiefase van tolerantie. Dit model 
lijkt tevens geschikt om de pathogenese van PTLD verder te bestuderen.
Samenvattend geven de studies beschreven in dit proefschrift aanleiding tot verder onder-
zoek naar milttransplantatie als methode om donor-specifi eke immunologische tolerantie te 
bewerkstelligen. Aangezien de milt van postmortale orgaandonoren vaak niet wordt gebruikt 
(afgezien van weefseltyperingsonderzoek), zou deze beschikbaar zijn voor transplantatie in 
combinatie met een ander orgaan, zoals een nier of hart. Als inderdaad bewezen kan worden 
dat de milt tolerantie induceert ten opzichte van een nier- of harttransplantaat, zodat bij pa-
tiënten alle immunosuppressiva gestaakt kunnen worden, zou dat een signifi cante vooruit-
gang zijn in orgaantransplantatie. Ook heeft de milt een potentiële rol bij tolerantie-inductie 
in xenotransplantatie en als bron van hematopoietische voorlopercellen.
Graag verwijs ik naar Future directions voor voorstellen betreff ende verder onderzoek.
Frank Dor BW.indd   236 18-08-2006   15:10:30
237
Addendum
A
d
d
en
d
u
m
FUTURE DIRECTIONS
1.  Confi rm the feasibility of spleen transplantation and the induction of immunological tol-
erance to concomitantly-transplanted donor-matched kidney grafts.
2.  Demonstrate immunological tolerance through spleen transplantation towards donor-
matched organs (other than kidneys), either by concomitant or by subsequent transplan-
tation, in a large animal model. 
3.  Investigate the mechanism of tolerance induction by spleen transplantation in a rodent 
model, e.g. the role of the thymus or the need for venous drainage of the spleen in the 
portal circulation. 
4.  Refi ne the immunosuppressive protocols in order to make them clinically acceptable, e.g. 
by replacing irradiation with a pharmaceutical agent.
5.  Study the mechanisms involved in the observed absence of graft-versus-host-disease as-
sociated with spleen transplantation.
6.  Preclinical studies in nonhuman primates undergoing concomitant spleen and kidney 
transplantation as a strategy to induce tolerance. 
 
7.  Explore possibilities of a clinical trial of concomitant spleen and kidney transplantation. 
8.  Explore the further possibilities of the spleen as a source of adult stem cells with potential 
therapeutic value.
9.  Further explore xenogeneic spleen transplantation in a pig-to-baboon transplantation 
model.
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LIST OF ABBREVIATIONS
APC antigen presenting cell
BFU-E burst-forming unit-erythroid
BM bone marrow
CAFC  cobblestone area-forming cell 
CAV chronic allograft vasculopathy
CFU colony-forming unit
CFU-E colony-forming unit-erythroid
CFU-GEMM  colony-forming unit-granulocyte-erythrocyte-macrophage-mega-
karyocyte
CFU-GM colony-forming unit-granulocyte-monocyte
cGy centi-Gray
CML cell-mediated lympholysis
CPP cyclophosphamide
CyA cyclosporine A
DST donor-specifi c transfusion
ELISA enzyme-linked immunosorbent assay
FACS fl uorescein activated cell sorting
FISH  fl uorescence in situ hybridization 
FITC fl uorescein isothiocyanate
Gal Galα1-3Gal
GC germinal center
GVHD graft-versus-host disease
HEV high endothelial venule
HPC hematopoietic progenitor cell
Ig immunoglobulin
IgD immunoglobulin D
IgG  immunoglobulin G
IgM immunoglobulin M 
ITN Immune Tolerance Network
LC lymphocyte corona
LF lymphoid follicle
LN lymph node
LPS lipopolysaccharides
LTC-IC  long-term culture-initiating cell
MHC Major Histocompatibility Complex
MLR mixed leukocyte reactivity
MPS mononuclear phagocytic system
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MZ marginal zone
OPSI  overwhelming post-splenectomy infections
PAA  pig allelic antigen
PALS  periarteriolar lymphocytic sheaths
PAS periodic acid-Schiff 
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
PLHV-1 porcine lymphotropic herpesvirus-1
PSL  percent specifi c lysis
PTLD post-transplant lymphoproliferative disease
SLA Swine Leukocyte Antigen
SMA α-smooth muscle actin
SMP splanchnic mesodermal plate
SpTx spleen transplantation
TI thymic irradiation
TuI TUNEL index
TI-2 antigens T-cell independent antigens type 2
Tx transplantation
WBI whole body irradiation
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Chapter 1 Figure 1. Anatomical position of the human spleen. 
1, spleen; 2, kidney; 3, duodenum; 4, pancreas; 5, abdominal aorta; 6, inferior vena cava.
Chapter 1 Figure 2. Anatomy of the upper abdomen with respect to the spleen.
Chapter 1 Figure 3A. Cross section of the spleen with white and red pulp zones (Giemsa-stained).
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Chapter 4 Figure 1. Surgical technique of spleen transplantation in miniature swine. 
(A) In the donor, excision of the spleen involves dissection of the splenic artery and celiac axis to the aorta and of the splenic vein to its confl uence 
with the superior mesenteric vein to form the portal vein, which necessitates total pancreatectomy. Before transplantation into the recipient, the 
hepatic artery stump will be shortened.
(B) Flushing of the spleen graft with cold (4oC) electrolyte solution for kidney preservation trough the splenic artery, while placed in a tray of cold 
(4oC) saline, until the effl  uent from the splenic vein is clear. 
(C) In the recipient, end-to-side anastomoses are performed between the cuff  of the donor aorta to the distal abdominal aorta and between the 
cuff  of the donor portal vein to the IVC.
venous anastomosis
arterial anastomosis
Aorta IVC
Spleen
Spleen
Celiac axis
Aortic cuff
Hepatic artery
Portal vein with cuff
C
B
A
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Chapter 5 Figure 1. Normal histology of porcine spleen is illustrated with various staining techniques. 
(A) Red pulp is predominant, and white pulp contains a small central artery (arrow), H&E 
(B) Capsule and trabeculae, containing abundant blue-stained collagen, trichrome stain
(C) Scant collagen fi bers (arrow heads) in periarteriolar lymphatic sheaths (PALS), reticulin stain
(D) Smooth muscle cells of trabeculae and of vessels and sinusoids in the white and red pulp express actin, SMA stain
(E) Red pulp, with delicately stained sinusoidal endothelial and/or smooth muscle cells, vimentin stain
(F) Normal cellular proliferative activity in red pulp and lymphoid follicle, with prevalence of staining in a germinal center (arrow), PCNA stain
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Chapter 5 Figure 2. Histology associated with expanded PALS (#14867, Group 1, 15 days after SpTx) can be compared to baseline fi ndings seen 
in Figure 1. 
(A) Marked expansion of PALS around central artery, H&E 
(B) High power view of pleomorphic, atypical lymphoid cells in the PALS, H&E 
(C) Increased density of collagen fi bers in PALS, reticulin stain 
(D) Increased smooth muscle cell staining in red pulp adjacent to PALS, SMA stain 
(E) Similar increase in staining of smooth muscle-like cells and/or endothelial cells (arrowhead) in expanded PALS, vimentin stain 
(F) Increased proliferative activity associated with expanded PALS, PCNA stain 
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Chapter 5 Figure 4. 
A TUNEL index at baseline on the day of SpTx (A) (#14867, Group 1) is increased more than two-fold 15 days after SpTx (B) (#14867, Group 
1) before a subsequent biopsy showed histologic evidence of rejection (arrows mark TUNEL-positive cells). Spleen allograft necrosis varied 
morphologically from focal, fi brinoid necrosis of sinusoidal walls (C) (#14526, Group 1, 57 days after SpTx) (arrow), associated with fi brin thrombi 
in small vessels (D) (#14526, Group 1, 57 days after SpTx) (arrows), to diff use liquefactive necrosis (E) (#14867, Group 1, 28 days after SpTx). 
Necrosis was usually associated with some hemorrhage (F) (#14867, Group 1, 28 days after SpTx).
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Chapter 5 Figure 5. 
Other features of late rejection included acute vasculitis accompanying vessel wall necrosis (A) (#14646, Group 2, 28 days after SpTx), and, in 
one graft, extramedullary hematopoiesis (#14832, Group 2, 47 days after SpTx) (B and C). Histological changes associated with prolonged graft 
survival included atrophic white pulp (D) (#15051, Group 2, 57 days after SpTx) (arrow points to a central artery); increased SMA expression in red 
pulp (E) (#14526, Group 1, 160 days after SpTx), SMA stain; and an increase in vacuolated histiocytes (arrows) in red pulp (F) (#14526, Group 1, 
160 days after SpTx).
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Chapter 5 Figure 7. 
Section of spleen which was transplanted from a female donor into a male recipient (#14840, Group 2, 43 days after SpTx). A notable number of 
recipient-derived cells with Y chromosomes (red signal) has populated the graft at the time of expanded white pulp (day 43), FISH technique, x400.
Chapter 5 Figure 8. Red blood cells (arrows) contain Howell-Jolly bodies in a peripheral blood smear of a recipient of a rejected (Grade 3) spleen 
allograft (#15311, Group 2, 75 days after SpTx, two weeks after spleen graft rejection (characterized by coagulative necrosis), Wright stain x640.
Frank Dor BW.indd   263 18-08-2006   15:14:07
Addendum
264
Chapter 6 Figure 7. Histopathology of kidney allografts in two Group B pigs tolerant to their spleen grafts and in two ‘control’ pigs (Groups A 
and C). Pig 15111 (tolerant to MHC class I-mismatched spleen graft, Group B); the kidney (MHC-matched to the spleen donor) showed (A) no 
features of rejection after almost 3 months (H&E x160). Pig 15410 (tolerant to full MHC-mismatched spleen graft, Group B); after 129 days the 
kidney showed (B) type 1 acute cellular rejection with an interstitial mononuclear cell infi ltrate, tubulitis, and glomerulopathy in the absence 
of vasculitis (H&E x160); evidence of chronic rejection was manifested by interstitial fi brosis and tubular atrophy, as well as (C and D) occlusive 
arteriopathy; arrows indicate internal elastic lamina (H&E x200 and Verhoeff  elastic stain x 640, respectively). Pig 15733 (Group A, that lost its 
full MHC-mismatched spleen graft from vascular pedicle compression on day 3) developed (E) acute cellular rejection of the kidney graft by day 
15; arrow indicates fi brinoid necrosis of arterial wall (H&E x160). Pig 15330 (Group C) received a kidney graft from a donor MHC-matched to the 
donor of a blood transfusion given on day 0, and developed severe acute cellular and humoral rejection within 4 days, marked by (F) tubular 
necrosis, proteinaceous casts, and interstitial hemorrhage (H&E x320), as well as (G) endothelialitis (arrow) (H&E x200). 
Frank Dor BW.indd   264 18-08-2006   15:14:10
